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Abstract 
 
Alzheimer’s disease (AD) and cancer represent two of the main causes of death worldwide. They are 
complex multifactorial diseases and several biochemical targets have been recognized to play a fundamental 
role in their development. Basing on their complex nature, a promising therapeutical approach could be 
represented by the so-called “Multi-Target-Directed Ligand” approach. This new strategy is based on the 
assumption that a single molecule could hit several targets responsible for the onset and/or progression of the 
pathology. 
In particular in AD, most currently prescribed drugs aim to increase the level of acetylcholine in the brain 
by inhibiting the enzyme acetylcholinesterase (AChE). However, clinical experience shows that AChE 
inhibition is a palliative treatment, and the simple modulation of a single target does not address AD 
aetiology. Research into newer and more potent anti-AD agents is thus focused on compounds whose 
properties go beyond AChE inhibition (such as inhibition of the enzyme β-secretase and inhibition of the 
aggregation of β-amyloid). Therefore, the MTDL strategy seems a more appropriate approach for addressing 
the complexity of AD and may provide new drugs for tackling its multifactorial nature. 
In this thesis, it is described the design of new MTDLs able to tackle the multifactorial nature of AD. 
Such new MTDLs designed are less flexible analogues of Caproctamine, one of the first MTDL owing 
biological properties useful for the AD treatment. These new compounds are able to inhibit the enzymes 
AChE, β-secretase and to inhibit both AChE-induced and self-induced β-amyloid aggregation. In particular, 
the most potent compound of the series is able to inhibit AChE in subnanomolar range, to inhibit β-secretase 
in micromolar concentration and to inhibit both AChE-induced and self-induced β-amyloid aggregation in 
micromolar concentration. 
Cancer, as AD, is a very complex pathology and many different therapeutical approaches are currently 
use for the treatment of such pathology. However, due to its multifactorial nature the MTDL approach could 
be, in principle, apply also to this pathology. Aim of this thesis has been the development of new molecules 
owing different structural motifs able to simultaneously interact with some of the multitude of targets 
responsible for the pathology. The designed compounds displayed cytotoxic activity in different cancer cell 
lines. In particular, the most potent compounds of the series have been further evaluated and they were able 
to bind DNA resulting 100-fold more potent than the reference compound Mitonafide. Furthermore, these 
compounds were able to trigger apoptosis through caspases activation and to inhibit PIN1 (preliminary 
result). This last protein is a very promising target because it is overexpressed in many human cancers, it 
functions as critical catalyst for multiple oncogenic pathways and in several cancer cell lines depletion of 
PIN1 determines arrest of mitosis followed by apoptosis induction. 
In conclusion, this study may represent a promising starting pint for the development of new MTDLs 
hopefully useful for cancer and AD treatment. 
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1.1 Introduction 
 
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for 50-60% of all cases. 
According to the World Health Organization, more than 37 million people worldwide have dementia and AD 
affects 18 million of them1.  
AD has been first described on November 4th, 1906, when Alois Alzheimer gave a lecture at a congress in 
Tubingen, Germany, showing the results of his post-mortem studies on a 51-years old woman from 
Frankfurt, called Auguste D. She showed progressive cognition and memory impairment, reduced 
comprehension, aphasia, disorientation and unpredictable behaviour2. What has been reported in that clinical 
description exemplified cardinal features of the disorder still observed nowdays. For many years, AD was 
considered a rare dementia occurred in presenile period and only in late 60’s it was recognized as a typical 
senile dementia. 
AD is a late-life dementia and, therefore, increasing age is one of the greatest risk factor. Due to the 
increasing life expectancy and the strong increase of age people, the number of people affected by AD is 
going to rise dramatically. In the next years, the number of people in Europe and in USA aged 80-90 years is 
expected to double and about one-third of the population will be older than 65 years and, thus, at risk of 
dementia diseases. It is estimated that currently in EU and USA the number of demented patients is 7-8 
million and 4-5 million, respectively; these numbers will increase up to 14 million in EU and 16 million in 
USA by 20503.  
With the expected increased in number of AD-affected people it will be observed an increasing in 
financial a social cost; according to Alzheimer’s Association, costs for beneficiaries with AD are expected to 
increase of about 75% from 91 million USA Dollars in 2005 to 160 million USA Dollars in 2010. Thus, AD 
is becoming an enormous public, social and economical problem. 
For these reasons, a growing number of scientists all over the world are focusing their investigations in 
finding new therapies to combat this devastating disease. Since the first AD description, little progress in 
defining the pathogenesis of AD occurred. In the early 70s, two characteristic lesions of this disease have 
been described and they are considered as typical hallmarks of the disease: the presence of neuritic plaques 
and neurofibrillary tangles. At the same time, it became clear that neurons involved in the biosynthesis of 
acetylcholine (ACh) went to a severe degeneration, especially in limbic and cerebral cortices. Based on these 
two findings, the oldest theory about the AD’s pathogenesis has been developed: the cholinergic hypothesis, 
which asserts that a serious loss of cholinergic function in the Central Nervous System (CNS) contributed 
significally to the cognitive symptoms associated with AD4. Until now, the only drugs approved by FDA for 
the treatment of AD are based on the cholinergic hypothesis: they are drugs which increase the ACh levels in 
the CNS.  
Within the last decades, a lot of studies have been devoted to identify the composition and the origin of 
the amyloid plaques and neurofibrillary tangles; based on these studies another new theory appeared and 
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becomes dominant in the AD research, the amyloid hypothesis5. The amyloid plaques were found mostly in 
the neocortex and contained a polypeptide known as β-amyloid protein. Because dense-core amyloid plaques 
are a specific lesion of AD, whereas neurofibrillary tangles are seen in a variety of neurodegenerative 
conditions, it has been argues that the accumulation of Aβ in the brain is the key step in the pathogenesis of 
AD. But, it is not completely clear how amyloid neurotoxicity induces neuronal death and how these 
mechanisms are linked with oxidative stress and redox-metal imbalance, phenomenon that have assumed a 
pivotal role in AD.  
However, the basic pathophysiology of AD is still not well understood. Different pharmaceutical 
approaches, targeting the several hypotheses, are currently under investigation; nevertheless, the current 
registered drugs for AD are very limited and they are not able to alter or to prevent disease progression and 
they were approved only for the symptoms management6. 
Considering the complexity of AD and the involvement of multiple and interconnected pathological 
pathways, a combination of therapeutic agents may result in a more effective strategy of cure than the 
monotherapy. Besides the combination of known drugs, acting on different imbalanced mechanisms, new 
therapeutic approaches are based on the development of multipotent molecules able to interfere with more 
than one pathological event. In principle, this research guideline would lead to the discovery of an effective 
strategy of cure of AD and other neurodegenerative diseases7. 
 
1.1.1 Alzheimer Disease 
AD is clinically characterized by a global decline of cognitive functions, together with behavioural 
disturbances and decreasing ability to perform basic activities of daily living. The cognitive symptoms 
include memory loss, disorientation, confusion, problems with reasoning and thinking, while behavioural 
symptoms include agitation, delusion, depression, hallucinations, insomnia and wandering.  
Although the pathogenesis of AD is not yet fully understood, a lot of evidences show that it is a 
multifactorial disease caused by environmental and endogenous factors and with a significant genetic 
background.  
Two forms of AD exist: a familial one (multiple family members are affected) and a sporadic one, in 
which one or few members of a family develop the disease. However, epidemiological studies suggest that 
more than 80% of AD cases are familiar1. At least 10 genes are associated with AD, and more than 50 genes 
are potentially involved in dementia. 
Familial AD is an autosomal dominant disorder; the first mutation causing this form of AD has been 
identified in the Amyloid Precursor Protein (APP) gene on chromosome 21 even if this kind of mutation only 
explains very few familial cases. For the most cases of familial disease, mutations are observed in the highly 
homologous presenilin 1 (PS1) and presenilin 2 (PS2)3. Concerning the sporadic form of AD, the 
apolipoprotein E (ApoE) plays an important role; despite its mechanism of action is not well clear, ApoE 
seems to be essential for Aβ deposition, promoting Aβ fibrillisation and plaques formation8. However, these 
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mutations account only for 10% of AD cases and it seems clear that other genetic factors may be involved in 
AD. 
Since Alois Alzheimer’s seminal report, pathologists have considered the defining characteristic 
hallmarks of the disease to be Aβ deposits in senile plaques and neurofibrillary tangles (NFT), derived from 
filaments of abnormally phosphorylated τ protein. These two lesions are implicated in the neuronal functions 
disruption observed in the post mortem brain of AD patients. Despite the growing number of studies 
concerning the AD pathogenesis, the mechanism how these two events lead to dementia is not fully 
understood yet.  
Different neurotransmitter systems go towards degeneration in AD progress; in particular, cholinergic 
neurons and synapses in the nucleus basalis, hippocampus and entorhinal cortex. Many evidences 
demonstrated that ACh is deeply involved in memory functions. Almost all the drugs currently in market for 
the treatment of AD have the cholinergic system as target of their pharmacological activity9,10. Moreover, 
other neurotransmitter systems are involved in the AD pathology development such as serotoninergic, 
dopaminergic and glutammatergic11. The last system represents also an important target for AD treatment; 
over-activation N-methyl-D-aspartate-sensitive glutamate (NMDA) receptors leads to excessive intracellular 
Ca2+ influx and the subsequent production of damaging free radicals contributing to cell injury and death. 
Moreover, both oxidative stress and increased intracellular Ca2+, generated in response to Aβ, have been 
reported to enhance glutamate-mediated neurotoxicity in vitro. Furthermore, it has been suggested that Aβ 
can also increase NMDA responses and therefore excitotoxicity. There is increasing evidence that glutamate 
excitotoxicity is associated with oxidative stress and Aβ formation12. For these reasons, Memantine, a non 
competitive NMDA receptor antagonist, is commercially available in US and Europe for the treatment of 
moderate to severe AD. This drug acts by reducing the calcium-mediate neurodegeneration in several brain 
areas13. 
Accumulating evidences suggest that oxidative stress is an early event in AD14. Extensive literature points 
to oxidative stress as pivotal in the pathogenesis of AD, suggesting that it occurs prior to the onset of 
symptoms in AD, and that oxidative damage occurs before plaques formation15. 
 
Cholinergic hypothesis 
The “cholinergic hypothesis” have been developed in 80’s when the importance of the cholinergic system 
in the process of memory have been clearly understood. Based on these evidences, different studies showed 
how reduction of the cholinergic transmission is one of the causes of AD.  
This theory have been proposed after the observation that low doses of natural cholinergic agents, such as 
atropine and scopolamine, could induce the same pattern of cognitive disorder seen in elderly volunteers. 
Different other studies using non human primates showed how scopolamine induces the same memory loss 
observed in aged monkeys16. These studies first showed that age memory loss could be reduced using drugs 
able to increase the cholinergic activity17. 
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The “cholinergic hypothesis” has been further validated by the observation that AD pathology is 
associates with a significant loss of presynaptic cholinergic markers, such as Choline AcetilTransferase 
(ChAT), a key enzyme in the biosynthesis of ACh18. Furthermore, other studies have demonstrated a 
reduction in the number of nicotinic and muscarinic M2 receptors subtype and acetylcholinesterase (AChE) 
in patients affected by Alzheimer Disease19,20. Moreover, disruption of the coupling between M1 receptor and 
its second messenger G protein has been observed21.  
These studies clearly demonstrated that cognitive and behavioural disorders associated with AD derived 
from the reduction of ACh and cholinergic transmission and, therefore, the “cholinergic hypothesis” 
represents the principal therapeutic approach to AD22. 
Acetylcholine is the neurotransmitter that interacts with cholinergic receptors and modulates different 
physiological function in the CNS e in the Peripheral Nervous System. It is produced in the cytoplasm of 
cholinergic neurons by the enzyme ChAT from choline and coenzyme A and it is stored in synaptic vesicles. 
After it is releasing in the synaptic cleft, it can have excitatory or inhibitory effect depending on the type of 
tissue and the nature of the receptor activated; it is metabolized into choline and acetic acid by enzyme 
Acetylcholinesterase (AChE). Cholinergic receptors can be divided in two types based on the 
pharmacological response to various agonist and antagonist: 
1) nicotinic receptors (nAChR), which have nicotine as natural ligand; 
2) muscarinic receptors (mAChR), which bind muscarine. 
These two receptor systems have different structures, localization, functions and are associated with 
different biochemical pathways. 
 
                 
 
Figure 1. Schematic representation of one subtype of nAChR (alfa7) and mAChR23,24. 
 
 
Both these two receptor systems are implicated in AD. 
Several experimental evidences have reported a reduction in central nicotinic receptors25 and M2 
muscarinic subtype receptors both located in presynaptic cholinergic terminals in AD patients. However, a 
relative preservation of postsynaptic M1 and M3 receptors has been observed. In addition, some evidences 
showed a disruption of the link between M1 receptor and its coupled G-protein18. 
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Therefore, such receptors system could be considered a valuable target for the treatment of AD (see 
section 1.2 for more detailed discussion). 
 
Acetylcholinesterase 
Cholinesterases are a ubiquitous class of serine hydrolyses that hydrolyze choline esters. Two forms of 
cholinesterases, encoded by two distinct genes, occur in mammalian: 
• Acetylcholinesterase (AChE) which selectively hydrolyzes ACh and its main role is the 
termination of impulse transmission at cholinergic synapses, by rapid hydrolysis of ACh in both 
central and peripheral nervous system; 
• Butyrylcholinesterase (BChE) which hydrolyzes other choline ester (BChE is less selective than 
AChE) but its role is not completely understood; from recent experimental evidences, BChE 
seems to be able to reduce β-amyloid precipitation26,27.  
 
 
 
 
 
Figure 2. Representation of the secondary structure of AChE28. 
 
AChE is present in nervous tissue, muscle, plasma and blood cells and it displays also non-cholinergic 
function, such as hydrolysing of encephalines and substance P. Since the discovery of “cholinergic 
hypothesis”, AChE has been widely investigated and it has become one of the most well known enzymatic 
systems. 
On the other hand, the functions of BChE are not completely clear; in brain, BChE has been found in 
association with dopaminergic system while in periphery it is abundant in liver as well as in the cardiac 
muscle. BChE has been suggested to act as a protective enzymatic system to guard AChE against inhibition 
by false substrates, preserving the critical function of AChE in its regulation of cardiovascular, 
neuromuscular and central cholinergic activities. 
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In 1991 Sussman and co-workers solved the three dimensional structure of Torpedo Californica AChE 
(TcAChE) that is structurally homologue to the muscle and nerve AChE of vertebrate. The enzyme monomer 
is a α/β fold protein, MW 65612, which contains 537 amino acids. It consists of a 12-strained central mixed 
β sheets surrounded by 14 α-helices and bears a striking resemblance to several hydrolases29.   
AChE is characterized by the presence of two main binding sites:  
1) catalytic active site, where the hydrolyse of the substrate ACh takes place; 
2) peripheral anionic site (PAS), which presents non-catalytic functions. 
 
                                        
 
            Figure 3. Structure of AChE29. 
 
 
TcAChE active site was found to be at the bottom of a deep and narrow gorge, lined by aromatic 
residues. AChE has been always classified as a serine hydrolase and it presents at the end of the gorge the so-
called catalytic triad formed by Asp-His-Ser. Ser200 is the residue responsible of the nucleophilic attack of 
carbonyl moiety of ACh and the following esterase activity. The nucleophilic properties of Ser200 are 
enhanced by His residue in the active site, identified as His440 by mutagenesis studies. The third residue has 
been indentified as Glu327 rather Asp by site-directed mutagenesis studies. In human AChE (hAChE) the 
catalytic triad includes Ser198, His483 and Glu327. Near the bottom of the cavity there is Trp84 which 
represents the anchoring site of the cationic portion of AChE, through a cation-π interaction30 .  
The Peripheral Anionic Site (PAS) is located at the rim of the gorge and it is formed by several amino 
acids such as Tyr72, Tyr123, Tyr341, Glu285, Asp74 and Trp28631. 
AChE presents many non-catalytic functions and it has been suggested that PAS could mediate 
heterologous protein association processes in synaptogenesis, neuronal differentiation and 
neurodegeneration. Several studies demonstrated that AChE could play a key role during the formation of 
senile plaques because it is able to accelerate the Aβ deposition. This process is affected by PAS inhibitors 
and not by active site inhibitors suggesting the crucial role of PAS in the senile plaques formation process32. 
In 2003, Bartolini et al. examinated different well known AChE inhibitors and no correlation between AChE 
inhibitory activity and the ability to prevent Aβ aggregation have been found33. Moreover, BChE, which 
lacks the PAS, was not able to affect the amyloid formation32. AChE-Aβ interaction has been characterized 
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in vitro: they form a complex that presents a fibrillogenic activity and determines also an increase in toxicity 
of the fibrils34,35.  
 
 
Figure 4. Docking simulation of Aβ on AChE35. 
 
Hence, AChE inhibitors able to interact with both catalytic and peripheral sites could offer an effective 
therapeutic approach for AD treatment. 
Indeed, with the exception of Memantine, all the anti-Alzheimer drugs currently in therapy are AChEI 
(see section 1.2 for further details). 
 
Amyloid hypothesis  
Amyloid β peptide was isolated for the first time 20 years ago from the brain of patients affected by AD 
and Down’s Syndrome and some years later this peptide has been recognized as the primary component of 
senile plaques of AD brain tissue36,37. Amyloid β peptide derived from an Amyloid Precursor Protein (APP), 
and the gene encoding for this protein is located on chromosome 21.  
The amyloid hypothesis states that Aβ plays a central role in the pathogenesis of AD; it is 
hypothesized that Aβ accumulation in plaques or as partial soluble filaments initiates a pathological 
cascade leading to neuronal dysfunction, tangles formation, inflammation, and oxidative damage, 
with neurodegeneration and dementia as the final outcome. The amyloid cascade hypothesis is 
based on a complex of subsequential events, starting with Aβ overproduction and/or a decreased 
clearance, which results in oligomerization and deposition as diffuse plaques. Several lines of 
evidence have recently demonstrated that soluble oligomers of Aβ, but not monomers or insoluble 
amyloid fibrils, might be responsible for synaptic dysfunction (Figure 5)38,39,40. 
In any case, Aβ aggregates might directly injure the synapses and neurites of brain neurons, activate 
microglia and astrocytes, modify kinase/phosphatase activity and ionic homeostasis, and promote a 
heterogeneous state of oxidative stress. 
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Senile plaques are extracellular deposits of amyloid fibrils formed by different fragments of peptide β: the 
major component of the amyloid core is the 42 amino acids residue Aβ4241.  
Aβ after being released from its precursor APP can coalesce into deposit called “diffuse plaques”; these 
plaques induce further deposition of other Amyloid plaques. Then, such plaques could reorganise into β-
pleated sheets and fibrilise into neuritic plaques leading to different events which culminate in neuronal loss 
and synaptic dysfunction42  
 
 
 
Figure 5. The amyloid cascade hypothesis42  
 
Amyloid plaques are deposit of β-amyloid insoluble peptides derived from the precursor APP43 which is 
widely expressed in cells throughout the body and its amounts are influenced by the physiological state of 
the cells. Several isoforms of APP exist but the most abundant form in brain is constituted APP69544. 
APP could be processed following two different pathways: the amyloidogenic and the non-amyloidogenic 
pathway45. The non-amyloidogenic pathway involved the enzyme α-secretase while the amyloidogenic 
involved two other secretases, β- and γ-secretase. The APP cleavage by α-secretase releases a large soluble 
fragment (α-APP) and the retention of an 83 amino acid fragment. In the amyloidogenic pathway, β-
secretase (BACE) cleaves APP generating an extracellular soluble fragment called β-APP and an 
intracellular COOH-terminal fragment called C99. Such fragment is further processed by γ-secretase to 
produce peptides of different length such as Aβ40 and the pathogenic Aβ4246,47. 
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Very interesting, the APP intracellular domain derived from the cleavage of C99 by γ-secretase could 
translocate into the nucleus and modulate the expression of different genes, such as apoptotic genes (Figure 
6)48. 
 
 
 
 
Figure 6. Pathways of APP processing42,44. 
 
However, other factors could contribute to Aβ formation such as high level of cholesterol in the cells49. 
Regarding the enzymes involved in the β-amyloid formation, BACE and γ-secretase have received many 
attentions as possible therapeutical targets. 
BACE1 is an aspartyl protease that requires two aspartates, Asp93 and Asp 289, for its activity. BACE-
RNAm is highly expressed in the brain and in other human tissues and it is mainly expressed in the Golgi 
and in endosomes50,51. 
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Figure 7. Ribbon model of the crystal structure 
of β-secretase catalytic domain52,53. 
 
γ-secretase has a central role in AD pathogenesis but for a long time it has been a mystery for all the 
scientists. Now, it is known that γ-secretase is a multiprotein complex of Presenilins (PS1 or PS2), Nicastrin, 
Aph1 and Pen2. Both PS1/2 regulate the activity of γ-secretase. However, studies carried out in animal 
lacking PS1 but not PS2 showed a decreased levels of β-amyloid suggesting that PS1 has a major role in 
APP processing than PS254,55. Indeed, also PS1 is an aspartyl protease. 
 
 
 
Figure 8. γ-secretase complex56. 
 
 
Fundamental for γ-secretase activity is Nicastrin and the N-terminal part of its transmembrane domain is 
involved in interaction with PS1. Nicastrin works as γ-secretase receptor since it binds the N-terminal side of 
APP and recruits it within the γ-secretase complex for further cleavage57. Pen2 and Aph1 seem to be 
necessary to stabilize the mature PS1-Nicastrin complex58  
γ-secretase complex has several different substrates other than APP, including NOTCH 1-4, and ErbB-4 
receptor59. The finding that knockout of the γ-secretase component PES-1 caused a lethal phenotype similar 
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to a NOTCH 1 knockout, indicate that γ-secretase cleavage of NOTCH 1 is essential during embryonic 
development. However, NOTCH signalling is also important in adult tissue and its inhibition might affect 
haematopoiesis and thymocyte differentiation. Recently, chronic in vivo administration of a potent γ-
secretase inhibitor at doses that inhibited Aβ production was shown to block thymocyte differentiation, 
inhibit splenic B-cell maturation, and cause severe changes in the gastrointestinal tract60. 
Recently it has been found that caspases could also cleave APP leading to a second apoptosis-promoter 
peptide called CT31 (Figure 9)61. 
 
 
Figure 9. Probable processing of APP by caspases62. 
 
β-amyloid is able to induce neurotoxicity through several mechanisms62. It has been demonstrated that Aβ 
induces formation of Reactive Oxygen Species (ROS) that cause lipid peroxidation and protein oxidation63. 
Moreover, Aβ causes accumulation of hydrogen peroxide in cultured hyppocampal neurons. 
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Figure 10. Neurotoxic action of Aβ involving ROS generation44. 
 
Furthermore, Aβ has effect on calcium homeostasis. Calcium is one of the most important messengers in 
the brain and it is essential for neuronal development and signal transmission. Aβ increases calcium influx 
through voltage-gated calcium channel, forms a cation-selective ion channel after Aβ peptide incorporation 
into the cell membrane and reduces magnesium blockade of NMDA receptors to allow increase of 
intracellular calcium62. 
 
 
Figure 11. Neurotoxic mechanisms of Aβ62. 
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Neurofibrillary tangles 
In addition to amyloid deposits, neurofibrillary tangles (NFTs) are typical AD markers and the discovery 
that Aβ in the vicinity of neurons enhanced τ phosphorylation in cellular cultures and in brain, suggested a 
link between the two lesions. 
NFTs, which are insoluble filamentous accumulation found in degenerating neurons42, are composed of 
highly phosphorylated aggregates of a microtubule-associate protein τ, self associated into paired helical 
filaments (PHF-τ).  
In AD, τ becomes hyperphosphorylated and self-aggregated and such resulting tangles accumulate within 
neurons leading to neuronal death. However, the mechanism of such aggregation is still not well understood 
even if it is clear that phosphorylation of τ is a key factor. 
τ, when is “normally phosphorylated”, plays many physiological roles in regulating neurite growth, axonal 
transport and microtubule stability64. τ is a neuronal protein that could exist in 6 different isoforms in adult 
brain. It possesses many sites that can be phosphorylated: for example, the longest adult brain form has 
almost eighty Ser and Thr and five Tyr residues65. Phosphorylation is essential for τ proper functions, 
however, its hyperphosphorylation has been observed in many neurodegenerative diseases66. 
 
 
 
 
Figure 12. Physiological and pathological roles of τ phosphorylation64. 
 
PHF-τ induces neurotoxicity through several mechanisms, such as: 
1. disassembly of microtubules67; 
2. comprising microtubule stability and functions68; 
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3. disruption of intracellular compartments essential for normal metabolism69. 
 
Oxidative stress 
Neurodegenerative diseases, such as AD, are characterized by an extensive evidence of oxidative stress, 
which might be responsible for the dysfunction or neuronal cells death contributing to the disease 
pathogenesis. Oxidative stress is the result of an imbalance in pro-oxidant/antioxidant homeostasis that leads 
to the generation of toxic ROS, such as hydrogen peroxide, nitric oxide, superoxide and the highly reactive 
hydroxyl radicals.  
 
 
 
Figure 13. Imbalance in pro-oxidant/antioxidant in normal and pathological condition70. 
 
 
Although many questions about the mechanism of oxygen regulation remain unanswered, it has been 
widely confirmed that oxidative stress contributes to the neurodegeneration process, and plays a key role in 
Aβ neurotoxicity70,71,72,73,74. Zn2+, Cu2+ and Fe3+ have been found in high concentration in different regions of 
brain and in vitro studies showed that Zn2+  could induce aggregation and precipitation of Aβ75. The same Aβ 
aggregation can be induced by Cu2+ and Fe3+ 76. 
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Figure 14. Oxidative stress in AD72. 
 
Aβ possesses histidine residues at 6, 13 and 14 position which are able to coordinate metal ions. Such 
interaction has been confirmed by spectroscopic studies77. Accordingly, it has been demonstrated that 
methylation of the histidine side chain abolishes the metal coordination. 
When such metals coordinate to Aβ redox reaction takes place that reduces the oxidation state of the 
metals and produces hydrogen peroxide from atmospheric oxygen.  
Oxygen is in a triplet-spin state and therefore interaction with most of the organic molecules is forbidden. 
However, different metallo-proteins could activate O2 to ROS following different pathways, such as Fenton 
and Haber-Weiss reaction78. 
Aβ reduces Cu2+ and Fe3+ and leads to production of ROS. The chemical reactions occur are the 
following: 
 
(Aβ)2     +     M(n+1)                                          Aβ:Aβ+·     +     Mn+ 
 
Then, reduced metals Cu2+ and Fe3+ react with molecular oxygen to produce superoxide anion: 
 
Mn+     +     O2                                      M
(n+1)
     +     O2
-
 
Superoxide anion can undergo to dismutation leading to hydrogen peroxide. 
 
 2 O2
- 
     +     2 H+                                                 H2O2     +      O2
 
 
Reduced metals then react with hydrogen peroxide following Fenton reaction to generate the highly 
reactive hydroxyl radical (OH·): 
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M(n+1)     +     H2O2                                       M
(n+1)  
   +     OH     +     OH-
 
 
Furthermore, OH· could be formed by the Haber-Weiss reaction catalyzed by M(n+1)/Mn+: 
 
O2
- 
    +     H2O2                                          OH     +     OH
-
     +     O2
 
 
 
Once generated, ROS can react with a multitude of different molecules leading to impaired cellular 
functions, formation of toxic species, and neuronal cell death. Lipid peroxidation, resulting from attack by 
radicals on the double bond of unsaturated fatty acids, such as arachidonic and linoleic acids, is a sensible 
marker of oxidative stress. This reaction generates highly reactive lipid peroxy radicals that produce 
downstream products, such as 4-hydroxy-2,3-nonenal (HNE), acrolein, malondialdehyde, and F2-
isoprostanes which have been detected at high level in cerebrospinal fluid of AD patients79. 
 
 
Figure 15. ROS generation by abnormal reaction of O2 with protein-bound Fe or Cu72. 
 
 
Moreover, HNE and acrolein generate further toxicity by cross linking to cysteine, lysine, and histidine 
residues via Michael addition, leading to an altered reuptake of glutamate and by promoting excitotoxicity80 
and stimulating apoptotic cascade. The beneficial effects of memantine, a NMDA receptors antagonist, in 
rescue AD pathology are thought to be related to the reduction of these excitotoxic phenomenons. 
 
 
Glutamate-induced toxicity 
Excessive activation of glutamate NMDA receptors (NMDAR) plays a fundamental role in AD81,82,83. 
Glutamate is the most important excitatory neurotransmitter and exerts its physiological and pathological 
binding to specific glutamate-receptors. Two classes of such receptors exist: 
 
1. metabotropic receptors, that belong to a G-protein coupled receptor family 
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2. ionotropic receptors, which are ion-channel receptors belonging to the ionotropic family84. 
 
The latter receptors system could be further divided basing on their sensitivity to synthetic agonist in: α-
amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptors, N-methyl-D-aspartate (NMDA) 
receptors and kainate receptors. In particular, the NMDA receptor is a cornerstone in AD pathogenesis. 
Pathological overactivation of NMDAR causes an excessive influx of Ca2+ triggering several cell-damages 
biochemical pathways, which include (Figure 16): 
• mitochondrial ROS formation leading to caspase activation and apoptosis; 
• activation of nitric oxide synthase leading to an increase production of toxic peroxinitrite (ONOO-); 
• stimulation of p38 MAPK that induces transcription of proapoptotic factors12. 
 
Figure 16. Death pathways triggered by excessive NMDAR activity12. 
 
Furthermore, several links exist between Aβ and NMDA-mediates events. In particular, Aβ seems to 
increase NMDA responses and, therefore, exicitoxicity85. Furthermore, Aβ could inhibit glutamate reuptake 
leading to an increase concentration of such neurotransmitter in the synaptic cleft86. In addition, NMDA 
hyperactivation seems to increase the hyperphosphorylation of τ-protein87 However, NMDAR present 
several binding sites that could represent potential target for blocking excitotoxicity. 
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1.1.2 Therapeutical Approaches to AD 
 
In the past years, important progresses have been made in understanding the pathomechanism leading to 
AD and new therapeutic targets have become available to design new molecular entities able to prevent the 
disease progression81,88. 
However, to date the therapeutic strategies for the treatment of AD have been mainly centred on the 
restoration of cholinergic functionality and until 2003, the only drugs licensed for AD treatment were 
acetylcholinesterase (AChE) inhibitors (AChEIs) such as Donepezil, Galantamine, Rivastigmine and 
Tacrine. This last AChEI, however, has been recently withdrawn from the market due to its serious side 
effects89. 
More recently, the role of an overactivation of glutamate receptors in neuronal death has been definitely 
cleared out, and the NMDA antagonist Memantine has been approved in the US in the late 2003 (Figure 
17)90. 
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Figure 17. Anti-AD drugs currently approved. 
 
 
Cholinomimetic Therapy 
Based on the “cholinergic hypothesis”, a drug able to potentiate central cholinergic function should be 
useful in the treatment of AD18. The treatment of the cholinergic deficit in AD could be addressed through 
several strategies. 
One of the first attempts to treat AD was focused on increasing the synthesis of ACh by supplying its 
precursors as lecithin and choline; however, this approach failed probably because there are sufficient levels 
of ACh precursor in AD brain and other factors are responsible for the cholinergic deficit91. 
Another useful approach is directed toward the modulation of cholinergic receptors. In particular, several 
pharmacological studies showed that M1 muscarinic receptor subtypes mediates many of the cognition-
enhancing effects of ACh and M1 activation could inhibit deposition of Aβ through different pathways24,92. 
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Therefore, many selective M1 agonists have been developed as cognition-enhancing drugs. Some of these 
drugs, such as Milameline, Sucomeline and SDZ 210-086, despite of exerting cognition-enhancing effects, 
showed several side effects93. 
Furthermore, M2 muscarinic receptor subtypes are important in learning, memory and neuronal plasticity. 
Presynaptic autoreceptors M2 mediate inhibition of hippocampal and cortical release of ACh94. Therefore, 
blockade of M2 autoreceptors should lead to an increase in ACh level by negative feed-back effect95. 
Selective M2 antagonists, such as BIBN-99 increase extracellular levels of ACh and cognitive function in 
both memory-impaired aged rats and normal rats96. A new class of M2 antagonists has been developed in the 
Schering-Plough laboratories, and the lead compound SCH 57790, although showing a promising in vivo 
profile, was not further developed because of the presence of a metabolic labile moiety97. Several analogues 
of SCH 57790 have been synthesized with a better pharmacokinetic profiles and improved M2 selectivity, 
and among others, SCH 76050 emerged as a potent and selective M2 antagonist, but with a poor 
pharmacokinetic profile98. 
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Figure 18. Chemical structure of M2 mAChR antagonists. 
 
 
Unfortunately, in the late stages of AD a severe M2 receptors degeneration is observed limiting the 
potential use of M2 antagonists in AD treatment. 
AD patients are characterized by a significant decrease of a wide number of nicotinic receptors (nAChR) 
and several experimental evidences show a strictly connection between AD and nAChR. 
Nevertheless, nowdays only few molecules interacting with the nAChR system are under investigation for 
the treatment of AD. ABT418 developed in the Abbot Laboratories is a α4β2 agonist actually in phase II 
clinical trials and many its analogues are currently under investigation99. In addition, analogues of alkaloid of 
Epibatin, such as SIB1553A, are currently study for AD treatment100. 
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Figure 19. Structure of nAChR agonists. 
 
However, several problems limit the development on nAChR ligands for AD therapy; perhaps, the main 
problem associate with the use of nAChR agonist is the fast desensitisation of these receptors to the effect of 
these agonists.  
ACh, after its release in the synaptic cleft, is rapidly hydrolyzed by the action of AChE and BChE. 
Inhibition of such enzymes should lead to an increase in concentration of ACh leading to an enhancement of 
the cholinergic tone. 
Nowdays, the most effective method to improve cholinergic deficit is to inhibit AChE even if clinical 
experience shows that cholinesterases inhibition is just a palliative treatment, which does not address AD’s 
etiology101,102. 
The first inhibitor of AChE (AChEI) approved in 1993 by FDA to treat AD was Tacrine (Cognex). 
Tacrine was synthesized more than 40 years ago; it is a reversible inhibitor of AChE with a strong affinity 
for the catalytic site but it is not able to interact with PAS. Furthermore, it is active towards monoamine 
oxidase. Tacrine appears to improve cognitive functions, and behavioural deficits but, unfortunately, serious 
adverse side effects have limited its use: it displays hepatotoxic effects and for this reason it has been 
withdrawn from the market103. 
Three other commercial drugs available for the treatment from mild to moderate AD in US and Europe 
are Donepezil, Rivastigmine and Galantamine. 
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Figure 20 
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Donepezil (Aricept) is a piperidine reversible inhibitor of AChE that displays increased activity and 
selectivity that means it has fewer adverse effects and can be tolerated in higher dose with limited side 
effects such as nausea and diarrhea104. Rivastigmine (Exelon) is a long-acting pseudo-irreversible AChE 
inhibitor generally well tolerated; indeed, the side effects usually concern the gastrointestinal system. 
Galantamine (Reminyl) has a more complex biological profile, because besides AChE inhibitory activity 
it is able to activate nicotinic acetylcholine receptors. This dual mechanism of action could potentially 
increase its potency as cognitive enhancer drug105. 
Several other natural compounds potentially active in AD treatment are currently under investigation as 
cognitive enhancing agents. Among these, Huperzine A, an alkaloid isolated from the Chinese traditional 
herb Huperzia Serrata, is a potent, selective, and long-acting AChE inhibitor, and it is endowed with high 
efficacy in improving memory in different animal models and clinical trials. (see section 1.3 for further 
discussion about AChE inhibitors) 
The palliative nature of AChE inhibitors based strategy is the most commonly objection against 
cholinergic hypothesis and, although reduction in ACh pathways has been shown in biopsies from AD 
patients within a year of onset of symptoms106. It is not completely clear if the cholinergic deficit occurs 
early in the course of the disease or it is a consequence of other pathological events. It seems clear that the 
AChEIs capability to relieve symptoms of AD may depend on the integrity of the neuronal cholinergic 
system and, in severe cases, it could result insufficient. Moreover, significant variability exists in the 
response to the AChE inhibitors treatment, with some subjects apparently resulting unresponsive at any 
tested dose. While the ultimate goal for AD treatment would obviously involve the pathogenesis and 
aetiology of the disease, clinical use of AChE inhibitors have shown a temporary stabilization of cognitive 
impairment. Despite the controversial debate upon the cholinergic hypothesis and the development of several 
new approaches for AD treatment not related to the modulation of cholinergic activity, this theory is far from 
being considerate merely an historical approach. Some investigators have recently reported an apparent 
retardation of the progression of the neurodegenerative process in patients treated with AChEIs. 
Furthermore, the finding that non classical modulation of AChE activity can interfere with the accumulation 
and precipitation of Aβ, hence, downstream, with the deposition of senile plaques, could afford a rational 
link between the two more important strategies of AD therapy107. Therefore, it seems that the cholinergic 
hypothesis will continue to drive drug discovery with the aim to design and synthesize new multipotent 
AChEIs combining the ability to increase the cholinergic response with inhibition of the Aβ-aggregation 
deposition. 
 
Anti-amyloid Strategies 
Within the years, the so called “Amyloid hypothesis” has assumed a central role in understanding the 
mechanisms leading to neuronal death in AD. Therefore, it is not surprising that many efforts have 
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concentrated in reducing/modulating Aβ-production42,108. Indeed, the decrease of Aβ in the brain should 
ameliorate the symptoms of Aβ and this could be achieved by interfering at different level of the Aβ cascade. 
 
 
• Lowering Aβ production: Secretase inhibition 
Two secretases are involved in the cleavage of APP leading to Aβ release and formation of β-amyloid 
plaques: β-secretase (BACE1 and 2) and γ-secretase. 
In particular, BACE1 seems to be an attractive drug target since BACE1 knockout mice do not produce 
Aβ109 and its crystal structure has been recently solved53. 
To date, many peptidomimetics and non-peptidomimetics BACE1-inhibitors have been developed52,110. In 
particular, several new peptidomimetics β-secretase inhibitors were developed starting from truncated 
polypeptides bearing non-cleavable transition state mimicking groups. 
The prototype of BACE1 peptidomimetic inhibitors of the first generation is represented by OM99-2 
designed as transition-state analogue and endowed with an IC50 of 0.002 µM. Furthermore, using X-Ray 
structure-based modification of OM99-2 new low molecular weight peptidomimetics BACE1 inhibitor have 
been developed (I) (Figure 21)111. 
 
                 a)                                                                  b) 
 
  
 
 
Figure 21. a) Chemical structure of peptidomimetic BACE1 inhibitors OM99-2 
and I; b) crystal structure of OM99-2 with BACE1110,111. 
 
 
Later, cell-permeable BACE1 inhibitors able to induce reduction of Aβ in human embryonic kidney 
(HEK) cells have been developed by Elan/Pharmacia. Their lead compound II showed an IC50 of 0.03 µM112; 
truncation of the N-terminus and C-terminus of II led to the identification of the smaller peptides inhibitor 
III, with an IC50 of 0.3 µM113. Further structural modification of III allowed to discover IV as potent and 
cell-permeable BACE1 inhibitor, with an IC50 of 0.12 µM; the corresponding diacid V was more potent (IC50 
= 0.02 µM) but, due the poor cell permeability, it showed no inhibition of Aβ in HEK cell (Figure 22)114. 
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In 2006, a potent BACE1 inhibitor have been designed in which the tetrazole ring were introduced as 
bioister of the carboxylic acid to give VI and VII, which displaied an IC50 of 4.8 and 1.2 nM, respectively 
(Figure 23)115. 
Furthermore, in order to obtain better pharmacokinetic profile, compounds, characterized by an 
hydroxyethylamino residue, were developed on the assumption that basic nitrogen could lead to an increase 
in inhibitory potency. The most potend compounds of this series were VIII and XI which displaied an IC50 
of 5 nM and 20 nM, respectively116. 
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Figure 23. Chemical structure of VI-VII and hydroxyehtylamino-based BACE1 inhibitors VIII-IX. 
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Inhibitors based on the peptidomimetic strategy suffer from well-known difficulties typical of 
polypeptides, such as poor blood–brain barrier crossing and poor oral bioavailability. 
Despite many BACE1 inhibitors peptidomimetics have been designed, also many non-peptidomimetic 
BACE1 inhibitors have been developed117. 
In 2001, aminoethyl-substituted tetraline have been discovered and the most potent compound of the 
series was X with an IC50 of 0.35 µM118. Also Vertex disclosed several BACE1 inhibitors able to inhibit the 
enzyme in a micro molar range and the most potent was XI119. 
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Figure 24. Most potent compound based on the aminoethyl-
substituted tetraline scaffold X, and Vertex’s inhibitor XI. 
 
 
A series of derivatives endowed with an aminoquinazoline scaffold were discovered (XII and XIII) all 
characterized by high BACE1 inhibitor activity (Ki = 0.9 µM and Ki = 11 µM, respectively)120. 
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Figure 25. Aminoquinazoline-based BACE1 inhibitors. 
 
 
As reported before, BACE1 represents a better pharmacological target than γ-secretase. Indeed, despite 
many efforts in designing γ-secretase inhibitors, interferences with Notch signalling lead to several side 
effects that precluded the clinical development of such inhibitors. However, compounds that inhibit γ-
secretase with little effect on Notch could result useful in AD therapy121. 
One of the first γ-secretase inhibitor is the dipeptidic compound DAPT that inhibits Aβ production with 
an IC50 of 115 nM in human primary neuronal cultures122. 
A very interesting inhibitor developed by Bristol-Myers Squibb is BMS-299897 that displayed an IC50 of 
7 nM and seemed to be selective for γ-secretase over Notch123. 
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However, the most potent γ-secretase inhibitor was LY-411575 with an IC50 of 119 pM124. Unfortunately, 
this compound in mice interferes with maturation of B- and T-lymphocytes once again due the inhibition of 
Notch signalling125. 
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Figure 26. Some γ-secretase inhibitors. 
 
 
Recently, an allotter binding site on the γ-secretase has been discovered121.  
Interestingly, some nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, indomethacin and 
sulindac sulfide, are able to reduce the release of Aβ42 and to increase the release of less amyloidogenic 
Aβ38126. The effect of NSAIDs on amyloidogenic-pathway is not mediated by interaction with COX but they 
interact directly with the γ-secretase complex. However, despite the mechanism of action of the NSAIDs on 
γ-secretase is not elucidated, seems that NSAIDs do not interfere with the Notch127. 
 
 
 
Figure 27. Modulation of γ-secretase cleavage by NSAIDs46. 
 
Thanks to these studies, the NSAID R-flurbiprofen (Tarenflurbil®) is now in Phase III clinical trials in the 
US for AD treatment. It modulates the Aβ-production without interacting with COX; however, it is important 
to point out, that the other enantiomer, S-flurbiprofen, is the active inhibitor of COX128. 
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Figure 28. NSAIDs modulators of γ-secretase. 
 
Recent studies led to the discovery of a nucleotide binding site on the γ-secretase complex; this site 
allows to allosteric modulation of γ-secretase without affecting the Notch pathways. ATP increase Aβ 
production and, therefore, compounds interacting with the ATP binding site could be potential useful in AD. 
Among these compounds, Imanib, an Abl kinase inhibitor, is able to inhibit the Aβ production and it does not 
interact with the Notch pathway129. 
 
• β-sheet breakers 
Amyloid plaques are one of the characteristic hallmarks of AD leading to neuronal death. Therefore, 
compounds able to interfere with the refold and/or the formation of Aβ-aggregates should have 
neuroprotective effects88,130. 
Soto and coworkers proposed that short peptide able to bind Aβ may destabilize, in principle, the 
amyloidogenic Aβ conformer and preclude amyloid formation131. They developed a series of peptides based 
on the structure of the central hydrophobic regions within the N-terminal domain of Aβ-protein; in order to 
disrupt β-sheet formation they inserted a proline moiety. Among the different small polypeptides designed, 
the most active on different models was XIV. 
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Figure 29. Structure of Soto’s pentapeptide. 
 
 32 
These peptides initially bind to Aβ and the formed complex is stabilized by hydrophobic interaction. 
Then, the peptides induce conformational changes in the β-sheet structure. This is probably due the presence 
of proline which can interconvert its cis and trans conformation.  
However, it is well known that peptides have poor drug-like profile mainly due their pharmacokinetic 
characteristics.  
Nevertheless, other compounds are able to induce disaggregation of Aβ-fibrils such as the antibiotic 
Rifampicin and Daunomicin132 . 
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Figure 30. Chemical structures of Rifampicin and Daunomycin. 
 
 
• Cholesterol-reducing approach 
Several experimental evidences show that cholesterol modulated the Aβ production46,108. Although the 
mechanism of how cholesterol can influence this metabolic pathway is not well clear, it seems that high 
cholesterol levels favourites the BACE-mediate APP proteolysis (the amyloidogenic pathway) while low 
cholesterol levels increase the APP processing via α-secretase133. Indeed, agents able to reduce the 
cholesterol concentration, such statins, show a decrease level of Aβ in mice and guinea pigs134,135. 
A very promising approach could be the use of inhibitors of acyl-coenzyme A cholesterol acyltransferase; 
this enzyme catalyzes the formation of cholesteryl-esters from cholesterol and its inhibition lead to a 
reduction in Aβ formation49. 
 
• Aβ immunotherapy 
This new approach directed towards Aβ42 derived from the first observation, by Shenk and coworkers, 
about the reduction of APP levels in transgenic mouse after vaccination with aggregated Aβ42136. 
The mechanism of how this reduction takes place is not well known, however, three different 
mechanisms81 have been proposed in order to explain such findings: 
1. antibodies bound to Aβ in the brain and trigger microglia to Aβ phagocytose via Fc-receptors; 
2. antibodies may behave as chaperone and destroy or prevent Aβ aggregation137 ; 
3. antibodies may sequester Aβ in the plasma inducing a rapid efflux of Aβ from the brain138,139. 
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Noteworthy, the first Aβ1-42 antigen in clinical trial displayed very promising results in ameliorate the Aβ-
associated AD’s signs; however, it had to be stopped in Phase II because it induces T-cell mediate 
autoimmune response140,141. 
 
• Metal-chelating approach 
High concentrations of metal ions, such as Cu2+, Fe2+, and Zn2+, have been found within Aβ deposits in AD 
brains. Metal ions have been shown to modify the Aβ peptide and to induce its aggregation. Therefore, 
metal-chelators can solubilise Aβ in AD brains142. 
Several metal chelators developed, such as diethylenetriaminepentaacetic acid (DTPA), triethylenetetraamine 
(TETA), and desferrioxamine (DFO), beside their ability to chelate metal ions, were able to reduce the 
production of hydrogen peroxide derived from the interaction of Cu2+ and Fe3+ with Aβ1-42 143. 
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Figure 31. Chemical structure of different metal-chelators. 
 
Another metal-chelator is clioquinol. Clioquinol, already known as antifungal and antiprotozoal drug, is 
able to chelate metal ions and to induce reduction of Aβ accumulation144. 
However, although a metal chelator could represent a promising agent to reduced metal-mediated brain 
injury, their protracted use could present serious side effects by interfering with the normal function of 
physiological metalloenzymes. 
 
• τ-hyperphosphorylation directed strategies 
Neurofibrillary tangles (NFTs) are typical AD markers and are aggregates composed of highly 
phosphorylated τ protein. Inhibition of the formation of such aggregates could represent a promising 
approach in AD’s treatment. This goal could be achieved following different approaches. 
The first one is the development of τ-kinases inhibitor; indeed; τ-protein posses many phosphorylation 
sites and many important kinase target τ, such as glycogen synthase kinase 3β (GSK-3), microtubule-affinity-
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regulating kinase (MAPK) and protein kinase A. Unfortunately, not so many inhibitors of these kinases have 
been developed. 
At the same time, activation of phosphatases could lead to a restoration of correct τ functionality. 
Nevertheless, also in this field the research did not provide significant progress yet; on the other hand, it was 
reported that Memantina inhibits τ hyperphosphorylation by restoration of protein Phosphatases PP2A 
activity145. 
Molecules that can inhibit τ-aggregation should be useful to protect neurons against neurofibrillary 
tangles. Therefore, many small molecules as τ-aggregation inhibitor have been developed146. 
An appealing class of τ-aggregation inhibitors is based on the rhodanine scaffold. In 2007 Waldmann and 
coworkers reported several derivatives of rhodanines (2-thioxothiazolidin-4-ones)147. 
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Figure 32. a) Structure of the hit compound rhodanine 
b) Variations of the core147. 
 
 
In general, the presence of a carboxylic acid function is important for the disassembly activity in vitro 
because its esterification or its replacement with an imidazole or benzimidazole group lead to a decreased 
activity. The modification of the heterocyclic side chain leads to reduction of the activity as well as 
modification of the aromatic side chain. These two elements seem to be important to establish hydrophobic 
or π-stacking interactions with τ-protein. Structure-Activity Relationships based on rhodanine-derivatives 
designed by Waldmann and coworkers are summarized in Figure 33: 
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Figure 33. Structure-activity relationships 
of rhodamine derivatives147. 
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Furthermore, N-phenylamines and Anthraquinones display inhibitory effects on τ-aggregation. In 
particular, in the anthraquinone series, it is important to point out that all derivatives, endowed with this 
particular biologica property, present a tricyclic structure with one or more β-hydroenone groups148. 
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Figure 34. Selected examples of N-phenylamines (B4D5) and  
Anthraquinones (PHF016). 
 
FMoreover, Benzothiazole-based compounds have been developed. Such compounds present a cationic 
charge that could interact by electrostatic bond with the target and the benzothiazole ring may establish 
additional hydrophobic interactions. Among these derivatives, N744 displays the higher activity with an IC50 
of 300 nM149. 
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Figure 35. Chemical structure of the Benzothiazole N774. 
 
 
Phenothiazine derivatives also display inhibitory activity toward τ-aggregation; in particular, Thionin 
display an IC50 of 12 µM and its activity is probably due to the planarity of the central core (Figure 36)148.  
Porphyrin, such as Hemin, is the only organometallic example of τ-aggregation inhibitor. The metal ion is 
fundamental for the activity since its analogue, lacking the metal, is less active. The mechanism of action is 
not clear; however, it is also able to inhibit Aβ42 aggregation by coordinating histidine residue and this could 
explain also the τ-aggregation inhibitory effect148. 
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Figure 36. Structure of Thionin and Hemin. 
 
• Targeting NMDAR-mediated neurotoxicity: 
Among the several biochemical pathways leading to neuronal death in AD, NMDAR plays a key role84. 
Its excessive activation, leading to toxic levels of Ca2+ in the cells, has been observed and therefore the use of 
NMDAR antagonist may represent a useful therapeutical approach81. However, many NMDA receptor 
antagonists also produce highly undesirable side effects at doses within their putative therapeutic range. 
Nevertheless, the only drug approved for AD treatment that does not interfere with the cholinergic system is 
an antagonist of NMDAR, Memantine. It was approved in 2003 in US for the treatment of moderate to 
severe cases of AD150. It is a non-competitive NMDAR antagonist derived from amantadine, an anti-
influenza agent. Memantine exerts its effect on NMDAR activity by binding at or near the Mg2+ site within 
the ion receptor channel. 
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Figure 37. Chemical structure of Amantadine and Memantine and 
its binding site on NMDAR84.  
 
 
• Antioxidant therapy 
ROS and other radical species are deeply involved in the cellular damage leading to neuronal death. 
Radical scavenger would protect cells from free radicals because they are able to accept a radical or a free 
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electron. Many free radical scavengers are known, such as vitamin E and C, melatonin, flavonoids and 
carotenoids, and none of them shows serious side effects88. 
Vitamin E (α-Tocoferol) and its analogue Raxofelast and MDL 74180DA, exerts antioxidant and anti-
apoptotic properties in various experimental models of AD; they have been successfully tested in clinical 
trials151. 
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Figure 38. Radical scavenger action151. 
 
 
Furthermore, it has been reported that derivatives of estradiol, as 17β-estradiol and its isomer 17α-
estradiol and their analogues, block the intracellular accumulation of ROS. Interestingly, 17β-estradiol 
reduces the formation of Aβ40 and Aβ42 from APP152. 
Perhaps, the most promising radical scavenger is Melatonin. It is a hormone able to react with 
hydroxyradical forming non-toxic derivatives that are easily metabolized153. In addition, it reacts with 
peroxynitrile and ROS and displaing other interesting activities, such as the inhibition of the amyloid fibril 
formation and anti-apoptotic effects154. 
N-acetylserotonin, a melatonin precursor, inhibits lipid peroxidation and shows higher anti-amyloid 
activity than melatonin155. 
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Figure 39. Selected examples of antioxidants. 
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1.1.3 The “Multi-Target-Directed Ligand” approach in AD 
 
The “one-molecule-one-target” paradigm has led to the discovery of many successful drugs, and it will 
probably remain a milestone for years to come. However, it should be noted that a highly selective ligand for 
a given target does not always result in a clinically efficacious drug. This may occur because: 
a. the ligand does not recognize the target in vivo,  
b. the ligand does not reach the site of action, 
c. the interaction with the respective targets does not have enough impact on the diseased system to 
restore it, effectively.  
 
Reasons for the latter might lie in the multifactorial nature of many diseases. Drugs hitting a single target 
may be inadequate for the treatment of diseases like neurodegenerative syndromes, diabetes, cardiovascular 
diseases, and cancer, which involve multiple pathogenic factors. When a single medicine is not sufficient to 
effectively treat a disease, a multiple-medication therapy (MMT) (also referred to as a “cocktail” or 
“combination of drugs”) may be used. Usually, an MMT is composed of two or three different drugs that 
combine different therapeutic mechanisms. But this approach might be disadvantageous for patients with 
compliance problems. A second approach might be the use of a multiple-compound medication (MCM) (also 
referred to as a “single-pill drug combination”), which implies the incorporation of different drugs into the 
same formulation in order to simplify dosing regimens and improve patient compliance. Finally, a third 
strategy is now emerging on the basis of the assumption that a single compound may be able to hit multiple 
targets. 
In the Multi-Target-Directed Ligand (MTDL) approach to drug discovery, a drug could recognize (in 
principle, with comparable affinities) different targets involved in the cascade of pathological events leading 
to a given disease. Thus, such medication would be highly effective for treating multifactorial diseases7,156. 
 
 
 
Figure 40. Pathways leading to the discovery of new medications: 
(a) Target-driven drug discovery approach; (b) MTDLs approach 
to drug discovery7. 
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Although the pathogenesis of AD is not yet fully understood, it is a multifactorial disease caused by 
genetic, environmental, and endogenous factors. The central event in AD pathogenesis is an imbalance 
between Aβ production and clearance. The enhanced activity of β- and γ-secretases leads to increased release 
of amyloidogenic Aβ42, which forms oligomers and then extracellular deposits (senile plaques). One way to 
confront AD pathogenesis may be to combat the oligomerization by means of small molecules. A role for 
metal ions and ROS in the Aβ oligomerization has also been advanced. Therefore, metal chelation and 
antioxidant activities are two general mechanisms to be considered in the search for disease-modifying anti-
AD drug candidates. Also, β- and γ-secretase inhibitors may be promising lead compounds because they 
tackle an early event in AD pathogenesis. Mitochondrial dysfunction plays a fundamental role in the 
neuronal death associated with AD, as it is likely that intracellular Aβ could compromise the function of this 
organelle. τ hyperphosphorylation leading to tangle formation is regarded as a downstream event but could 
contribute to reinforcing neuronal dysfunction and cognitive impairment. Moreover, neuroinflammation of 
CNS cells has been recognized as an invariable feature of all neurodegenerative disorders. Therefore, 
MTDLs emerge as valuable tools for hitting the multiple targets implicated in AD aetiology. 
 
 
Figure 41. Possible molecular causes of neuronal death and 
protective mechanisms in AD. 
 
To obtain novel MTDLs, a design strategy is usually applied in which distinct pharmacophores of 
different drugs are combined in the same structure to afford hybrid molecules. In principle, each 
pharmacophore of these new drugs should retain the ability to interact with its specific site(s) on the target 
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and, consequently, to produce specific pharmacological responses that, taken together, should slow or block 
the neurodegenerative process. One of the most widely adopted approaches in the field has been to modify 
the molecular structure of an AChEI in order to provide it with additional biological properties useful for 
treating AD. Some MTDLs developed for the treatment of AD are following reported. 
 
Dual Binding AChEI 
In the MTDL design strategy context, major research efforts have been devoted to the development of the 
so-called “dual binding site” AChEIs. By simultaneously interacting with AChE catalytic and peripheral 
sites, these AChEIs might address the disease mechanisms by reducing Aβ aggregation157. Indeed, Inestrosa 
and coworkers discovered that AChE exerts Aβ pro-aggregating action158. AChE promotes the formation of 
Aβ fibrils by PAS of the enzyme and therefore, AChE inhibitors able to bind at PAS can block pro-
aggregating action of the enzyme107,159. 
Several molecules are able to bind PAS such as propidium, decametonium, ambenonium, and also 
donepezil. 
The above mentioned involvement of AChE in non-cholinergic action drives medicinal chemists to 
design molecule able to bind simultaneously both sites of AChE160. 
Pang and coworkers developed dimers of tacrine with the aim to increase its affinity towards AChE. The 
most potent of the series was XV, which resulted 500-folds more potent than tacrine in inhibiting hAChE161. 
Furthermore, this compound acts NMDAR as antagonist162, as inhibitor of the nitric oxide synthase and it is 
able to reduce in vitro Aβ formation by inhibition of BACE-1163. 
Several structure-activity relationships have been carried out on these compounds that are summarized in 
Figure 42. 
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Figure 42. Structure-Activity relationships of Bis-tacrine derivatives160. 
 
In 2003, Sharpless and coworkers developed an elegant target-guided in situ click-chemistry approach to 
obtain new dual-binding AChE inhibitors164. In this approach, they chose tacrine as catalytic-site inhibitor 
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and phenylphenanthridium and other molecules as PAS-inhibitor and these compounds were decorated with 
alkyl-azide and alkyl-acetylene of varying chain length to allow to undergo to a Huisgen 1,3-dipolar 
cycloaddition leading to 1,2,3-triazole ring. The reaction was carried out in the presence of AChE to 
facilitate the formation of the desired product. Therefore, a series of 49 binary mixture of reagent were 
incubates in Electrophorus electricus AChE potentially give rise to 98 products but only one was formed 
(XVI) (Figure 43 and 44).  
 
 
 
Figure 43. a) Huisgen 1,3-dipolar cycloaddition; b) In situ AChE-mediated click chemistry164,165,166. 
 
 
XVI is one of the most potent AChE inhibitor having Kd values between 77 fM (Torpedo Californica 
AChE) and 410 fM (murine AChE) while tacrine and propidium are 18 and 1100 nM on murine AChE 
respectively. It is important to point out that the XVI anti isomer was not obtained using this approach and it 
was chemically synthesized and resulted less active by two-order of magnitude in comparison with its syn 
isomer. 
X-Ray structure of both syn and anti isomer of XVI complexes with murine AChE confirmed that XVI is 
a dual-binding inhibitor and the triazole ring is not just a passive linker but establish hydrogen-bonding and 
stacking interactions with amino acids in the AChE mid gorge165,166. 
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Figure 44. a) Chemical structure of XVI; b) X-Ray of XVI in mouse 
AChE164,165,166. 
 
 
Caproctamine represents one of the first examples of a successfully designed dual-binding AChEI 
endowed with additional pharmacological effects beneficial in AD. Caproctamine, developed from 
Benextramine using the universal template approach (Figure 45), emerged as an effective pharmacological 
tool in AD because of a well-balanced affinity profile as AChEI and competitive muscarinic M2 receptor 
antagonist167. Caproctamine is able to interact with both AChE sites, and antagonism of muscarinic M2 
autoreceptors would facilitate the release of ACh in the synapse. 
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Figure 45. Design of Caproctamine and derivatives. 
 
 
SAR studies carried out on Caproctamine structure were expanded the role of the octamethylene spacer 
separating its two amide functions. This was performed by its replacement with less flexible dipiperidine and 
dianiline moieties (Figure 45). Compound XVII and XVIII were the most potent AChEIs and they displayed 
significant muscarinic M2 receptor antagonism. Although all the derivatives caused a mixed type of AChE 
inhibition (active site and PAS), only XVII and XVIII, which bear an inner constrained spacer, were able to 
inhibit AChE-induced Aβ aggregation to a greater extent than donepezil (see section 1.4 for further details 
about caproctamine and derivatives). 
Another interesting compound is AP2238 that was designed by combining in the same molecule two 
different moieties for an optimal interaction with both AChE sites (Figure 46). It showed the ability to 
counteract Aβ aggregation with a higher potency than other tested AChEIs168. 
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Figure 46. Design strategy leading to AP2238. 
 
 
Dual binding site AChEIs were designed by linking pharmacophoric groups of both AChE sites ligand 
with a polyamine chain as spacer. The structural motif of propidium was linked to the 
tetrahydroaminoacridine system of tacrine affording novel heterobivalent polyamine ligands (Figure 47). 
Heterodimerization resulted in a remarkable increase in AChE potency. Indeed, compound XIX was nearly 
20000-fold more potent than propidium and 300-fold more potent than tacrine in preventing the 
proaggregating effect of AChE toward Aβ169. 
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Figure 47. Design strategy leading to XIX. 
 
An improved AChE-induced Aβ aggregation inhibitory profile was shown by a series of heterodimers in 
which a 1,2,3,4-tetrahydroacridine moiety of tacrine was linked through a proper spacer to an indole ring 
suitable for PAS interaction (Figure 48). In particular, compounds XX and XI emerged as the most potent 
AChEIs of the series, displaying IC50 values of 20 and 60 pM, respectively and they are the most potent 
derivatives so far reported to inhibit the AChE-mediated Aβ aggregation170 . 
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Figure 48. Design strategy leading to dual binding site AChEIs. 
 
 
AChEIs Targeting Other Neurotransmitter Systems 
There is a well-documented link between neurotransmitter systems changes occurring in the brain of AD 
patients and clinically observed symptoms, such as cognitive decline and neuropsychiatric abnormalities. 
However, behavioural change is related not only with the severity of cholinergic loss but also to alterations 
in the serotoninergic and noradrenergic systems. 
Ladostigil is an important example of multimodal drug which combines in a single molecule the 
neuroprotective effects of a selective monoamine oxidase (MAO)-B inhibitor (rasagiline), with the AChE 
inhibitory activity of the anti-Alzheimer drug rivastigmine. Ladostigil is now finishing phase II clinical 
studies for the treatment of dementia with PD-like symptoms and depression171 . It was rationally designed 
by assuming that the ability to inhibit AChE activity might be conferred by the introduction of a carbamate 
moiety in the structure of rasagiline, which is a MAO-B inhibitor with in vitro and in vivo neuroprotective 
activity (Figure 49). MAO inhibition is an interesting property to be taken into account when designing 
MTDLs against AD. Indeed, MAOs during their catalytic activity of deamination of neurotransmitters 
(noradrenaline, dopamine, and serotonin), produces hydrogen peroxide, which represents a source of ROS 
for vulnerable neurons affected by AD172. 
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Figure 49. Drug design leading to Ladostigil. 
 
In addition to MAO inhibitors, depression in AD patients has been successfully treated with inhibitors of 
serotonin transporter (SERT), antidepressants that lack anticholinergic action. Thus, it was reasoned that 
combining SERT and AChE inhibitory activities could offer greater therapeutic benefits in AD. Successful 
design strategy was based on coupling rivastigmine (AChEI) and fluoxetine (SERT inhibitor), which were 
chosen as lead compounds to design AChE/SERT inhibitors (Figure 50)173. Compounds of the A series were 
designed by linking the methyleneoxyphenyl moiety of fluoxetine to the ethylamine function of 
rivastigmine174, whereas ring-closed compounds of the B series were designed to explore the effect of the 
conformational restriction175. Between the obtained compounds, (S)-RS-1259 exhibited potent inhibitory in 
vitro activities against AChE and SERT (IC50 values of 101 and 42 nM, respectively) and, following oral 
administration in mice, in the brain as well. 
 
 48 
ONMe
N
Me
Me
Me
O
Et
Rivastigmina
AChE IC50 0.92 µM
SERT > 1 µM
CF3
O
Ph
NHMe
Fluoxetine
AChE IC50 > 10 µM
SERT 0.18 µM
N
Me
R3
ONR1
R2
O
X
R4
m
 (S)-RS-1259
R1 = R2 = Me, R3 = H, R4 = 4-NO2, X = O, m = 1 (S configuration)
AChE IC50 101 nM
SERT IC50 42 nM
ONR1
R2
O
n
X
R4
R3
m
A
B
 
 
Figure 50. Drug design leading to dual inhibitors of AChE 
and SERT. 
 
 
Oxidative stress is recognized as a central feature of AD pathogenesis. Treatments that specifically target 
sources of ROS have, therefore, attracted particular attention. On this purpose, the structure of Lipoic acid 
(LA), an antioxidant, was combined with that of an inhibitor of the AChE catalytic site, such as tacrine; 
moreover, it has argued that the cyclic moiety of LA could interact with AChE PAS, which is associated 
with Aβ aggregation. Thus, this strategy allowed to combine the antioxidant properties of LA with the AChE 
inhibition ability of tacrine to improve cholinergic transmission, inhibit Aβ aggregation, and control 
oxidative damage176: this led to a new class of compounds whose prototype was Lipocrine (Figure 51).  
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Figure 51. Design strategy leading to Lipocrine. 
 
Lipocrine is a potent, mixed-type AChE inhibitor, exhibiting an IC50 value of 0.25 nM. It also inhibits 
AChE-induced Aβ aggregation with an IC50 at 45 µM and, as expected, the fragment of LA confers 
antioxidant properties, as revealed by the ability of 50 µM, to inhibit ROS formation in a cellular assay177. 
Dishomeostasis of cerebral metals in brain is another clear-cut factor contributing to the neuropathology 
of AD. On the basis of a novel “pharmacophore conjugation” concept, the bifunctional molecule XXII 
(Figure 52) has been reported as an innovative metal-complexing agent that specifically targets amyloid. 
XXII contains in its structure one metal-chelating and two amyloid-binding moieties and it reduced Zn2+-
induced Aβ precipitation and in vitro APP expression and attenuated cerebral Aβ amyloid pathology in 
PS1/APP transgenic mouse model178. 
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Figure 52. Structure of XXII. 
 
In 2007, Melchiorre and coworkers reported on a strategy to convert dual-binding AChEI, bis-(7)-tacrine, 
in triple function agents. The inner polymethylene spacer of bis-(7)-tacrine, a well known AChEI, has been 
replaced by the inner spacer characteristic of bw284c51 and ambenonium. These spacers have been choosing 
because they are endowed with carbonyl and oxamide functions characterized by metal-chelating properties. 
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Figure 53. Design strategy leading to bis-tacrine metal-chelating. 
 
Indeed, the designed compounds, beyond their biological properties mediate by AChE-inhibition, have 
additional properties by acting as metal-chelators179. 
A very promising MTDL developed in the Melchiorre’s group is Memoquin. It derives from the 
incorporation of the benzoquinone fragment of coenzyme Q10 into the flexible chain of caproctamine 
(Figure 54). The selection of this moiety was based on the finding that coenzyme Q10 has been reported to 
have two different beneficial actions against AD. Not only coenzyme Q10 scavenges ROS, but it might also 
directly inhibit the deposition of Aβ in the brain180.  
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Figure 54. Drug design for Memoquin. 
 
The biological profile of Memoquin was then widely explored by means of both in vitro and in vivo 
assays to assess its therapeutic potential as MTDL for combating AD. The antioxidant activity of Memoquin 
was confirmed by its in vitro ability to neutralize radicals and to act as a substrate for the NADPH quinone 
oxidoreductase 1 (NQO1), an enzyme responsible for the in vivo transformation of Memoquin into the more 
antioxidant hydroquinone form. Memoquin maintained a nanomolar inhibitory potency against human 
 51 
AChE, and it was able to inhibit the AChE-induced Aβ aggregation, inhibited self-assembly of Aβ. 
Moreover, the antiamyloidogenic profile of Memoquin was also investigated by testing its ability to act as an 
inhibitor of BACE-1. The compound was found to have an IC50 value of 108 ±23 nM. In addition, 
Memoquin has been tested in vivo in an AD 11 transgenic mouse model: it was able to ameliorate the 
cholinergic and cognitive impairment, and to reduce Aβ deposition and τ hyperphosphorylation at three 
different stages of neurodegeneration (2, 6, and 15 months of age). Moreover, Memoquin showed other 
promising properties, such as good oral bioavailability, efficacy in crossing the blood-brain barrier, and a 
favourable safety profile in preclinical non-regulatory acute and chronic toxicology studies181,182. 
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1.1.4 Caproctamine and derivatives 
 
In 1998, Melchiorre and coworkers published a study aimed to produce novel ligands based on a 
polyamine backbone having affinity for both AChE active and PAS sites and for M2 AChR receptor, as well, 
useful for the treatment of AD169. 
This study started from the observation that Benextramine183, a tetraamine disulfide developed as an 
irreversible α-adrenoreceptor antagonist, displayed also a significant affinity for cardiac muscarinic M2 
receptor and potentiate the effect of ACh on the frog rectus muscle, as well. 
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Structure-Activity Relationships studies on Benextramine have been performed by studying the effect of 
the disulfide bridge, the distance between the two nitrogen atoms and the conversion of the secondary central 
amines into amide functions.  
 
Table 1. Biological activities of compounds XIII-XXX. 
 
R1 N
N
Y
N
R2 X
R3
N
R1
R3
X R2
XXIII-XXX
 
 
      pIC50 pA2 
no R1 R2 R3 X Y AChE BChE M1 M2 M3 
Benextramine 2-MeOC6H5CH2 H H H2 S-S 5.14 5.21 nd nd nd 
XXIII H H H H2 S-S 3.30 3.19 nd nd nd 
XXIV 2-MeOC6H5CH2 H H H2 CH2 5.14 5.06 nd 6.67 5.89 
XXV 2-MeOC6H5CH2 H H H2 (CH2)2 5.19 5.86 nd 6.98 5.76 
XXVI 2-MeOC6H5CH2 H H H2 (CH2)3 5.35 5.43 nd 7.64 5.92 
XXVII 2-MeOC6H5CH2 H H H2 (CH2)4 5.27 6.01 6.85 7.92 6.06 
XXVIII 2-MeOC6H5CH2 H H O (CH2)4 5.73 4.94 nd 6.30 5.35 
XXIX 2-MeOC6H5CH2 H Me O (CH2)4 6.51 5.22 nd 6.67 5.21 
XXX 2-MeOC6H5CH2 Me Me O (CH2)4 6.77 4.93 5.66 6.39 5.55 
tacrine      6.66 6.44 nd nd nd 
 
 
All the polyamines designed were effective inhibitors of AChE and BChE with the exception of XXIII 
suggesting that the 2-methoxybenzyl group on the terminal nitrogen of benextramine contribute significantly 
to the binding with the enzyme. Replacement of the disulfide bridge of benextramine with two methylene 
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units led to XXV that was more potent than benextramine in inhibiting both enzymes. Chain length 
modification between the two inner nitrogen of XXV, affording XXIV-XXVII, did not affect significantly 
the affinity for AChE. Transforming the inner amine functions of XXVII (methoctramine) into amide groups 
affording XXVIII resulted in a reduced affinity for M1 and M3 muscarinic receptors and an increase potency 
as AChEI. Furthermore, N-methylation of XXVIII, affording XXIX and XXX (caproctamine) resulted in a 
further increase in affinity for AChE. Caproctamine resulted 42-fold more potent at AChE than benextramine 
and a weak antagonist at both M1 and M3 receptors while displaying an affinity towards muscarinic M2 
receptor similar to the affinity for AChE. 
Caproctamine is a mixed type inhibitor able to inhibit both sites of AChE. Docking studies showed that 
caproctamine was able to simultaneously contact both sites and to establish favourable interactions with a 
number of residues in the gorge. At one end of the molecule, the 2-methoxybenzylamine moiety can interact 
with a set of residues near Trp84, while, at the opposite end, the second 2-methoxybenzylamine group can 
reach the peripheral binding site that was postulated to correspond to Trp279167. 
SAR studies on caproctamine structure were performed in order to determine the effect of different 
substituents on the phenyl rings and the N-substituents on the four nitrogen atoms of XXX: 
• the 2-methoxy groups have been replaced with several other groups in order to determine the 
influence of the steric and the electronic effects on AChE inhibition. Their replacement with 
halogen atoms, such chlorine (XXI) or bromine (XXXII), do not increase the affinity towards 
AChE suggesting that variations of electronic density on the aromatic rings are not important in 
the interaction with AChE. In order to determine the possibility of establish H-bond with the 
enzyme, the methoxy group has been shifted from 2- position to 3- and 4- position leading to 
derivative XXXIII, XXXIV respectively. Compound XXXV, without any substituent on the 
phenyl ring is slightly more active than XXXIII and XXXIV.  
• in order to investigate the role of the methyl substituents on the two basic functions, they were 
substituted with ethyl groups obtaining an ethyl series of derivatives (XXXVII-XLI) in which the 
most potent resulted XLI. The relative free base XL was chosen as lead compound thanks to its 
better pharmacokinetic profile. 
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Table 2. Biological activities of compounds XXXI-XL. 
 
             
N
N
N
R1
R2 O
R
R
O
N
R1
R2
X
X
XXX-LX
 
 
 
No. 
 
 
R 
 
R1 
 
R2 
 
X 
 
pIC50 AChE 
caproctamine Me Me H 2-OMe 6.77 
XXXI Me Me H 2-Cl 6.68 
XXXII Me Me H 2-Br 6.57 
XXXIII Me Me H 3-OMe 6.30 
XXXIV Me Me H 4-OMe 5.34 
XXXV Me Me H H 6.97 
XXXVI H Me H 2-OMe 6.06 
XXXVII H Et H 2-OMe 6.66 
XXXVIII Me Et H H 7.15 
XXXIX Me Et Me H 7.77 
XL Me Et H 2-OMe 7.73 
XLI Me Et Me 2-OMe 7.92 
 
 
Further optimization studies were performed on XL by replacing the amide groups by an oxygen atom, 
leading to XLII and XLIII that were less potent toward AChE. Furthermore, the replacement of the ethyl 
group on the two basic amine nitrogen atoms with an i-propyl residue did not affect the AChE inhibition 
activity (XLIV).  
Finally, to verify whether the 2-methoxy functions of XL have a role in the interaction with the enzyme, 
they were replaced by selected groups that have different values of π and σ parameters based on the 
liphophilic (π) and electronic (σ) characteristic of the substituent, respectively. Once again the most potent 
compound resulted XL, indicating the important role of the two aromatic substituents to improve the basicity 
of the two amide functions. This property allows the protonation of the two basic functions at physiological 
pH, for an optimal interaction with AChE, as confirmed by a directed correlation between AChE inhibiting 
activity and the pKa of different substituted compounds. The better substituent was found to be 2-methoxy, 
probably because it increases the percentage of protonate amine at physiologically pH by increasing the 
basicity of nitrogen through mesomeric and inductive effects. Indeed, a direct correlation between pKa and 
AChE-inhibitory activity has been found for compounds XLV-LI184. 
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Table 3. Biological activities of compounds XLII-LVIII. 
 
X
O
OMe 2
X
N
R1
O
R2
2
LII-XLIII XLIV-LVIII
 
 
 
 
no 
 
 
R1 
 
 
X 
 
 
R2 
 
 
pIC50 
AChE 
 
pIC50 
BChE 
 
AChE/BChE 
 
caproctamine 2-OMe NMe Me 6.77 4.93 68 
XL (1) 2-OMe NEt Me 7.73 5.65 121 
XLII  NEt  6.69 5.58 13 
XLIII  N+(Me)Et  7.11 6.12 10 
XLIV 2-OMe NEt iPr 7.74 5.67 118 
XLV H NEt Me 7.31 5.97 21 
XLVI 2-Cl NEt Me 6.95 5.39 37 
XLVII 2-CF3 NEt Me 5.34 3.78 36 
XLVIII 2-OnPr NEt Me 7.47 6.78 5 
XLIX 2-Me NEt Me 7.25 5.13 132 
L 2-NO2 NEt Me 6.10 4.26 69 
LI H N+(Me)Et Me 7.43 5.60 69 
LII 2-Cl N+(Me)Et Me 7.71 5.59 133 
LIII 2- CF3 N+(Me)Et Me 7.93 5.12 640 
LIV 2-OMe N+(Me)Et Me 7.92 5.85 118 
LV 2-OnPr N+(Me)Et Me 7.76 7.08 5 
LVI 2-Me N+(Me)Et Me 7.78 5.19 388 
LVII 2-NO2 N+(Me)Et Me 7.91 5.62 196 
LVIII 2-OMe N+(Me)Et iPr 8.09 5.78 204 
 
 
 
A previous docking study carried out on the diprotonated form of caproctamine revealed that it is able to 
interact simultaneously with both active and peripheral sites of AChE and to establish favourable interactions 
with a number of residues in the gorge thanks to the flexibility of the molecule, which allows it to assume 
many conformations. To reduce the conformational freedom of the polymethylene chain of polyamines, a 
series of compounds have been designed in which the inner octamethylene chain of XL is incorporated 
partially or totally into a more constrained moiety as shown in Figure 55.  
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Figure 55. Design strategy leading to less flexible derivatives of XL. 
 
 
These structural modifications would afford compounds in which the inner diamide moiety is forced to 
assume a more definite arrangement that would allow the two basic terminal chains to orient themselves in 
different spatial regions relative to each other. Therefore, the highly flexible polymethylene chain connecting 
the two amide functions of XL was replaced by the less flexible dipiperidine or dianiline moieties, affording 
LIX-LXII or LXIII-LXV, respectively. 
 
Table 4. Biological activities of compounds LIX-LXV. 
 
 
OMe
N
N
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(CH2)n
OMe
N
H
N
Et O
(CH2)n
LIX-LXII LXIII-LXV
 
 
 
no 
 
n 
 
pIC50 
AChE 
 
pIC50 
BuChE 
 
% inhibition  
Aβ (AChE) 
caproctamine  6.77 4.93 <5 
LX  7.73 5.65 <5 
LIX (2) 0 8.48 5.07 41 
LX 1 8.48 5.19 nd 
LXI 2 8.13 5.44 15 
LXII 3 8.18 5.47 nd 
LXIII 0 7.55 5.73 35 
LXIV 1 7.20 5.74 nd 
LXV 2 6.77 5.77 nd 
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Replacements of the octamethylene inner spacer of caproctamine with bicyclic moieties lead to an 
increase of activity towards AChE. In particular, the most active compounds were the dipiperidino 
derivatives LIX and LX and the dianiline derivative LXIII. All the new compounds designed inhibited both 
catalytic and peripheral binding sites, but only the less flexible LIX and LXIII were able to inhibit AChE-
induced Aβ-aggregation. In addition, LXI also inhibited the self-induced Aβ-aggregation185. 
Caproctamine is able to interact with PAS but it does not inhibit AChE-induces Aβ-aggregation. 
Therefore, the authors hypothesized that the inhibition of PAS is not sufficient condition to inhibit AChE-
induced Aβ-aggregation and the insertion of less flexible moieties in the structure of caproctamine is 
required to gain the ability to inhibit Aβ-aggregation induced by AChE.  
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1.2 Drug Design 
 
The “one-molecule-multiple-targets” paradigm suggests that a single molecule could hit several targets 
responsible for the onset and/or progression of AD7,186. To this end, the design and synthesis of several 
examples of MTDLs for combating neurodegenerative diseases have been published187. This seems to be the 
more appropriate approach for addressing the complexity of AD and may provide new drugs for tackling the 
multifactorial nature of AD, and hopefully stopping its progression. 
In 1998, Melchiorre and coworkers reported on derivatives displaying affinity for (i) AChE active and 
peripheral binding sites and (ii) muscarinic M2 receptors. The prototypes caproctamine and its ethyl analogue 
(1) directly derived from methoctramine, an irreversible muscarinic M2 antagonist. The methoctramine-
structure was modified in order to improve its lipophilicity, by replacing the two inner amine functions with 
amide groups and by introducing a methyl substituent on the four nitrogen atoms. These studies led to the 
discovery of caproctamine, a new lead in the research of MTDLs because endowed with the ability to inhibit 
AChE and M2 muscarinic subtype receptors, in order to improve the release of ACh in the synaptic cleft by 
blocking the presynaptic M2 muscarinic receptor respectively167. Further studies carried out on caproctamine 
demonstrated that the AChE inhibitory potency was enhanced by the replacement of the methyl groups 
located on the two side nitrogen atoms with two ethylene groups leading to 1. In the same study, was also 
demonstrated that a 2-methoxy group on the two phenyl rings of 1 conferred the highest AChE inhibition 
potency by improving the basicity of the two basic nitrogen atoms184,188.  
Because AChE may act as a chaperone in inducing Aβ aggregation through the interaction of its 
peripheral anionic site (PAS) with the peptide, the inhibition of PAS might be relevant to the search for 
AChEIs endowed with Aβ antiaggregating properties189. Although caproctamine and 1 contacted PAS and 
active AChE binding sites, they did not inhibit the AChE-induced Aβ aggregation. To verify whether this 
failure was due to their high structural flexibility, their inner octamethylene spacer was partially or totally 
incorporated into a more constrained moiety. This led to the discovery of the dipiperidino derivative 2, which 
displayed improved AChE inhibitory potency and the ability to partially inhibit AChE-induced Aβ 
aggregation, suggesting that inhibition of Aβ aggregation is achieved by polyamines incorporating a 
constrained spacer between the two inner nitrogen atoms rather than a flexible polymethylene chain185. It is 
known that aromatic residues may give additional interactions with the aromatic rings lined in AChE 
gorge190 and may confer β-sheet-breaking properties that might lead to the inhibition of self-mediated Aβ 
aggregation191. Thus, to obtain new AChE-inhibiting MTDLs endowed with additional properties such as 
inhibition of AChE-induced Aβ aggregation and β-sheet-breaking ability192, the dipiperidino moiety of 3 has 
been replaced with less flexible cyclic systems, leading to 3-15 (Figure 56). Monoamine 15 was included in 
this study to verify the importance, if any, of the two aminoalkyl side chains in the interaction with AChE 
and Aβ. 
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Figure 56. Drug design leading to compounds 3-15. 
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1.3 Methods 
 
1.3.1 Synthesis 
Diamine diamides 34-38 were obtained by reacting N-[(benzyloxy)carbonyl]-6-aminocaproic acid with 
piperazine, cis-cyclohexane-1,2-diamine, (±)-trans-cyclohexane-1,2-diamine, trans-cyclohexane-1,4-
diamine, and ethane-1,2-diamine, respectively. Removal of the N-(benzyloxy)carbonyl group by acidic 
hydrolysis gave diamine diamides 39-43, which were treated with 2-methoxybenzaldehyde followed by 
reduction with NaBH4 of the formed Schiff base to the corresponding dibenzyl derivatives 44-48. 
Diethylation of 44-48 with diethyl sulphate gave 3-6 and 49 (Figure 56). Reduction of 49 afforded 50, which 
was condensed with diethyloxalate to give 8 (Scheme 1). 
Acylation of 1,2,3,6,7,8-hexahydrobenzo[lmn][3,8]phenanthroline193 with 6-bromohexanoyl chloride gave 
51, whereas N-alkylation of piperazine-2,5-dione, 1,4-dihydroquinoxaline-2,3-dione, and imidazolidin-2-one 
with the appropriate dibromoderivative afforded intemediates 52-54, which were diaminated with ethyl-(2-
methoxybenzyl)amine to give 7, 9-11, respectively (Scheme 2). 
Finally, 12-15 were obtained through the condensation of the commercially available anhydrides 
[5,5′]biisobenzofuranyl-1,3,1′,3′-tetraone, benzo[1,2-c;4,5-c′]difuran-1,3,5,7-tetraone, isochromeno[6,5,4-
def]isochromene-1,3,6,8-tetraone,benzo[de]isochromene-1,3-dione, respectively, with N-ethyl-N-(2-
methoxybenzyl)hexane-1,6-diamine181 (Scheme 3). Different salts (dioxalates for 2-9, 11, and 14 and di-para 
toluenesulfonates for 11, 12, 13 and 15) were prepared to obtain derivatives easier to handle. 
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                                                      Scheme 1 
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Conditions: Cbz = C6H5CH2OCO-; (i) Et3N, EtOCOCl, dioxane, room temp, 72 h; (ii) 30% HBr 
in CH3COOH, CH3COOH, room temp, 4 h; (iii) (a) 2-MeOC6H4CHO, toluene, reflux, 6 h; (b) 
NaBH4, EtOH, room temp, 6 h; (iv) (EtO)2SO2, toluene, reflux, 48 h; (v) a) 
borane-N-ethyl-N-isopropylaniline complex, diglyme, reflux, 4 h; (b) 6 N HCl, reflux, 1 h; (vi) 
diethyloxalate, EtOH, reflux, 12 h.
A = B = C = D =
(Figure 
56)
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Scheme 2 
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Conditions: (i) Et3N, CH2Cl2, room temp, 96 h; (ii) 60% NaH, anhydrous DMF,                     
piperazine-2,5-dione or 1,4-dihydroquinoxaline-2,3-dione or imidazolidin-2-one, room 
temp for 36 and 51 and reflux for 52, 24 h; (iii) for 9 and 10, KI, K2CO3, 1-pentanol, 
reflux, 40 h; for 7 and 11, CH3CN and Et3N, reflux, 64 h.
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Scheme 3 
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1.3.2 Biology 
To determine the potential interest of compounds 3-15 for the treatment of AD, their inhibitory potency 
against recombinant human AChE and BChE was evaluated by studying the hydrolysis of acetylthiocholine 
(ATCh) following the method of Ellman et al. The inhibitory potency was expressed as IC50 values, which 
represent the concentration of inhibitor required to decrease enzyme activity by 50%. To allow comparison 
of the results, caproctamine 1, 2, donepezil, galantamine, and donepezil were used as the reference 
compounds. The nature of AChE inhibition caused by these compounds was investigated by the comparison 
of the graphical analysis of steady-state human AChE inhibition data of the most potent compound of this 
series (14).  
The ability of such compounds to inhibit both self-induced and AChE-induced Aβ-aggregation was 
assessed by purposely optimized Thioflavin T-based fluorimetric assay194,195. 
The ability of some compounds to inhibit BACE-1 was assesses through  FRET-assay112. 
 
1.3.3. Computational studies 
To disclose a possible binding mode of 14 at the AChE, BChE, and BACE-1 binding pockets, docking 
simulations were performed using the available crystallographic structures of the three enzymes (PDB codes 
1B41 for AChE196, 1P0M for BChE197, and 1FKN for BACE-153. Furthermore, calculation of electrostatic 
potential maps for compounds 8 and 14 have been performed198. 
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1.4 Results and Discussion 
 
To determine the potential interest of 3-15 for AD treatment, their inhibitory potency was evaluated on 
recombinant human AChE and isolated BChE from human serum in comparison with caproctamine, 1-2 and 
the marketed drugs donepezil and galantamine. 
An analysis of the results (Table 5) reveals that replacement of the dipiperidino moiety of 2 with 
constrained moieties strongly influenced the ability to inhibit AChE and BChE. The new derivatives 
inhibited AChE activity in the nanomolar range with the exception of 4-6. The low affinity of 4-6 for AChE 
might be due to the difficulty of the two amide functions to assume a planar arrangement to each other, as is 
probably possible for 3, 8, 9, and 11, which were only slightly less potent than 1. The most potent 
compounds of the present series (7, 10, 12-14) were characterized by an aromatic residue in the middle of 
their structure. This suggests the possibility of establishing more π-π interactions with several aromatic 
residues located in the AChE gorge. In particular, 14, endowed with a 1,4,5,8-naphthalenetetracarboxylic 
diimide (NTD) moiety, showed a very high AChE inhibitory activity and a 9-fold improvement in potency in 
comparison with 2. All the synthesized compounds showed a selective inhibitory activity for AChE relative 
to BChE, and 14 was the most selective and potent of the series with an AChE/BChE selectivity ratio greater 
than 5000, perhaps relevant when considering the emerging role of BChE in AD199 and the importance of 
selectivity toward AChE in AD treatment200. Finally, 15, characterized by only one side chain, was 144-fold 
less potent than 14, highlighting the importance of the presence of two side chains for an optimal interaction 
with both sites of AChE. 
PAS is well-established as important for β-fibrils formation mediated by AChE189,201; thus, compounds 
able to interact with amino acids located in the PAS area may reduce the formation of neurotoxic Aβ fibrils. 
PAS may thus be an attractive target when developing potential AD-modifying drugs. A Lineweaver-Burk 
plot obtained at increasing concentrations of substrate and inhibitor showed that 14 interacted with the 
catalytic site and PAS (Figure 57). Therefore, the ability of 3 and 6-15 to inhibit AChE-induced Aβ (1-40) 
aggregation was assessed through a thioflavin T-based fluorometric assay188. 4 and 5 were not evaluated 
because of their poor AChE inhibitory activity. 3, 7, and 8 were as active as 2 (Table 5), while 9-14 were 
more potent than 2. It appears that an inner spacer bearing aromatic residues may be optimal for inhibiting 
AChE-induced Aβ aggregation. 
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Table 5. Inhibition of AChE and BChE Activities and of AChE-Mediated and Self-Induced Aβ 
Aggregation by 3-15 and Reference Polyamines 1-2 
 
 
IC50 (nM)b 
 
Inhibition of Aβ aggregation (%) 
 
Compounda 
AChE BChE AChE-inducedc self-inducedd 
 
AChE/BChEm 
 
caproctaminee 
 
170 ± 2e 
 
11600 ± 300e 
 
<5f 
 
20.3 ± 1.9 
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1 (XL) 16.1 ± 0.5e 2250 ± 60e <5 ndh 138 
2 (LIX) 3.32 ± 0.12g 8490 ± 610g 41.2 ± 2.0 13.7 ± 6 2570 
3 25.7 ± 1.9 10700 ± 1900 38.9 ± 4.0 <5f 417 
4 4160 ± 200 30800 ± 2300 ndh ndh 7.0 
5 5470 ± 240 36800 ± 3300 ndh ndh 6.7 
6 8550 ± 40 25300 ± 4200 25.6 ± 4.6 ndh 3 
7 4.83 ± 0.16 1040 ± 30 42.1 ± 2.2 12.7 ± 2.9 219 
8 68.9 ± 2.4 10300 ± 400 47.5 ± 1.6 ndh 148 
9 15.9 ± 0.6 2090 ± 130 61.4 ± 4.4 4.8 ± 1.3 132 
10 1.41 ± 0.03 95.8 ± 1.5 70.8 ± 3.2 8.8 ± 2.9 68 
11 72.4 ± 3.2 876 ± 24 53.8 ± 3.7 <5 12 
12 14.0 ± 0.6 293 ± 23 70.2 ± 4.83 16.5 ± 1.3 21 
13 7.70 ± 0.27 3000 ± 200 51.1 ± 0.3 <5 389 
14 0.37 ± 0.02 1910 ± 120 >90i 54.5 ± 5.4j 5129 
15 53.5 ± 5.7 416 ± 32 19.5 ± 2.8 <5 8 
donepezil 23.1 ± 4.8 7420 ± 390 22k <5  
galantamine 2010 ± 150l 20700 ± 1500l 17.9 ± 0.1l <5  
propidium 32300l 13200l 82.0 ± 2.5k 61.1 ± 4.6l  
Congo Red ndh ndh ndh 78.8 ± 0.9  
a
 1, dihydrochloride; 1-9, 11, and 14, dioxalate; 10, 12, 13, di-para toluenesulfonate; 15, para-
toluenesulfonate. See Figure 56 for structures. b Human recombinant AChE and BChE from human 
serum were used. IC50 values represent the concentration of inhibitor required to decrease enzyme 
activity by 50% and are the mean of two independent measurements, each performed in triplicate. c 
Inhibition of AChE-induced Aβ (1-40) aggregation. The concentrations of the tested inhibitor and 
Aβ (1-40) were 100 and 230 µM, respectively, whereas the Aβ (1-40)/AChE ratio was equal to 
100:1. d Inhibition of self-induced Aβ (1-42) aggregation (50 µM) produced by the tested compound 
at 10 µM concentration. e Data from ref 167. f Not significant. g Data from ref 168. h nd, not 
determined. i IC50 = 8.13 ± 0.97µM. j IC50 = 9.69 ± 1.09 µM. k Data from ref 189. l Data from ref 
196.m  The AChE/BChE selectivity ratio is the antilog of difference between pIC50 values at AChE 
and BChE. 
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14 was the most potent inhibitor with an IC50 lower than that of the reference compound propidium189. 
Notably, neither 2 nor any of the marketed AChE inhibitors, when tested in the same conditions, showed 
comparable antiaggregating activity189,202. The most potent published compounds acting as AChE-induced 
Aβ aggregation inhibitors display a potency in the same range as 14170,169,203. The low inhibitory activity 
shown by 14 emphasizes the importance of the two aminoalkyl side chains for an optimal interaction with 
the two AChE binding sites.  
 
 
Figure 57. Steady-state inhibition by 14 of AChE hydrolysis of 
acetylthiocholine. Lineweaver-Burk reciprocal plots of initial velocity and 
substrate concentrations are presented. Reciprocal plots of initial velocity in 
the absence of inhibitor gave an estimate kapp for acetylthiocholine of 170 ± 
15 µM (four experiments). Lines were derived from a weighted least-
squares analysis of the data points. 
 
Since it was previously reported that compounds endowed with a polyamine scaffold may interfere with 
Aβ polymerization and aggregation204, the ability of 3, 7, 9, 10, 12, 14 to inhibit self-promoted Aβ (1-42) 
aggregation was also determined (Table 5)189. Again, 14, although less potent that the reference compound 
Congo red, displayed an IC50 comparable with that of propidium. This activity might be due to the ability of 
14 to behave as a β-sheet breaker because of its planar and constrained aromatic system201. Unfortunately, 
because of its low solubility, the contribution, if any, of the NTD moiety benzo[lmn][3,8]phenanthroline-
1,3,6,8-tetraone193 and, consequently, its possible contribution to the different biological properties of 14 
could not be determined. 
Moreover the ability of some compounds to inhibiting BACE1 was also investigated. The founded value 
for 14 was 392 ± 31 nM, whereas the most known BACE inhibitors, based on peptide structure, showed 
higher potency in the same range205. The other compounds tested, 3, 7, 9, showed inhibition values in 
micromolar range (3, 6% inhibition at 500 nM, 7, 8% inhibition at 500 nM and 9, 16% inhibition at 500 nM). 
To disclose a possible binding mode of 14 at AChE and BChE binding pockets, docking simulations were 
performed using the available crystallographic structures of the two enzymes (PDB codes: 1B41 for 
AChE196, 1P0M for BChE197). Because of 14’s flexibility, several docking runs were carried out with 
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GOLD206. The outcomes were clusterized by AClAP207. In Figure 58 a low energy pose representative of a 
statistically populated cluster is reported for binary complexes of AChE and 14 (Figure 58A) and of BChE 
and 14 (Figure 58B). The binding mode of 14 at the AChE gorge shows that the ligand can interact with 
Trp86 of the internal anionic site and with Trp286 of PAS. The latter could explain 14’s ability to inhibit 
AChE-induced Aβ aggregation. 14 might also interact with several aromatic residues of the enzyme mid-
gorge208. In particular, the NTD moiety could establish favourable π-π stacking or simple hydrophobic 
interactions with Tyr341, Phe338, and Phe295. 
 
 
Figure 58. Docking model of 14 at the binding sites of AChE (A), and BChE 
(B). The residues relevant for the interaction between 15 and the biological 
counterparts are reported. 
 
Moreover, Tyr72 may interact by H-bonding with the methoxy substituent of one of the 
benzylammonium ends. This could account for the high inhibitory potency of 14 against human AChE. 
Conversely, although 14 could favourably interact with several BChE amino acids (Figure 58A), the lack of 
the same pool of aromatic residues at the BChE mid-gorge may explain 14’s AChE/BChE selectivity. 
Indeed, besides a cation-π interaction between 14 and the Trp82 indole ring of BChE, the only other striking 
interaction was between 14 and Tyr332. Moreover, 14 seemed unable to interact with Phe278, a fundamental 
residue for inhibiting BChE activity208. The presence of BChE Asp70 close to one of the two imide moieties 
of the NTD scaffold may further decrease the molecule’s affinity toward this target. 
To identify a possible binding mode of 14 in BACE-1 docking simulation were performed (Figure 59). It 
can be seen that 14 was actually able to interact with Asp32, one of the aspartic acids of the catalytic dyad of 
the enzyme. In particular one carbonyl oxygen of 14 could accept a proton H-bond interaction with the 
residue. Moreover the naphtalentetracarboxylic diimide moiety could establish H-bond interaction with 
Thr231 and Thr72 side chains. Finally the benzylamonium groups could interact with Phe47 and Tyr198. 
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Figure 59. Docking model of 14 at the binding sites of 
BACE-1. The residues relevant for the interaction between 14 
and the biological counterparts are reported. 
 
 
Furthermore, electrostatic potential study has been carried out on 14 and 7 in order to explain their 
different inhibitory activity on BACE-1198(Figure 60). It has been observed a different charge density in the 
two aromatic moieties, in particular the naphtalentetracarboxylic diimide moiety seemed to present a more 
positive charge density thanks to the presence of the four carbolyl groups which exerted an inductive 
electron withdrawing effect. This different potential charge could facilitate the interaction between the 
negative charged aspartic residue of BACE-1 and 14. The same did not happen for 7 which is characterized 
by a more negative charge density. Finally, the higher inhibition potency of 14 in comparison with 7 might 
be due by the complete planar disposition of the central nucleus which could better fit in the enzyme cavity. 
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                                       Figure 60. Electrostatic potential study carried out on 14 and 7. 
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1.5 Conclusion 
 
In this work it has been demonstrated that constraining the dipiperidino moiety of 2 led to derivatives 
with a better biological profile. The most potent was 14, endowed with an NTD moiety. It inhibited AChE in 
the subnanomolar range, AChE induced and self-promoted Aβ-aggregation in micromolar concentration and 
BACE1 in nanomolar concentration. Thus, 14 emerges as an MTDL able to hit several targets of the AD 
pathogenesis cascade. 
However, the rational design of compounds that simultaneously modulate different protein targets at a 
comparable concentration for each target remains a challenging task. In the present case, proof of the concept 
of the biological profile of 14 in vivo is needed to confirm the relevance of the NTD moiety in the design of 
new derivatives for AD treatment. 
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1.6 Experimental section 
 
1.6.1 Chemistry  
Melting points were taken in glass capillary tubes on a Buchi SMP-20 apparatus and are uncorrected. 
ESI-MS spectra were recorded on Perkin-Elmer 297 and WatersZQ 4000. 1H NMR and 13C NMR were 
recorded on Varian VRX 200 and 300 instruments. Chemical shift are reported in parts per millions (ppm) 
relative to peak of tetrmethylsilane (TMS) and spin multiplicities are given as s (singlet), br s (broad singlet), 
d (doublet), t (triplet), q (quartet) or m (multiplet) Although IR spectral data are not included (because of the 
lack of unusual features), they were obtained for all compounds reported, and they were consistent with the 
assigned structures. The elemental compositions of the compounds agreed to within ±0.4% of the calculated 
value. Where the elemental analysis is not included, crude compounds were used in the next step without 
further purification. Chromatographic separations were performed on silica gel columns by flash (Kieselgel 
40, 0.040-0.063 mm, Merck) or gravity (Kieselgel 60, 0.063-0.200 mm, Merck) column chromatography. 
Reactions were followed by thin layer chromatography (TLC) on Merck (0.25 mm) glass-packed precoated 
silica gel plates (60 F254) and then visualized in an iodine chamber or with a UV lamp.The term “dried” 
refers to the use of anhydrous sodium sulfate. 
 
General Procedure for the Synthesis of 34-38. Ethyl chloroformate (0.95 mL, 10 mmol) in dry dioxane 
(20 mL) was added dropwise to a stirred and cooled (5 °C) solution of N-[(benzyloxy)carbonyl]-6-
aminocaproic acid (2.65 g, 10 mmol) and Et3N (1.4 mL, 10 mmol) in dioxane (30 mL), followed after 
standing for 30 min by the addition of the suitable diamine (5 mmol) in dioxane (20 mL). After the mixture 
was stirred at room temperature for 72 h, the solvent was evaporated, affording a residue that was suspended 
in water (100 mL). The solid residue was filtered off and washed with 2 N NaOH, 2 N HCl, and brine, to 
afforded the desired crude products 34-38. 
{6-[4-(6-Benzyloxycarbonylamin-hexanoyl)piperazin-1-yl]-6-oxohexyl}carbamic acid benzyl ester (34): 
from anhydrous piperazine as starting diamine; pink solid; 93% yield; mp 123-125 °C; 1H NMR (200 MHz, 
CDCl3) δ 1.24-1.79 (m, 10H + 2H exchangeable with D2O), 2.34 (t, J= 6.0, 4H), 3.14-3.28 (q, J = 9.0, 4H), 
3.39-3.54 (m, 4H), 3.64-3.76 (m, 4H), 4.64-4.74 (br s, 2H), 5.10 (s, 4H), 7.29-7.42 (m, 10H). 
cis-{5-[2-(6-Benzyloxycarbonylamino-hexanoylamino)-cyclohexylcarbamoyl]-pentyl}carbamic acid 
benzyl ester (35): from cis-cyclohexane-1,2-diamine as starting diamine; whitesolid; 49% yield; mp 103-105 
°C; 1H NMR (200 MHz, CDCl3) δ 1.22-1.73 (m, 20H), 1.85 (br s, exchangeable with D2O, 2H), 2.19 (t, J = 
6.0, 4H), 3.18 (q, J = 4.0, 4H), 4.08 (br s, exchangeable with D2O, 2H), 4.96 (br s, 2H), 5.20 (s, 4H), 7.22-
7.38 (m, 10H). 
(±)-trans-{5-[2-(6-Benzyloxycarbonylaminohexanoylamino)cyclohexylcarbamoyl]pentyl}carbamic acid 
benzyl ester (36): from (±)-trans-cyclohexane-1,2-diamine as starting diamine; white solid; 60% yield; mp 
112-115 °C; 1H NMR (200 MHz, CDCl3) δ 1.16-1.90 (m, 20H), 1.97-2.20 (m, 4H + 2H exchangeable with 
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D2O), 3.16 (q, J = 6.0, 4H), 3.60-3.78 (m, 2H), 5.18 (s, 4H), 5.88-5.95 (m, exchangeable with D2O, 2H), 
7.29-7.42 (m, 10H). 
trans-{5-[4-(6-Benzyloxycarbonylaminohexanoylamino)cyclohexylcarbamoyl]pentyl}-carbamic acid 
benzyl ester (37): from trans-cyclohexane-1,4-diamine as starting diamine; red solid; 89% yield; mp 123-
125 °C; 1H NMR (300 MHz, DMSO) δ 1.12-1.52 (m, 16H + 2H, exchangeable with D2O), 1.63-1.82 (m, 
4H), 2.03 (t, J = 6.0, 4H), 2.98 (q, J = 4.0, 4H), 3.45 (br s,2H), 3.88 (br s, exchangeable with D2O, 1H), 4.52 
(br s, exchangeable with D2O, 1H), 5.03 (s, 4H), 7.25-7.43 (m, 10H); MS (ESI+) m/z = 631 (M+Na)+. 
{5-[2-(6-Benzyloxycarbonylaminohexanoylamino)ethylcarbamoyl]pentyl}carbamic acid benzyl ester 
(38): from ethane-1,2-diamine as starting diamine; white solid; 64% yield; mp 172-174 °C; 1H NMR (200 
MHz, DMSO) δ 1.10-1.62 (m, 12H + 2H exchangeable with D2O), 2.15-2.19 (t, J = 6.0, 4H), 2.89-3.15 (m, 
8H), 5.02 (s, 4H), 7.17.7.42 (m, 10H), 7.76-7.84 (br s, exchangeable with D2O, 2H). 
 
General Procedure for the Synthesis of 39-43. A solution of 30% HBr in acetic acid (25 mL) was added 
to a solution of 34-38 (3.1 mmol) in acetic acid, and the resulting mixture was stirred for 4 h at room 
temperature. Ether (100 mL) was then added, yielding a solid, which was washed with ether (3 x 20 mL) and 
dissolved in water (50 mL). The solution was made basic with KOH pellets and extracted with CH2Cl2 (3 x 
30 mL). Removal of the dried solvent gave compounds 39-43 in quantitative yields. 
6-Amino-1-[4-(6-aminohexanoyl)piperazin-1-yl]hexan-1-one (39): white solid; mp 109-111°C; 1H NMR 
(300 MHz, CDCl3) δ 1.08-1.27 (br s, 4H), 1.38-1.76 (m, 8H + 4H exchangeable with D2O), 2.39 (t, J = 6.0, 
4H), 2.70 (t, J = 7.0, 4H), 3.43-3.54 (m, 4H), 3.61-3.73 (m, 4H). 
cis-6-Aminohexanoic acid [2-(6-aminohexanoylamino)cyclohexyl]amide (40): yellow foam solid; 1H 
NMR (200 MHz, CDCl3) δ 1.25-1.71 (m, 20H + 4H exchangeable with D2O), 2.19 (t, J = 6.0, 4H), 2.69 (t, J 
= 7.1, 4H), 3.87-4.08 (m, 2H), 6.19-6.31 (br s, exchangeable with D2O, 2H). 
(±)-trans-6-Aminohexanoic acid [2-(6-aminohexanoylamino)cyclohexyl]amide (41): white powder; mp 
75-77 °C; 1H NMR (200 MHz, CDCl3) δ 1.18-1.82 (m, 20H + 2H exchangeable with D2O), 2.05 (br s, 
exchangeable with D2O, 2H), 2.18 (t, J = 6.3 4H), 2.68 (t, J = 7.2, 4H), 3.58-3.71 (m, 2H), 6.31 (br s, 
exchangeable with D2O, 2H). 
trans-6-Aminohexanoic acid [4-(6-aminohexanoylamino)cyclohexyl]amide (42): grey powder; mp 87-89 
°C; 1H NMR (300 MHz, CDCl3) δ 1.05-1.72 (m, 20H + 4H exchangeable with D2O), 2.18 (t, J = 6.2, 4H), 
2.70 (t, J = 7.1, 4H), 3.75 (m, 2H), 5.38 (br s, exchangeable with D2O, 2H). 
6-Aminohexanoic acid [2-(6-aminohexanoylamino)ethyl]amide (43): foam solid; 1H NMR (200 MHz, 
CDCl3) δ 1.18-1.47 (m, 4H), 1.56-1.77 (m, 8H + 4H exchangeable with D2O), 2.16-2.21 (t, J = 6.3, 4H), 
2.70-2.81 (t, J = 7.2, 4H), 3.35-3.47 (m, 4H), 6.38-6.45 (br s, exchangeable with D2O, 2H). 
 
General Procedure for the Synthesis of 44-48. A mixture of 39-43 and 2-methoxybenzaldehyde (in a 1:2.2 
molar ratio) in toluene (50 mL) was stirred at the refluxing temperature in a Dean-Stark apparatus for 6 h. 
Following solvent removal, the residue was taken up in EtOH (30 mL), NaBH4 (0.19 g, 5 mmol) was added, 
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and the stirring was continued at room temperature for 6 h. The mixture was then made acidic with 3 N HCl, 
filtered, and evaporated. The residue was dissolved in water, and the resulting solution was washed with 
ether, made basic with 2N NaOH, and extracted with CH2Cl2 (3 x 30 mL). Removal of the dried solvent gave 
the desired crude products 44-48, which were purified by flash chromatography. 
6-(2-Methoxybenzylamino)-1-{4-[6-(2-methoxybenzylamino)hexanoyl]piperazin-1-yl}hexan-1-one (44): 
yellow oil; 66% yield; eluting solvent, toluene/MeOH/EtOAc/aqueous 33%ammonia (2:6:2:0.15); 1H NMR 
(300 MHz, CDCl3) δ 1.20-1.75 (m, 12H), 2.10-2.22 (br s, exchangeable with D2O, 2H), 2.30 (t, J = 6.0, 4H), 
2.57 (t, J = 7.1, 4H), 3.29-3.40 (m, 4H), 3. 49-3.60 (m, 4H), 3.74 (s, 4H), 3.81 (s, 6H), 6.77-6.94 (m, 4H), 
7.11-7.24 (m, 4H); MS (ESI+) m/z = 553 (M+H)+. 
cis-6-(2-Methoxybenzylamino)hexanoic acid-{2-[6-(2-methoxybenzylamino) 
hexanoylamino]cyclohexyl}amide (45): yellow oil; 84% yield; eluting solvent, CHCl3/petroleum 
ether/MeOH/toluene/aqueous 33% ammonia (5:2:2:1:0.15); 1H NMR (200 MHz, CDCl3) δ 1.28-1.91 (m, 
20H), 2.08-2.28 (m, 4H + 2H exchangeable with D2O), 2.62 (t, J = 6.0, 4H), 3.78 (s, 4H),3.84 (s, 6H), 3.95-
4.08 (m, 2H), 6.56 (br s, exchangeable with D2O, 2H), 6.82-6.96 (m, 4H), 7.15-7.32 (m, 4H). 
(±)-trans-6-(2-Methoxybenzylamino)hexanoic acid {2-[6-(2-
methoxybenzylamino)hexanoylamino]cyclohexyl}amide (46): yellow oil; 82% yield; eluting solvent, 
CHCl3/petroleum ether/MeOH/toluene/aqueous 33% ammonia (5:2:2:1:0.15); 1H NMR (200 MHz, CDCl3) δ 
1.18-1.72 (m, 20H), 1.82-1.98 (m, exchangeable with D2O, 2H), 2.06 (t, J = 6.0, 4H), 2.52 (t, J = 6.0, 4H), 
3.42-3.61 (m, 2H), 3.68 (s, 4H), 3.73 (s, 6H), 6.67-6.85 (m, 4H + 2H exchangeable with D2O), 7.06-7.18 (m, 
4H). 
trans-6-(2-Methoxybenzylamino)hexanoic acid {4-[6-(2-methoxybenzylamino) 
hexanoylamino]cyclohexyl}amide (47): yellow oil; 71% yield; gravity column chromatography, eluting 
solvent, CHCl3/petroleum ether/MeOH/toluene/aqueous 33% ammonia (5:2:2:1:0.15); 1H NMR (200 MHz, 
CDCl3) δ 1.18-1.71 (m, 20H), 1.82 (br s, exchangeable with D2O, 2H), 2.07-2.32 (t, J = 6.0, 4H), 2.53 (t, J = 
6.0 4H), 3.75(s, 4H), 3.82 (s, 6H), 3.95-4.06 (m, 2H), 6.22 (br s, exchangeable with D2O, 2H), 6.81-6.93 (m, 
4H), 7.13-7.28 (m, 4H); MS (ESI+) m/z = 581 (M+H)+. 
6-(2-Methoxybenzylamino)hexanoic acid {2-[6-(2-methoxybenzylamino) hexanoylamino]ethyl}amide 
(48): yellow oil; 65% yield; gravity column chromatography, eluting  solvent, 
toluene/MeOH/CH2Cl2/aqueous 33% ammonia (3:3:4:0.05); 1H NMR (300 MHz, CDCl3) δ 1.35-1.66 (m, 
12H), 1.93-1.99 (br s, exchangeable with D2O, 2H), 1.15-2.2 (t, J = 7.0, 4H), 2.58- 2.63 (t, J = 7.0, 4H), 
3.31-3.33 (m, 4H), 3.78 (s, 4H), 3.85 (s, 6H), 6.75-6.82 (br s, exchangeable with D2O, 2H), 6.87 (m, 4H), 
7.22-7.26 (m, 4H). 
 
General Procedure for the Synthesis of 3-6, and 49. A mixture of 44, 45, 46, 47 or 48 and diethylsulfate 
(1:2.5 ratio) was heated at the refluxing temperature for 48 h in toluene. Following removal of the solvent, 
the residue was taken up in water and made basic with KOH pellets and immediately extracted with CHCl3 
(3 x 20 mL) or directly purified by column chromatography to avoid the quaternarization of amine functions. 
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Removal of the dried solvent gave a residue that was purified by gravity column chromatography, providing 
the desired compound 3-6, and 49. 3-6 were finally converted into the dioxalate salt (foam solid). 
6-[Ethyl-(2-methoxybenzyl)amino]-1-(4-{6-[ethyl-(2-methoxybenzyl) amino] hexanoyl} piperazin-1-
yl)hexan-1-one (3): yellow oil; 54% yield; eluting solvent, MeOH/toluene/EtOAc/aqueous 33% ammonia 
(6:2:2:0.2); 1H NMR (free base, 300 MHz, CDCl3) δ 1.08 (t, J = 5.4, 6H), 1.21-1.77 (m, 12H), 2.29 (t, J = 
7.4, 4H), 2.20-2.44 (m, 8H), 3.25-3.4 (m, 8H), 3.60 (s, 4H), 3.82 (s, 6H), 6.79-7.01 (m, 4H), 7.10-7.25 (m, 
2H), 7.39-7.48 (m, 2H); 13C NMR (free base, 300 MHz, CDCl3) δ 11.95, 25.37, 27.11, 27.55, 33.52, 41.62, 
45.45, 47.85, 51.51, 53.58, 55.49, 105.32, 120.27, 127.58, 128.16, 130.09, 162.53, 172.95; MS (ESI+) m/z = 
609 (M+H)+. Anal. (C40H60N4O12) C, H, N. 
cis-6-[Ethyl-(2-methoxybenzyl)amino]hexanoic acid (2-{6-[ethyl-(2-methoxybenzyl)amino] 
hexanoylamino}cyclohexyl)amide (4): yellow oil; 30% yield; eluting solvent, CHCl3/petroleum 
ether/toluene/MeOH/aqueous 33% ammonia (4:3:2:1:0.10); 1H NMR (free base, 300 MHz, CDCl3) δ 1.08 (t, 
J = 6.3, 6H), 1.22-1.83 (m, 20H), 2.18 (t, J = 7.0, 4H), 2.42-2.58 (m, 8H), 3.58 (s, 4H), 3.78 (s, 6H), 4.01 (br 
s, 2H), 6.71-6.67 (br s, exchangeable with D2O, 2H), 6.78-6.93 (m, 4H), 7.1 (m, 2H), 7.41 (d, J = 6.0, 2H); 
MS (ESI+) m/z = 637 (M+H)+. Anal. (C42H64N4O12) C, H, N. 
(±)-trans-6-[Ethyl-(2-methoxybenzyl)amino]hexanoic acid (2-{6-[ethyl-(2-  
methoxybenzyl)amino]hexanoylamino}cyclohexyl)amide (5): yellow oil; 41% yield; eluting solvent, 
CHCl3/petroleum ether/toluene/MeOH/aqueous 33% ammonia (4:3:2:1:0.10); 1H NMR (free base, 300 MHz, 
CDCl3) δ 1.08 (t, J = 6.3, 6H), 1.21-1.79 (m, 20H), 2.15 (t, J = 7.0, 4H), 2.41-2.60 (m, 8H), 3.60 (s, 4H),  
3.81 (s, 6H), 4.04 (br s, 2H), 6.05-6.12 (br s, exchangeable with D2O, 2H), 6.78-6.93 (m, 4H), 7.18 (m, 2H), 
7,41 (d, J = 6.0, 2H); 13C NMR (free base, 300 MHz, CDCl3) δ 13.70, 24.97, 26.02, 27.09, 27.44, 32.60, 
37.13, 47.89, 51.58, 53.66, 53.87, 55.58, 110.46, 120.53, 127.75, 128.47, 130.30, 157.92, 174.05; MS (ESI+) 
m/z = 637 (M+H)+. Anal. (C42H64N4O12) C, H, N. 
trans-6-[Ethyl-(2-methoxybenzyl)amino]hexanoic acid (4-{6-[ethyl-(2-methoxybenzyl) 
amino]hexanoylamino}cyclohexyl) amide (6): colorless oil; 26% yield; eluting solvent, CHCl3/petroleum 
ether/EtOAc/MeOH/ aqueous 33% ammonia (4:3:2:1:0.05); 1H NMR (free base, 200 MHz, CD3OD) δ 1.12 
(t, J = 6.3, 6H), 1.18-1.71 (m, 16H), 2.18 (t, J = 7.0, 4H), 2.41-2.62 (m, 8H), 3.52-3.64 (m, 6H), 3.82 (s, 6H), 
4.12 (q, 4H), 6.31 (br s, exchangeable with D2O, 2H), 6.82-7.02 (m, 4H), 7.18-7.38 (m, 4H); 13C NMR (free 
base, 200 MHz, CD3OD) δ 9.87, 13.23, 25.15, 26.38, 30.52, 30.80, 35.25, 48.66, 50.27, 52.24, 53.88, 59.59, 
109.57, 119.26, 125.49, 127.57, 130.15, 157.40, 173.20. MS (ESI+) m/z = 637 (M+H)+. Anal. (C42H64N4O12), 
C, H, N. 
6-[Ethyl-(2-methoxybenzyl)amino-hexanoic acid (2-{6-[ethyl-(2-methoxybenzyl)amino] 
hexanoylamino}ethyl)amide (49): yellow oil; 30% yield; eluting solvent, MeOH/EtOAc/toluene/aqueous 
33% ammonia (4:3:3:0.08); 1H NMR (free base, 300 MHz, CDCl3) δ 1.09-1.14 (t, J = 7.2, 6H), 1.28-1.36 (m, 
4H), 1.57-1.67 (m, 8H), 2.18-2.23 (t, J = 7.5, 4H), 2.53-2.58 (t, J = 7.5, 4H), 2.60-2.67 (q, J = 6.0, 4H), 3.36-
3.38 (m, 4H), 3.71 (s, 4H), 3.85 (s, 6H), 6.31-6.42 (br s, 2H), 6-81-6.98 (m, 4H), 7.16-7.20 (m, 2H), 7.44-
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7.47 (m, 2H); 13C NMR (free base, 300 MHz, CDCl3) δ 11.2, 25.3, 26.1, 26.8, 36.3, 40.1, 47.5, 51.1, 53.1, 
55.3, 110.3, 120.4, 128.2, 129.1, 130.5, 157.8, 174.2; MS (ESI+) m/z = 583 (M+H)+. 
 
Synthesis of N-Ethyl-N'-(2-{6-[ethyl-(2-methoxybenzyl)amino]hexylamino}ethyl)-N-(2-   
methoxybenzyl)hexane-1,6-diamine (50). A solution of 2 M borane-N-ethyl-N-isopropylaniline complex 
(BACH-EI) in tetrahydrofuran (2 mL) was added dropwise at room temperature to a solution of 32 (0.160 
mg, 0.27 mmol) in dry diglyme (10 mL) under a stream of dry nitrogen. When the addition was completed, 
the reaction mixture was heated at the refluxing temperature for 4 h. After cooling at room temperature, 
excess borane was destroyed by cautious dropwise addition of water (10 mL) and 6 N HCl (12 mL). The 
resulting mixture was then heated at the refluxing temperature for 1 h. After solvent evaporation, the crude 
product was washed with ethyl ether (3 x15 mL), then the mixture was made basic with aqueous 35% NaOH 
and extracted with CHCl3 (4 x50 mL). Removal of the dried solvent gave a residue that was purified by 
gravity column chromatography, eluting with MeOH/EtOAc/toluene/aqueous 33% ammonia (4:3:3:0.1), to 
give 33 as colorless oil (0.035 g, 23% yield); 1H NMR (200 MHz, CDCl3) δ 1.09-1.14 (t, J = 7.2, 6H), 1.27-
1.51 (m, 16H), 1.96-2.09 (m, 2H), 2.43-2.65 (m, 12H), 2.75 (s, 4H), 3.61 (s, 4H), 3.84 (s, 6H), 6.89-6.95 (m, 
4H), 7.11-7.31 (m, 2H), 7.40-7.45 (m, 2H); 13C NMR (300 MHz, CDCl3) δ 11.7, 26.8, 27.2, 27.4, 29.4, 47.5, 
48.3, 49.5, 51.3, 53.4, 55.3, 110.1, 120.1, 127.5, 130.1, 157.6; MS (ESI+) m/z = 555 (M+H)+. 
1,4-Bis-{6-[ethyl-(2-methoxybenzyl)amino]hexyl}piperazine-2,3-dione (8). Diethyloxalate (9 µl, 0.063 
mmol) was added to a solution of 50 (0.035 g, 0.063 mmol) in EtOH and the resulting mixture was heated at 
the refluxing temperature for 12 h. The crude material obtained, after the evaporation of the solvent, was 
purified by flash cromatography eluting solvent, MeOH/EtOAc/toluene/aqueous 33% ammonia (3:4:3:0.05) 
to give 8 as colorless oil, which was finally converted into the dioxalate salt; 42% yield; 1H NMR (300 MHz, 
CDCl3) δ 1.09-1.14 (t, J =7.2, 6H), 1.35-1.63 (m, 16H), 2.53-2.58 (t, J = 7.5, 4H), 2.60-2.67 (q, J = 6.0, 4H), 
3.45-3.53 (m, 8H), 3.81 (s, 4H), 3.87 (s, 6H), 6.90-6.99 (m, 4H), 7.29-7.31 (m, 2H), 7.50-7.53 (m, 2H); 13C 
NMR (300 MHz, CDCl3) δ 10.9, 25.9, 26.4, 26.9, 27.1, 44.4, 47.3, 50.8, 52.8, 55.4, 110.4, 120.5, 128.6, 
131.0, 157.3, 157.8; MS (ESI+) m/z = 609 (M+H)+. Anal. (C40H60N4O12) C, H, N. 
 
6-Bromo-1-[7-(6-bromo-hexanoyl)-3,6,7,8-tetrahydro-1H-benzo[lmn][3,8]phenanthrolin-2-yl]-hexan-1-
one (51): 6-Bromohexanoyl chloride (1.627 g, 7.6 mmol) was added dropwise at 0 °C to a solution of 
1,2,3,6,7,8-hexahydrobenzo[lmn][3,8]phenanthroline1 (0.800 g, 3.80 mmol) and Et3N (0.771 g, 7.6 mmol) in 
CH2Cl2. The resulting reaction mixture was stirred at room temperature for 96 h. The solution was washed 
with 2 N HCl, H2O, 2 N NaHCO3 and then the solvent was removed under vacuum. The obtained crude 
material was washed several time with petroleum ether/ether 7:3 and then purified by flash chromatography 
eluting solvent, ethyl acetate/petroleum ether (8:2) to afford 51 as yellow foam solid (0.2 g, 9% yield); 1H 
NMR (200 MHz CDCl3) δ 1.16-1.30 (m, 4H), 1.35-1.53 (m, 4H), 1.60-1.77 (m, 4H), 2.45 (t, J = 6.0, 4H), 
3,38 (t, J = 6.4, 4H), 4.90(s, 4H), 5.12 (s, 4H), 7.07-7.40 (m, 4H). 
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General Procedure for the Synthesis of 52-54. Powdered 60% NaH (1.6 g, 20 mmol) was added to a 
cooled (0 °C) solution of piperazine-2,5-dione (10 mmol), 1,4-dihydroquinoxaline-2,3-dione (10 mmol), and 
imidazolidin-2-one (10 mmol), respectively, in 10 ml of anhydrous DMF under nitrogen atmosphere. The 
resultant solution was stirred for 30 min at room temperature, then, the 1,6-dibromohexane (9.75 g, 40 
mmol) was added dropwise and the solution was stirred for 24 h at room temperature (or at refluxing 
temperature for 54). After evaporation of the solvent, the resulting crude material was washed with ether and 
purified by flash chromatography. 
1,4-Bis-(6-bromohexyl)piperazine-2,5-dione (52): foam solid; 46% yield; eluting solvent,EtOAc/petroleum  
ether (8:2); 1H NMR (200 MHz, CDCl3) δ = 1.27-1.62 (m, 16H), 3.32-3.51 (m, 8H), 3.97 (s, 4H).  
1,4-Bis-(6-bromohexyl)-1,4-dihydroquinoxaline-2,3-dione (53): yellow oil; 18% yield; eluting solvent, 
EtOAc/petroleum ether (8:2); 1H NMR (300 MHz, CDCl3) δ 1.48-1.58 (m, 8H), 1.78-1.92 (m, 8H), 3.42 (t, J 
= 6.6, 4H), 4.23 (t, J = 7.5, 4H), 7.16-7.26 (m, 2H), 7.44-7.48 (m, 2H); MS (ESI+) m/z = 511 (M+Na)+. 
1,3-Bis-(6-bromohexyl)imidazolidin-2-one (54): yellow oil; 22% yield; eluting solvent, EtOAc/petroleum 
ether (5:5); 1H NMR (300 MHz, CDCl3) δ 1.27-1.83 (m, 16H), 3.03-3.20 (m, 4H), 3.35-3.47 (m, 4H), 3.60-
3.65 (t, J = 6.0, 4H); 13C NMR (200 MHz, CDCl3) δ 25.8, 27.4, 27.8, 33.5, 33.7, 42.6, 44.0, 161.3. 
 
General Procedure for the Synthesis of 7 and 11. A mixture of ethyl(2-methoxybenzyl)amine (0.125 g, 
0.76 mmol) and triethylamine (0.077 g, 0.76 mmol) was added to a solution of the dibromoderivative 51 or 
54 (0.38 mmol) in CH3CN (20 mL). The reaction mixture was stirred at the refluxing temperature for 64 h. 
After solvent evaporation, the crude material was poured in water, made basic, and extracted with CH2Cl2 (3 
× 50 mL). After evaporation of the solvent, the crude material was purified by flash chromatography. 
The two purified compounds were converted into the dioxalate salts as described for 3-6. 
2,7-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexyl}-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone 
(7): It was synthesized from 51: yellow oil; 27% yield; eluting solvent, 
toluene/EtOAc/MeOH/CH2Cl2/aqueous 33% ammonia (4:4:1:1:0.05); 1H NMR (free base, 200 MHz, 
CDCl3) δ 1.01 (t, J=5.4, 6H), 1.17-1.68 (m, 12H), 1.68-2.51 (m, 12H), 3.38 (s, 6H), 3.58 (s, 4H), 4.88 (s, 
4H), 5.06 (s, 4H), 6.68-6.96 (m, 4H), 7.17-7.42 (m, 8H); 13C NMR (200 MHz, CDCl3) δ 11.9, 25.3, 27.0, 
27.5, 44.7, 47.8, 48.8, 51.4, 53.5, 55.4, 110.3, 120.3, 127.6, 127.9, 128.2, 130.2, 157.7, 198.1; MS (ESI+) m/z 
733 (M +H)+. Anal. (C50H64N4O12), C, H, N. 
1,3-Bis-{6-[ethyl-(2-methoxybenzyl)amino]hexyl}imidazolidin-2-one (11). It was synthesized from 54; 
yellow oil; 30 % yield; eluting solvent, EtOAc/MeOH/toluene/aqueous 33% ammonia (5:1:4:0.05); 1H NMR 
(free base, 300 MHz, CDCl3) δ 1.51-1-93 (t, J = 7.2, 6H), 1.29-1.56 (m, 16H), 2.48-2.57 (m, 8H), 3.18-3.21 
(m, 4H), 3.29 (s, 4H), 3.61-3.64 (m, 4H), 3.85 (s, 6H), 6.82-6.98 ( m, 4H), 7.17-7.26 (m, 2H), 7.39-7.48 (m, 
2H); MS (ESI+) m/z = 581 (M+H)+. Anal. (C39H60N4O11), C, H, N. 
 
General Procedure for the Synthesis of 9 and 10. KI (1.6 g,10 mmol), K2CO3 (4.7 g, 17 mmol), and 
ethyl(2-methoxybenzyl)amine (0.313 g, 1.9 mmol) were added to a solution of the dibromoderivative 52 or 
 78 
53 (0.38 mmol) in n-pentanol (20 mL). The resulting mixture was heated at the refluxing temperature for 40 
h. After evaporation of the solvent the crude product was washed with water and taken up with a 1:1 mixture 
of ether and ethyl acetate (50 mL). The organic phase was dried and the solvent evaporated. The crude 
mixture was purified by flash chromatography to afford the desired compound. 8 was converted into the 
dioxalate salt as described for 3-6, and 9 was converted into the di-p-toluenesulfonate salt by adding 2 equiv 
of p-toluenesulfonic acid in ether to an ether solution of the free base. 
1,4-Bis-{6-[ethyl-(2-methoxybenzyl)amino]hexyl}piperazine-2,5-dione (9). It was synthesized from 52; 
yellow oil; 57% yield; eluting solvent, toluene/EtOAc/MeOH/CH2Cl2/aqueous 33% ammonia (4:4:1:1:0.05); 
1H NMR (free base, 200 MHz, CDCl3) δ 1.08 (t, J = 6.8, 6H), 1.28-1.34 (m, 8H), 1.52-1.56 (m, 8H), 2.49 (t, 
J = 7.4, 4H), 2.55-2.59 (m, 4H), 3.38 (t, J = 7.4, 4H), 3.60 (s, 4H), 3.84 (s, 6H), 3.95 (s, 4H), 6.85-6.96 (m, 
4H), 7.23-7.26 (m, 2H), 7.42-7.44 (m, 2H); 13C NMR (200 MHz, CDCl3) δ 11.6, 24.6, 26.5, 26.6, 46.1, 47.7, 
50.0, 51.3, 53.1, 55.4, 110.4, 120.5, 126.9, 127.4, 130.1, 157.8, 163.5; MS (ESI+) m/z = 631 (M+Na)+. Anal. 
(C40H60N4O12), C, H, N. 
1,4-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexyl}-1,4-dihydro-quinoxaline-2,3-dione (10). It was 
synthesized from 53: yellow oil; 11% yield; eluting solvent, toluene/EtOAc/MeOH/ aqueous 33% ammonia 
(4:5:1:0.03); 1H NMR (free base, 200 MHz, CDCl3) δ 1.07 (t, J ) 6.0, 6H), 1.38-1.77 (m, 16H), 2.50 (t, J ) 
15, 4H), 2.55 (q, J ) 7.5, 4H), 3.61 (s, 4H), 3.83 (s, 6H), 4.19 (t, J ) 7.8, 4H), 6.85-7.44 (m, 12H); 13C NMR 
(200 MHz, CDCl3) δ 11.7, 26.8, 26.9, 43.2, 47.6, 51.3, 53.2, 55.3, 110.2, 115.1, 120.3, 124.0, 126.7, 127.6, 
130.1, 151.0, 154.1, 157.6; MS (ESI+) m/z  657 (M + Na)+. Anal. (C54H72N4O10S2) C, H, N. 
 
General Procedure for the Synthesis of 12-15. A solution of N1-ethyl-N1-(2-methoxybenzyl)hexane-1,6-
diamine (0.08 mmol, for 15 0.04 mmol) and the appropriate anhydride (0.4 mmol) in ethanol (40 mL) was 
heated at the refluxing temperature for 60 h. After the mixture was cooled to room temperature, the solvent 
was evaporated to give a crude material which was purified by flash chromatography. 12 and 13 were 
converted into the di-p-toluenesulfonate salts, whereas 14 and 15 were converted into the dioxalate and p-
toluenesulfonate salt, respectively. 
2,2'-Bis-{6-[ethyl-(2-methoxybenzyl)amino]hexyl}-[5,5']biisoindolyl-1,3,1',3'-tetraone (12). It was 
synthesized from [5,5']biisobenzofuranyl-1,3,1',3'-tetraone; yellow oil; 51% yield; eluting solvent, 
CH2Cl2/MeOH/aqueous 33% ammonia (9:1:0.1); 1H NMR (free base, 200 MHz, CDCl3) δ 1.45-1.22 (t, J = 
7.0, 6H), 1.27-1-70 (m, 16H), 2.58-2.73 (m, 8H), 3-68-3.75 (t, J = 7.4, 4H), 3.81 (s, 4H), 3.85 (s, 6H), 6.87-
7.01 (m, 4H), 7.24-7.30 (m, 2H), 7.50-7.53 (d, J = 5.8, 4H), 7.97-7.98 (d, J= 1, 2H), 8.10 (s, 2H); MS (ESI+) 
m/z = 787 (M+H)+. Anal. (C62H74N4O12S2), C,H,N. 
2,6-Bis-{6-[ethyl-(2-methoxybenzyl)amino]hexyl}pyrrolo[3,4-f]isoindole-1,3,5,7-tetraone (13). It was 
synthesized from benzo[1,2-c;4,5-c']difuran-1,3,5,7-tetraone; yellow oil; 35% yield; eluting solvent, 
CH2Cl2/MeOH/aqueous 33% ammonia (9:1:0.02); 1H NMR (free base, 200 MHz, CDCl3) δ 1.22 (t, J = 6.8, 
6H), 1.36-1.43 (m, 8H), 1.68-1.71 (m, 8H), 2.67-2.78 (m, 8H), 3.74 (t, J 
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(m, 4H), 7.27-7.35 (m, 4H), 7.53-7.57 (m, 2H); MS (ESI+) m/z =711 (M+H)+. Anal. (C56H70N4O12S2), C, H, 
N. 
2,7-Bis-{6-[ethyl-(2-methoxy-benzyl)-amino]-hexyl}-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone 
(14). It was synthesized from isochromeno[6,5,4-def]isochromene-1,3,6,8-tetraone: colorless oil; 43% yield; 
eluting solvent, toluene/EtOAc/CH2Cl2/MeOH/aqueous 33% ammonia (4:4:1:1:0.05); 1H NMR (free base, 
CDCl3) δ 1.05 (t, J ) 7.4, 6H), 1.43-1.76 (m, 16H), 2.43-2.59 (m, 8H), 3.58 (s, 4H), 3.82 (s, 6H), 4.19 (t, J ) 
7.6, 4H), 6.18-6.96 (m, 4H), 7.15-7.28 (m, 2H), 7.89-7.43 (m, 2H), 8.77 (s, 4H); 13C NMR (free base, 
CDCl3) δ 1.12, 11.96, 27.07, 27.16, 27.37, 28.22, 41.02, 47.74, 51.44, 53.58, 55.41, 110.25, 120.35, 125.38, 
126.69, 127.52, 128.29, 128.40, 129.10, 130.13, 130.94, 157.73, 162.85; MS (ESI+) m/z 761 (M + H)+. Anal. 
(C50H60N4O14) C, H, N 
2-{6-[Ethyl-(2-methoxybenzyl)amino]hexyl}benzo[de]isoquinoline-1,3-dione (15). It was synthesized 
from benzo[de]isochromene-1,3-dione; yellow solid; 41% yield; eluting solvent, 
toluene/CHCl3/MeOH/aqueous 33% ammonia (4:0.5:0.5:0.01); 1H NMR (200 MHz, CDCl3) δ 1.06-1.13 (t, J 
= 7.0, 3H), 1.41-1.75 (m, 8H), 2.48-2.62 (m, 4H), 3.67 (s, 2H), 3.84 (s, 3H), 4.15-4.23 (t, J= 7.4, 2H), 6,84-
6.99 (m, 2H), 7.16-7.20 (m, 1H), 7.45-4.48 (d, J = 6.6, 1H), 7.78 (t, J = 7.6, 2H), 8.21-8.25 (d, J = 7.4, 2H), 
8.61-8.64 (d, J = 7.2, 2H); MS (ESI+) m/z = 445 (M+H)+. Anal. (C35H40N2O6S) C, H, N. 
 
1.6.2 Biology 
Determination of the Inhibitory Effect on AChE and BChE Activities 
The method of Ellman et al.209 was followed. Prototypes caproctamine, 1, and 2 and the AChEIs 
donepezil, galantamine, and propidium were used as reference compounds. Five different concentrations of 
each compound were used to obtain inhibition of AChE or BChE activity comprised between 20% and 80%. 
The assay solution consisted of a 0.1 M phosphate buffer, pH 8.0, with the addition of 340 µM 5,5’-
dithiobis(2-nitrobenzoic acid), 0.02 unit/mL human recombinant AChE or human serum BChE (Sigma 
Chemical), and 550 µM substrate (acetylthiocholine iodide or butyrylthiocholine iodide). Test compounds 
were added to the assay solution and preincubated at 37 °C with the enzyme for 20 min followed by the 
addition of substrate. Assays were done with a blank containing all components except AChE or BChE to 
account for nonenzymatic reaction. The reaction rates were compared, and the percentage of inhibition due 
to the presence of test compounds was calculated. Each concentration was analyzed in triplicate, and IC50 
values were determined graphically from log concentration-inhibition curves. 
 
Determination of the Mode of Action 
To obtain estimates the mode of action of 14, reciprocal plots of 1/V versus 1/[S] were constructed at 
relatively low concentration of substrate (below 0.5 mM). The plots were assessed by a weighted least square 
analysis that assumed the variance of V to be a constant percentage of V for the entire data set. Data analysis 
was performed with GraphPad Prism 4.03 software (GraphPad Software Inc.). Reciprocal plots involving 15 
inhibition show both increasing slopes (decreased Vmax at increasing inhibitor’s concentrations) and 
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increasing intercepts (higher Km) with higher inhibitor concentration. This pattern indicates mixed-type 
inhibition, arising from a significant inhibitor interaction with both the free enzyme and the acetylated 
enzyme. 
 
Determination of the Inhibitory Effect on Aβ Aggregation Induced by AChE 
Aliquots of 2 µL of Aβ(1-40) (Bachem AG, Switzerland), lyophilized from 2 mg/mL HFIP and dissolved 
in DMSO at a final concentration of 230 µM, were incubated for 24 h at room temperature in 0.215 M 
sodium phosphate buffer (pH 8.0). For coincubation experiments, aliquots of AChE (2.30 µM, ratio 100:1) 
and AChE in the presence of the tested compound (100 µM) were added. Blanks containing Aβ, AChE, Aβ 
plus the tested compound, and AChE plus the tested compound in 0.215 M sodium phosphate buffer (pH 
8.0) were prepared. The final volume of each vial was 20 µL. To quantify amyloid fibril formation, the 
thioflavin T fluorescence method was used210,211,201. Thioflavin T binds to amyloid fibrils, giving rise to an 
intense specific emission band at 490 nm in its fluorescent emission spectrum. Therefore, after incubation, 
the samples were diluted to a final volume of 2 Ml with 50 mM glycine-NaOH buffer (pH 8.5) containing 
1.5 µM thioflavin T. A 300 s time scan of fluorescence intensity was carried out (λexc = 446 nm, λem = 490 
nm), and values at the plateau were averaged after subtraction of the background fluorescence of the 1.5 µM 
thioflavin T solution. 
 
Determination of the Inhibitory Effect on the Self-Mediated Aβ(1-42) Aggregation 
HFIPpretreated Aβ(1-42) samples (Bachem AG) were resolubilized with a CH3CN/Na2CO3/NaOH 
(48.4:48.4:3.2) to have a stable stock solution ([Aβ] = 500 µM). Experiments were performed by incubating 
the peptide in 10 mM phosphate buffer (pH 8.0) containing 10 mM NaCl at 30 °C for 24 h (final Aβ 
concentration 50 µM) with and without the tested compound at 10 µM. To quantify amyloid fibril formation, 
the thioflavin T fluorescence method was used. After incubation, the samples were diluted to a final volume 
of 2.0 mL with 50 mM glycine-NaOH buffer (pH 8.5) containing 1.5 µM thioflavin T. A 300 s time scan of 
fluorescence intensity was carried out (λexc = 446 nm, λem = 490 nm) 490 nm), and values at the plateau 
were averaged after subtraction of the background fluorescence of the 1.5 µM thioflavin T solution. 
 
Inhibition of BACE-1 activity 
Purified Baculovirus-expressed BACE-1 (α-secretase) and rhodamine derivative substrate were purchased 
from Panvera (Madison, WI, U.S). Sodium acetate and DMSO were from Sigma Aldrich (Milan, Italy). 
Purified water from Milli-RX system (Millipore, Milford, MA, USA) was used to prepare buffers and 
standard solutions. Spectrofluorometric analyses were carried out on a Fluoroskan Ascent multiwell 
spectrofluorometer (excitation: 544 nm; emission: 590 nm) by using black microwell (96 wells) Cliniplate 
plates (Thermo LabSystems, Helsinki, Finland). 
Stock solutions of the tested compounds were prepared in DMSO and diluted with 50 mM sodium acetate 
buffer pH=4.5.  
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Specifically, 20 µL of BACE-1 enzyme (25 nM) were incubated with 20 µL of test compound for 60 
minutes. To start the reaction, 20 µL of substrate (0.25 µM) were added to the well. The mixture was 
incubated at 37 °C for 60 minutes. To stop the reaction, 20 µL of BACE-1 stop solution (sodium acetate 2.5 
M) were added to each well. Then the spectrofluorometric assay was performed by reading the fluorescence 
signal at 590 nm.  
Assays were done with a blank containing all components except BACE-1 in order to account for non 
enzymatic reaction. The reaction rates were compared and the percent inhibition due to the presence of test 
compounds was calculated. Each concentration was analyzed in triplicate. The percent inhibition of the 
enzyme activity due to the presence of increasing test compound concentration was calculated by the 
following expression: 100-(vi/vo × 100), where vi is the initial rate calculated in the presence of inhibitor and 
vo is the enzyme activity. To demonstrate inhibition of BACE-1 activity, statine-derived inhibitor 
(Calbiochem, Darmstadt, Germany) was used as reference inhibitor (IC50=18 nM)112. 
 
1.6.3 Computational studies 
Docking simulations were carried out by means of the GOLD software212 (v. 3.0.1) and using the 
crystallographic structures of AChE, BChE, and BACE-1 obtained by the Protein Data Bank (PDB codes 
1B41 for AChE196, 1P0M for BChE197 and 1FKN for BACE-153). BACE-1 was always simulated in the 
monoprotonated state, namely with a proton on one aspartic acid of the catalytic dyad. Therefore, docking 
simulations were carried out either with BACE-1 Asp32 inner oxygen or with BACE-1 Asp228 inner oxygen 
protonated. 14 was built in Sybyl 7.1.1 (Tripos Associates; Inc: St. Louis; MO 2001, USA) and then 
geometry optimized optimized at density functional level of theory (B3LYP/6-31G**) by means of the 
Gaussian03 software213,214. 14 was always modeled and docked in the diprotonated state. 14 was docked 100 
times at the active site of the three enzymes and the poses ranked according two scoring functions: 
GOLDSCORE and CHEMSCORE. As suggested by the GOLD212 authors, genetic algorithm default 
parameters were set: the population size was 100, the selection pressure was 1.1, the number of operations 
was 10, the number of islands was 5, the niche size was 2, migrate was 10, mutate was 95, and crossover was 
95. 
Both sets of poses (i.e., those ranked with GOLDSCORE and those ranked with CHEMSCORE) were 
then clustered with AClAP v.1.0207,215. Briefly, AClAP is a newly developed clustering protocol 
implemented in a MATLAB metalanguage program, which combines a hierarchical agglomerative cluster 
analysis with a clusterability assessment method and a user independent cutting rule. In particular, when 
applied to docking outcomes, we demonstrated that the combination of the average linkage rule with the 
cutting function developed by Sutcliffe and co-workers216 turned out to be an approach that meets all of the 
criteria required for a robust clustering protocol. 
Finally, a low energy docking pose representative of a statistically populated cluster was taken into 
account to identify a possible binding mode of 14 at AChE, BChE, and BACE-1 active sites. 
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All molecular modeling studies were performed on a dualcore Intel(R) Xeon(TM) CPU 3.00GHz running 
Linux Fedora Core 5. 
 
1.6.4 Elemental Analysis of Reported Compounds 
 
 
No. 
 
Formula 
Calcd, % 
C                       H                      N 
Found, % 
C                       H                      N 
3 C40H60N4O12 60.90 7.67 7.10 60.95 7.61 7.06 
4 C42H64N4O12 61.75 7.90 6.86 61.79 7.95 6.81 
5 C42H64N4O12 61.75 7.90 6.86 61.80 7.85 6.82 
6 C42H64N4O12 61.75 7.90 6.86 61.77 7.87 6.80 
7 C50H64N4O12 65.77 7.07 6.14 65.78 7.04 6.12 
8 C40H60N4O12 60.90 7.67 7.10 60.85 7.65 7.06 
9 C40H60N4O12 60.90 7.67 7.10 60.86 7.68 7.05 
10 C54H72N4O10S2 64.77 7.25 5.60 64.78 7.23 5.58 
11 C39H60N4O11 61.56 7.95 7.36 61.57 7.94 7.33 
12 C62H74N4O12S2 65.82 6.59 4.95 65.80 6.60 4.93 
13 C56H70N4O12S2 63.73 6.69 5.31 63.74 6.68 5.30 
14 C50H60N4O14 63.82 6.43 5.95 63.93 6.45 5.90 
15 C35H40N2O6S 68.16 6.54 4.54 68.15 6.53 4.52 
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2.1 Introduction 
 
Cancer is a term generally used to describe a group of diseases characterized by uncontrolled cell-growth. 
Cancer is a leading cause of death worldwide: it is responsibly for 7.9 million deaths, around 13% of all 
death, in 2007 and deaths from cancer worldwide are projected to continue rising, with an estimated value of 
12 million in 2030. The main types of cancer leading to overall cancer mortality each year are lung cancer 
(1.4 million deaths/year), stomach cancer, (866,000 deaths/year), liver cancer (653, 99 deaths/year), colon 
(677, 00 deaths/year) and breast cancer (548,000 deaths/year). In Italy, in 2005 cancer killed approximately 
157,000 people, 57,000 of them were under the age of 70 and it is predicted that it is going to rise from 
26.5% of all death in 2005 to 26.8% of all death in 2009217.  
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Figure 61. Main causes of death in Italy in 2005217. 
 
Cancer arises when cells escape from their normal control mechanisms and being to grow and to spread in 
different part of the organism through a process called metastasis. Cancer begins from one single cell and the 
transformation from a normal cell into a tumour cell is a multistage process that involved several 
biochemical pathways. 
Cancer therapy is based on surgery, radiotherapy and chemotherapy. Killing cancer cells with chemical 
agents is a very difficult challenge because such transformed cells do not present different biochemical 
characteristics from normal cells. Treatment of cancer has mainly involved the use of agents directed to 
target that are not specific and, therefore, chemotherapeutic agents are in most of the cases aspecific and this 
lead to a wide spectrum of side effects in patients.  
The drug resistance is another problem associate with cancer chemotherapy. Cancer cells are able to 
develop many mechanisms that make them resistant to anticancer drugs, by increasing the efflux of the drug, 
and/or the enzyme-mediated deactivation of the drug, and/or by altering the binding site or the metabolic 
pathways. Furthermore, many drugs which showed promising activity in preclinical in vitro studies did not 
confirm the same results in clinical trials. This is associate with the difficult to find clinical relevant 
preclinical models.   
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Along time, many different classes of antiproliferative drugs have been developed and they are able to hit 
several biochemical pathways implicated in the cancer development. 
Cancer is a multifactorial disease and, therefore, a single medicine is not sufficient to effectively treat it. 
Among different therapeutically approaches useful for cancer treatment, an emerging strategy is represented 
by the so called “Multi-Target Direct Ligand” approach (MTDL). This approach is base on the assumption 
that a single drug may simultaneously modulate targets involved in the cascade of a pathological events 
leading to a multifactorial disease. This approach seems to be the more adequate for cancer treatment. 
Herein, it is reported on the development of potential new MTDLs as anticancer drugs able to hit different 
target involved in cancer pathogenesis. In particular, the MTDLs described in the present study should be 
able, in principle, to act as: 
 intercalator agents; 
 apoptosis activators: 
 PIN1 inhibitors. 
 
 
 
2.1.1 Polyamines  
Polyamines are simple organic compounds having low-molecular weight and two or more amino groups 
charged at physiologically conditions. Natural polyamines, such as putrescine (Put), spermine (Spm) and 
spermidine (Spd) are widely distributed in living organism and they are involved in several ways in cell 
proliferation and in homeostasis preserving218,219,220,221.  
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Figure 62. Chemical structure of Putrescine 
(Put), Spermidine (Spd) and Spermine (Spm). 
 
 
Metabolism of Polyamines and their involvement in cellular homeostasis  
In mammalian cells, the natural polyamines are found in millimolar concentration and their intracellular 
concentration is tightly regulated by multiple pathways such as synthesis from amino acids precursor, 
cellular uptake which provide polyamines from diet and intestinal microorganism as well as degradation and 
efflux. In eukaryotic cells, Put, Spd and Spm are synthesized from the amino acids L-ornithine and L-
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methionine. Put derives from decarboxylation of ornithine by ornithine decarboxylase (ODC); this is the 
rate-limiting step in the polyamine’s biosynthesis. Both Spd and Spm derived from Put; Spd is synthesized 
by the addition of an aminopropyl group thanks to Spermidine synthase. Adding another aminopropyl group 
to Spd yields to Spm by the action of Spermine synthase. The two aminopropyl groups used in this 
biosynthetic pathway directly derived from decarboxylated S-adenosylmethionine; such compound comes 
from methionine that is firstly transformed in S-adenosylmethionine and then decarboxylated by S-
adenosylmethionine decarboxylase to give decarboxylated S-adenosylmethionine (Figure 63)222. 
 
 
Figure 63. Polyamines metabolism222. 
 
Polyamines catabolism is driven by Spd/Spm N1-acetyltransferase (SSAT). Such enzyme system use 
acetyl-CoA as acetyl source to obtain N1-acetylspermine and N1-acetylspermidine. The acetylation removes 
the positive charge on the amino group and, therefore, acetylated polyamines are less potent than non-
acetylated compounds. These two acetylderivatives could be either extracted from the cell or oxidized by 
FAD-dependent polyamine oxidase (PAO): acetylated Spm is cleaved into Spd and acetylated Spd is cleaved 
into Put223. Polyamines could also be degradated by oxidative deamination catalyzed by a copper dependent 
amino-oxidase. Oxidation of acetylated polyamines leads to a great quantities of γ-aminobutiric acid, 3-
acetamidopropanal, hydrogen peroxide and ammonia. In particular, hydrogen peroxide and aminoaldehydes 
are very toxic compounds and could lead to oxidative stress and apoptotic-induction; moreover, hydrogen 
peroxide positively modulates the enzymatic activity of SSAT (Figure 64)224,225.  
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Figure 64. Polyamine metabolism and cell death222. 
 
Furthermore, cells possess uptake and efflux systems for polyamines. It has been suggested that the 
Polyamine Transporter (PAT) is carrier-mediated, energy-dependent and saturable. Moreover, despite some 
cells posses just one carrier for all three natural polyamines, some other cells are characterized by two 
classes of carrier: one for Put and the other for Spd and Spm222,226. PAT are more expressed in rapidly 
growing cells, such as cancers cells. PAT is not so selective and, therefore, different polyamines analogues 
could use such carrier to get into the cells227. Furthermore, cells posses systems able to transport polyamines 
outside the cells. This system is tightly regulated by the growth status of the cell228. 
Concerning all the enzymes involved in polyamines metabolism ODC resulted one of the most 
interesting. It is a highly inducible enzyme with an extremely short half-life. It requires for its activity 
pyridossal 5`-phosphate as cofactor which binds at Lys69; moreover, a thiol-group reducing agents are 
necessary for the enzyme activity229. ODC activity is dependent by the formation of a dimer and critical 
residues in the active site were Lys169 and His197230. ODC’s expression could be regulated by oncogenes 
and its activity is controlled by polyamines through positive or negative feedback: high polyamines 
concentration reduces its activity while low polyamines levels increase it. Furthermore, different studies 
show an increase in ODC activity after inducing apoptosis and this suggest its involvement in programmed 
cell death231. ODC binds to a small regulatory protein induced by an increase of polyamines level, called 
Antyzime AZ.232. 
SSAT is a homotetramer of molecular mass about 80 KDa; it is induced by a number of stimuli including 
various toxic agents, hormones, growth factors and polyamines themselves233. SSAT acetylates specifically 
primary amino group and its substrates are Spd and Spm but not Put. Acetyl-CoA is used as acetyl-donor and 
its binding site is located in a highly conservated region of 20 AA and Arg142 and Arg148 play a critical 
role for its binding234. 
Polyamines are deeply involved in regulation of cellular functions and they are able to modulate cell 
growth and death. During cell cycle, changing in polyamines and ODC levels has been observed. In Chinese 
Hamster Ovary (CHO) during the progression of the cell cycle, Put levels are increased in S and G2 phases, 
Spm concentrations are increased for the period of S and G1 phase and Spd is increased during all the cell 
cycle222. 
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Cellular growth is critically regulated by the rising or the reduction of proteins and kinase-proteins known 
as cyclin and cyclin-dependent kinase (Ckds) and many evidences show a link between such proteins and 
polyamines. Growth factors and hormones cause an acceleration of cell cycle by increasing the level of 
cyclins. Different cyclins have been identified and they act on specific phases of the cell cycle; for example, 
in the G1 phase, cyclin D1, D2, D3 and E activate the appropriate Cdk that is responsible for the 
phosphorylation of particular substrates leading to cell cycle progression235. Polyamines have a critical role 
in cell growth and, therefore, interaction occurs between them and cyclin/Cdks. Changes in expression of the 
cyclin and Cdks take place during the different phases of cell cycle together with changes in ODC and 
polyamines concentration (Figure 65). 
 
 
 
Figure 65. Effect of polyamines on cell cycle222. 
 
 
The exact mechanism of how polyamines affect the cyclin/Cdks system is still not completely defined but 
seems that polyamines regulated cyclin degradation236. Thomas and coworkers showed as polyamines were 
able to modulate cyclin D1. They treated MCF-7 cells with polyamine analogues causing a decrease in Put, 
Spd and Spm levels. Such decrease has been associated with a decrease in cyclin D1 level and cell cycle 
arrest in G1. Furthermore, they valuated the effect of difluoromethylornithine (DMFO), an inhibitor of ODC, 
and CGP 48664, an S-adenosylmethionine decarboxylase inhibitor, on cyclin D1 and E in MCF-7 cells 
(Figure 66). In this study, DMFO induces a decrease of cyclin D1 whereas CGP 48664 led to an increase of 
two-fold in Cyclin D1: these results suggested a possible regulation of cyclin D1 by Put. Moreover, DMFO 
had no effect on cyclin E while CGP 48664 increased its level suggesting that Spm has a role in cyclin E 
regulation220.  
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Figure 66. Chemical structure of DMFO and CGP 48664. 
 
 
This and other studies237 demonstrated a strictly link between polyamines and cell cycle regulation and 
how polyamines could be involved in cell growth desregulation. Therefore, it is not surprising that in the last 
decades many efforts have been performed to determine relationships between polyamines and cellular 
proliferation in order to develop drugs able to act on polyamines-mediated biochemical pathways. 
In the early 70’s, several studies revealed the presence of high levels of polyamines in serum and urine of 
people affected by leukaemia, melanoma, adenocarcinome and myeloma and, therefore, polyamines have 
been suggested as biochemical cancer marker. Furthermore, an increase in polyamines level have been notice 
in patients having cystic fibrosis, psoriasis and in pregnant girls; all these evidences point out that almost 
every pathological condition leading to a cellular death or pathological growth, such as inflammation, yield 
to an increase in polyamines concentration238. Polyamines and cancer are deeply connected and this address 
the research in finding new therapeutical entities that, inhibiting enzymes involved in polyamines 
biosynthesis could reduce their intracellular concentration leading to a cytostatic effect.  
In addition to their connection with cell cycle regulation, polyamines, being generally charged at 
physiological pH, can interact with nucleic acids and, in particular, with DNA in non-sequence specific 
manner239. Polyamines are able to stabilize duplex and triplex B-DNA structure240 and to promote B- to Z-
DNA transition in recombinant plasmid241. Furthermore, it has been demonstrated that polyamines have an 
important role in the formation of nucleosome242. 
Beyond their interaction with DNA, polyamines interact also with phospholipids, and membrane 
protein243. In addition, natural and synthetic polyamines can interact with several important receptor systems, 
such as muscarinic, nicotinic and glutamate receptors244,245. 
Recently, it has been demonstrated that polyamines can act as protector agents against ROS by acting 
directly as free radical scavenger246,247,248. 
An increasing number of evidences are linking polyamines with programmed cell death. Nevertheless, the 
biochemical pathways that connect such compounds with increasing or decreasing of the apoptotic process is 
quite complex and some results appear contradictory249.  
Apoptosis is a programmed cell death that involved just a single cell and polyamines are important factors 
in its control. Packham and Cleveland discovered a marked increase of ODC activity after inducing apoptotic 
cell death suggesting a direct role of ODC as mediator of apoptosis. Furthermore, they suggested that ODC is 
an effector of c-Myc induced apoptosis (c-Myc is a gene which encodes for transcription factors; a mutated 
version of c-Myc is found in many cancers). Increase of ODC activity will lead to an increase in polyamine 
synthesis and, therefore, in their metabolism leading to an increase of ROS formation (Figure 67)250. 
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Figure 67. Model for c-Myc-induced apoptosis250. 
 
On the other hand, in human leukaemia cells HL-60 apoptotic induction has been blocked by using 
DMFO whereas adding exogenous polyamines restore the apoptotic process; therefore, an increase of 
polyamines could revert the inhibitory effect of DMFO on ODC251. Moreover, addition of exogenous 
polyamines prevens the apoptotic induction by DNA-fragmentation caused by etoposide (apoptotic-
inductor); these evidences support the hypothesis that polyamines act as apoptotic-inhibitors. In studies on 
HL-60 cells treated with etoposide, an increased of ODC’s activity has been observed, in the first 2-4 hours, 
followed by an almost completely inhibition of its activity; this may indicate that an increase of ODC is 
necessary for apoptosis induction while its decreasing is fundamental for holding the apoptotic process. 
The in vitro cytotoxicity of Spm and Spd is well documented; in several experiments it is shown how they 
could be metabolized by a serum amine oxidase lead to cytotoxic compounds such as amino aldehydes, 
ammonia and hydrogen peroxide252. Moreover, the oxidation of polyamines catalyzed by PAO lead to 
hydrogen peroxide which is implicated in the induction of apoptosis; however, in several rat tissues PAO has 
been localized only in peroxisome where hydrogen peroxide could be reduced by the action of peroxisomal 
peroxide and other detoxifying enzymes253. Recent studies suggested that polyamines themselves could exert 
cytotoxic effects. Spm at millimolar concentration is cytotoxic to baby-hamster kidney cells; this effect is not 
due to the formation of toxic amino aldehydes because serum amino-oxidases were not present. It has been 
observed that inhibitors of amino-oxidase, such as aminoguanidine, could partially prevent the observed 
toxicity while treatment of the cells with MDL 72527, a PAO inhibitor, enhances the toxicity254.  
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p53 is the major tumor suppressor protein of the body. It is a transcription factor involved in cell cycle 
regulation, the initiation of apoptotic death and DNA repairing255. 
Li et al. investigated the mechanism of regulation of p53 gene expression by polyamines. In intestinal 
mucosal epithelial cells, they found that polyamines negatively regulated post-transcription of p53. In 
particular, depletion of polyamines enhances expression of p53 gene. Moreover, accumulation of p53 
activates the transcription of cell cycle arrest genes leading to growth-inhibition (Figure 68)256. 
 91 
 
 
Figure 68. Regulation of expression of the p53 
gene by cellular polyamines256. 
 
Some authors reported the influence of polyamines on the activity of nuclear factor κB (NF-κB). Such 
factor could have either pro- and anti-apoptotic effects depending on cell type and kind of death stimuli. 
They found that polyamines depletion induced an increase in NF-κB activity probably due the decrease of 
IKBα protein levels (IKBα bound NF-κB in the cytoplasm keeping it in an inactive form)257. In contrast, in 
another study, Shah et al. reported that Spm has a stimulatory effect on NF-κB MCF-7 breast cancer cells258. 
Nowdays, it is clear that polyamines and caspases are strictly connected259,260,261. Caspases are proteases 
that play a fundamental role in signalling and executing apoptosis262,263,264. They posses in their active site a 
cysteine residue which cleaved substrates at Asp-Xxx bound and acted in concert in a cascade triggered by 
apoptotic signalling. At least 14 distinct mammalian caspases have been identified and 11 of them are 
humans (Figure 69). Of these 11 caspases not all are involved in apoptotic cascade: caspases-1, -4 and -5 are 
mediator of inflammation and cleaved proinflammatory cytokines. The other seven caspases are apoptotic 
and generally are divided in two classes: 
• initiator caspases, which includes caspases-2, -8, -9 and -10; 
• effector caspases, which includes caspases-3, -6 and -7. 
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Figure 69. Apoptotic caspases in mammalian264. 
 
The initiator caspases activate the effectors which are able to degrade several substrates such as nuclear 
protein and cytoplasm. The activation of caspase effectors could be carried out also by non-caspase proteases 
such as catepsin and calpains265.  
All caspases are produced in cells as inactive proenzymes that contain three domains: an NH2-terminal 
domain, a large subunit (~20 KDa) and a small subunit (~10 KDa). Proteolytic cleavage of the caspases 
precursor results in the separation of large and small subunit. 
The caspases-cascade may initiate by different pathways depending on the origin of the death stimuli. The 
extrinsic pathway is initiated by the binding of a death ligand such as Fas-I to the respective death receptor. 
This pathway is receptor-dependent and several death receptors family has been identified such as TNF-R1, 
Fas and NGF-R. Among these families the Fas is the best characterized. Fas activates procaspase-8 and the 
active caspase-8 can activate caspase-3, hydrolyzing several apoptotic substrates.  
Alternatively, caspases-cascade could be triggered in a receptor-independent pathway by different stimuli 
including chemotherapeutic agents. 
The intrinsic pathway is mediated by mitochondria: apoptotic signals can influence the permeability of 
mitochondrial membrane inducing release of some pro-apoptotic proteins into the cytoplasm, such 
cytochrome C259. Cytochrome C released in the cytoplasm becomes part of the apoptosome which mediates 
activation of caspases-9; this pathway is strictly regulated by Bcl-2 family protein. In addition, another pro-
apoptotic factor released by mitochondria is the apoptotic inducing factor (AIP) which can activate caspase-3 
or can move into the nucleus and induces DNA fragmentation266. Both receptor-dependent and mitochondrial 
pathways converge at level of caspases-3 (Figure 70). 
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Figure 70. Involvement of caspases in apoptosis259. 
 
How caspases kill cells is not fully understood but seems that they could inactivate proteins that protect 
cells from apoptosis or they could destroy important cell structures as nuclear lamina. 
Due to their fundamental role in homeostasis maintenance, caspases could represent an attractive 
pharmacological target for the treatment of pathologies caused by cell growth desregulation. For example, 
caspases inhibition could be helpful in all the diseases triggered by an excessive apoptosis such as 
neurodegenerative diseases. On the other hand, caspases activation could be useful in cancer treatment where 
an excessive cell proliferation occurs. Therefore, they may be promising biochemical target for designing 
new therapeutical instrument for the treatment of such diseases267. 
Stefanelli and coworkers studying the link between polyamines and caspases observed that in HL60 cells 
polyamines induce activation of caspases; in particular, they showed that Spm was more efficient than Spd in 
activation of caspases-3 while Put resulted inactive. Moreover, they observed that Spm is able to bind to 
mitochondria and to induce the release of cytochrome C268,269,270 . On the other hand, Nitta et al. showed that 
in different cell lines depletion of intracellular polyamines caused disruption of mitochondrial membrane 
potential leading to caspases activation271.  
As above discussed, many evidences link polyamines to different apoptotic pathways; nevertheless, the 
exact role of such molecules in these biochemical cascades is still controversial. The overall picture is quite 
complicate and seems that polyamines may behave as pro-apoptotic or anti-apoptotic agents depending on 
the particular physiopathological condition.   
 
Biochemical and Medicinal Chemistry aspects of polyamines 
Polyamines are essential in maintaining homeostasis and variation in their concentration is associated 
with different pathological conditions. Therefore, several groups have focused their research in discovering 
new molecular structures able to interfere with all the biochemical pathways in which polyamines are 
involved. For example, agents able to inhibit polyamines biosynthetic enzymes will prevent cell growth and, 
therefore, could be used as antiproliferative agents. Moreover, polyamines analogues have been developed in 
order to induce apoptosis in transformed cells. In addition, polyamine residues could be used as delivering 
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agents by using Polyamines Transporter System (PAT) to facilitate the entreance of different drugs into the 
cells272,273. 
The discover of molecules targeting the enzymes involved in polyamines metabolic pathways has been 
the first approach used in order to developed potential therapeutic agents (Figure 71).  
 
 
 
Figure 71. Targets in the polyamine metabolic pathway272. 
 
Perhaps the most known enzyme involved in polyamines metabolism is ODC and one of the most 
important inhibitor of such enzyme is 2-difluromethylornithine (DMFO) that acting as suicide inhibitor 
induces the arrest of cell growth274. DMFO is an enzyme-activated irreversible inhibitor: it first competes 
with ornithine for the binding site and then it is decarboxylated by the enzyme to create a highly reactive 
intermediate that forms a covalent bind with Cys360 or Lys69 leading to enzyme inactivation275. In vitro, 
DMFO induces arrest of cell growth by depletion of Put and Spd even if the levels of Spm are variable. 
However, in vivo DMFO was found to display cytostatic effect and not cytotoxic effect; nevertheless, it is 
under investigation as chemopreventive agent in prostate and colon cancer in combination with non-steroidal 
anti-inflammatory drugs.  
Moreover, several inhibitor of S-adenosylmethionine (SAM) decarboxylase have been developed. One of 
the earliest inhibitor developed is methylglyoxal bis -guanylhydrazone (MGBG). It has been reported that it 
is active as antileukemic agent but its clinical use has been limited due to its severe toxicity276. MGBG is a 
competitive inhibitor of SAM and, moreover, it seems to be able to interact with mitochondria. Nevertheless, 
MGBG could be considered as lead compound for the development of additional agents. For example, 
SAM486A developed by Novartis is a potent inhibitor of AdoMetDC and it does not present any 
mitochondrial activity and its possible use as therapeutic agent is currently under investigation276. In 
 95 
addition, some S-adenosyl methionine (AdoMet) analogues have been developed but, unfortunately, these 
compounds could not be used in vivo due their insufficient methabolic stability277. 
Other target enzymes are Spd and Spm-synthasse for which analogues of the transition state have been 
designed. S-adenosyl-3-thio-1,8-diaminooctane (AdoDATO) is a specific inhibitor of Spd synthase; 
unfortunately, it causes depletion of Spd but increases Put and Spm leading to few growth-inhibitory effect 
(Figure 72)278,279. 
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Figure 72. Chemical structure of DMFO, MGBG, 
SAM 486A and AdoDato. 
 
A more recent approach to inhibith polyamine biosynthesis is based on the design and synthesize new 
polyamines analogues. Such compounds should be able to entry into the cells using the PAT, downregulate 
biosynthetic enzymes and/or upregulate catabolic enzymes272,273. 
The first generation of these polyamines analogues were the N,N1-bis(ethyl)polyamines; they are 
terminally alkylated analogues of Spd and Spm (Figure 73). The more active of these polyamines analogue 
are BESpd (N1,N8bis(ethyl)spermidine), BESpm (N1,N12bis(ethyl)spermine), DENSpm 
(N1,N11bis(ethyl)norspermine) and BEHSpm (N1,N14bis(ethyl)homospermine) which induce depletion of 
intracellular polyamines and exhibit several anticancer activities against cancer cells. These analogues get 
into the cells through PAT and induce depletion of polyamines by acting on ODC, AdoMetDC and SSAT. 
For example, BESpd was found to be active on DMFO-resistant human non-small-cell lung-cancer line, NCI 
H157280. Very important was the discovery that the respond to these agents was dependent by phenotype of 
the cell: DMFO-sensitive human non-small-cell lung-cancer line NCI H82 is more resistant to BESpd than 
NCI H157 cells281. In NCI H157 cells, bis-ethylpolyamines have shown to increase the activity of SSAT in 
dose- and time-dependent manner and, in addition, they cause down-regulation of ODC and AdoMetDC282. 
In particular, SSAT induction seems to be strictly linked with cell death even if such connection depend on 
the type of polyamines analogues and of cell lines: for example, DMSpm (1,12-dimethylspermine) in human 
large-cell lung carcinoma cells is a very potent SSAT inducer but it shows no-toxicity283. How the induction 
of SSAT leads to cytotoxicity is not totally clear; it seems that a high induction of SSAT causes production 
of substrates for PAO whose activity is responsible of  cytotoxic concentration of hydrogen peroxide.  
Among the different analogues synthesized, DENSpm is a very active SSAT-inducer, it is taken up by the 
polyamines transporter, it downregulates ODC and S-adenosyl methionine decarboxylase (AdoMetDC) and 
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it upregulated polyamines catabolism; for these reasons it has been recognized to be a good candidate for 
clinical trials but, in such tests, unfortunately it showed an unacceptable neurotoxicity284,285. 
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Figure 73. Chemical structure of N,N1-bis(ethyl)polyamines: BESpd, 
BESpm, DENSpm, BEHSpm. 
 
Furthermore, asymmetrically substituted polyamines analogues have been synthesized and tested (Figure 
74). Derivatives such as PENSpm (N1-propargyl-N11-ethylnorspermine), CPENSpm (N1-cyclopropylmethyl-
N11-ethylnorspermine), CHENSpm (N1-cycloheptylmethyl-N11-ethylnorspermine) and IPENSpm ((S)-N1-(2-
methyl-1-butyl)-N11-ethyl-4,8-diazaundecane) exert significant antiproliferative activity by inducing SSAT, 
downregulating ODC and AdoMetDC286,287. Among these compounds, CHENSpm, despite its low SSAT-
inducing activity, induces apoptosis in non-small-cell lung cancer producing G2/M block by interfering with 
normal tubulin polymerization288,289. 
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Figure 74. Chemical structure of asymmetrically substituted 
polyamines: PENSpm, CPESpm, CHESpm, IPENSpm. 
 
 
In addition, several derivatives have been developed by replacing the polymethylene chain between the 
amine functions with conformational restricted group able to reduce the free rotation around the C-C bound 
(Figure 75)290. Two “frozen” polyamines analogues are CGC-11047 and CGC-11093 in which the 
replacement of the polymethylene chain with a more rigid double bond and cyclopropane moiety affects both 
the activity and the toxicity291,292. Despite the similar structure, only CG-11047 is able to induce SSAT and 
SMO; moreover, CGC-11093 is in phase-1 trial as antiproliferative agent while CGC-11047 is in phase-1 as 
single agent and in phase-1b in association with Bevacizumab, docetaxel or gemcitabin. 
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Figure 615. Structure of “frozen” 
polyamines analogues: CGC-11047 and 
CGC-11093 
 
Despite their effect on their own metabolism, polyamines are able to interact DNA and chromatine and, 
therefore, many efforts have been made in order to develop compounds able to target them. Oligoamines 
with many amine functions in the side chains have been developed and they displaied antiproliferative 
activity in submicromolar range in human prostate cell line (Figure 76)293 In particular, CGC-11444 was 
active also against human breast cancer cells in vitro and in vivo by inducing cytochrome C release and 
caspase-3 activation and, in addition, it seemed to alter the expression of estrogen receptor294. 
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Figure 76. Oligoamines CGC-11157, CGC-11159, CGC-
11144. 
 
 
Bis(benzyl)polyamine MDL 27695 showed the ability to inhibit proliferation of HeLa cells. Interestingly, 
no correlation between DNA binding properties and antitumor activities of MDL 27695 and its analogues 
was detected295. 
 
N
H
N
H
N
H
N
H
MDL 27695
 
 
In addition, MDL 27695 seems able to gain into cells using PAT or some other specific polyamine 
transporter. 
Recently, it has been demonstrated that different types of cancers showed an increased activity of the PAT 
due to the increased requirement of polyamines. Moreover, several studies reveal that many polyamines 
analogues use PAT to enter into cells and such transport system lacks of selectivity. Therefore, such system 
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could be used to selectively deliver polyamine-anticancer drug conjugate preferentially into cancer cells 
avoiding the side toxic effects towards normal cells normally exerted by anticancer agents. 
Unfortunately, not only cancer cells but also some normal cells system such as bone marrow, intestinal 
epithelium and hair folliculi, are rapidly growing cells; however, the real therapeutic effectiveness of this 
strategy needs to be verify. 
Both Spd and Spm have an high affinity toward DNA and the development of conjugate between 
polyamine and structure able to interact with DNA could lead to an increase of affinity toward DNA thanks 
to the establishment of additional electrostatic interactions. One of the first example of application of this 
strategy is represented by the conjugate clorambucile-Spd (Figure 77); this derivative showed a DNA affinity 
10000 times higher than clorambucile alone suggesting the role of polyamines chain to establish additional 
interactions with phosphate moieties of DNA: in addition, it penetrates into cells through PAT system296,297.  
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Figure 77. Conjugate clorambucile-Spd. 
 
 
In 2000, Phanstiel and coworkers developed a series of conjugate polyamines-DNA intercalator in order 
to target DNA and/orTopoisomerase II (TOPOII) activity. Such derivatives have a Spm fragment covalented 
linked at its N4 position to an acridine (LXVI, LXVII) or to an anthracene (LXVIII, LXIX) moiety.  
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All these derivatives showed the ability to interfere with TOPOII in a dose- and time-dependent manner 
and acridine-derivatives are more active in inhibit TOPOII than anthracene-derivatives. In contrast, in L1210 
(murine leukaemia cell line) anthracene derivatives were more potent than the acridine-based conjugate. 
Concerning their ability to use PAT to gain into cells, this study revealed that spermidine-based ligands may 
not represent the right architecture to use PAT whereas the activity of LXX, which is based on spermine 
moiety, was more efficacious PAT ligand. 
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Soon later, the same authors reported on the synthesis and the biological evaluation of a new series of 
polyamine-DNA intercalator agents (LXXI-LXXVI). 
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Such compounds have been tested in order to evaluate their inhibitory activity towards DNA-TOPOII: the 
bis-Spm derivatives, LXXI-LXXIV are more efficient at 5 µM than mono-Spm derivatives. Moreover, bis-
derivatives containing the C5 tether length, LXXII and LXXIV, were more active than the corresponding 
containing the C4 tether length, LXXI and LXXIII. Concerning the possibility to gain into cells by PAT, the 
mono-intercalator-Spm moiety, LXXV, had the highest affinity for the L1210 PAT298. Basing on the high 
cytotoxicity of anthracene moiety over the acridine analogue, a series of tetraamine-anthracene derivatives 
have been synthesized and evaluated for their intracellular uptake via PAT. Furthermore, in this study it has 
been evaluated also the affinity of unsubstituted polyamines system for the PAT. 
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LXXIX:   m=1, n=1           IC50= 5120 nM 
LXXX:    m=1, n=2           IC50= 2460 nM 
LXXXI:   m=2, n=2           IC50= 2300 nM 
LXXXII:  m=1, n=1, o=1   IC50=1510 nM 
LXXXIII: m=1, n=2, o=1   IC50= 1340 nM 
LXXXIV: m=2, n=2, o=2   IC50= 730 nM
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From this evaluation appeared that in L1210 cells, tetraamines showed more affinity to PAT than triamine 
and diamines; moreover, it was observed that the better distance between two nitrogens atoms corresponded 
to 4 carbon atoms. 
However, such cell line results to be more susceptible to triamines conjugate LXXVII than tetraamines 
LXXVIII. Of course, these results depend on polyamine architecture; in particular in terms of vector design, 
the 4,4-triamine motif was found to be optimal chemical signal to gain into cells via PAT. That could be 
explain considering that tetraamines are high-affinity PAT ligands that slowly dissociate from the receptor 
while triamines have lower binding affinity and dissociate rapidly from PAT to exert the cytotoxic effect. 
Indeed, a deconvolution microscopy study in A375 melanoma cells reveled a rapid internalization for the 
intercalator-4,4 triamine conjugate whereas the intercalator-4,4,4 tetraamine remained mostly at the cell 
surface299. 
In addition, in 2004 Phanstiel et al. synthesized a new series of anthracene-polyamine conjugate in order 
to prove the sensibility of PAT to small changes in its substrates. Based on these compounds and previous 
works, they presented a model which related polyamine-anthracene conjugate to PAT-mediated cytotoxicity 
(Figure 78). 
 
 
 
Figure 78. Architecture of PAT299. 
 
They showed that the best results were obtained when x is equal to 1 or 2 and when y is 2 or 3; increasing 
y value from 3 to 4 in anthracenyl-containing conjugate lead to a dramatically decrease of selectivity for 
PAT. This decreasing in uptake and cytotoxicity reveals that the hydrophobic cavity cannot accommodate 
groups bigger than the anthracenyl ones. In addition, if R is a smaller group then antracenyl, as napthyl 
moiety, it is possible to increase the length of N1-tether from methyl to ethyl holding a good selectivity 
toward PAT. Furthermore, based on a computational model developed studying compounds LXXXV, 
LXXXVI and LXXXVII they proposed a two-step model, “where first the conjugate binds primarily 
through its polyamine portion to PAT and then hydrophobic substituent seeks out its associated pocket to 
initiate the receptor-mediated endocytosis event300. 
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compound n N1-H10 (Å) N1-H3 (Å) 
LXXXV 1 6.0 6.7 
LXXXVI 2 7.5 7.9 
LXXXVII 3 8.4 8.7 
 
Figure79. Model for polyamines-PAT interaction300. 
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2.1.2 Peptidil-prolyl cis/trans isomerase (PIN1) 
PIN1 is a member of evolutionarily conserved enzymes, peptidyl-prolyl isomerase (PPIase family) and 
catalyze the cis/trans isomerisation of peptidyl-prolyl amide bonds. PPIases, by changing the 
conformation of the peptide bond, may alter the conformation of their substrates and, therefore, their 
function. PPIases are highly expressed and have been divided in three groups differing in the amino acids 
sequences of their catalytic domain and their substrate specificity: 
1. cyclophilins, which bind the immunosuppressant drug cyclosprin A; 
2. FK506 binding proteins, which bind the immunosuppressant drugs FK506 and 
Rapamycin; 
3. parvulins, which do not bind any immunosuppressant drugs301. 
 
PIN1 belongs to a parvulin subfamily of PPIases to this subfamily belong also PAR10 in bacteria, 
PAR14 and PAR10 in eukaryotic302. 
PIN1 is an 18 kDa protein form by 163 AA; it is composed by two domain organized around a 
hydrophobic cavity: an amino-terminal WW domain (amino acids 1-39) and a carboxylic-terminal 
domain (amino acids 45-163) (Figure 80). The amino-terminal domain is involved in protein-protein 
interaction while the carboxylic-terminal domain represented the PPIase domain which catalyzed the 
isomerisation of the proline peptide bond between the cis-trans conformations. 
 
 
 
Figure 80. Stucture of PIN1301. 
 
The crystal structure of PIN1 reveals that the active site is located at the surface of the enzyme; it is a 
hydrophobic pocket composed by Leu122, Met130, and Phe134 which binds the cyclic side chain of the 
prolyl residue. The peptide bond undergoing the catalyzed cis/trans isomerisation is surrounded by His59, 
Cys113, Ser154, and His157; Lys63, Arg68, and Arg69 form a basic cluster, which binds the 
phosphorylated Ser/Thr of the substrate (Figure 81)303. 
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 a)                                                          b)          
                      
Figure 81. a) Ribbon representation of PIN1. b) Ribbon and molecular surface 
representation of the PIN1 interdomain cavity. The WW domain is orange and 
the PPIase domain is light blue303. 
 
A closer look to the crystal structure of PIN1 with an Ala-Pro dipeptide shows an important role for 
two structural motifs: the loop between residues 66 and 77 and Cysteine113. This loop is involved in 
binding the phosphate moiety of the substrate303 and, in yeast, Lys63 is essential for the anchoring 
function of the phosphorylated substrate. Cys113 is spatially close to the Ala-Pro bound; this suggested a 
possible catalytic mechanism through a nucleophilic attack on the carboxylic carbon of the substrate by 
the sulphur of Cys113. Later, it has been shown that Cys113 has a very low pKa suggesting that this 
residue is ionized under physiologically conditions. Moreover, the local environment around Cys113, 
particularly Ser111 and Ser115, would maintain Cys113 with a negative, full or partially, charge; 
therefore, Cys113 will present its negative charge to the carbonyl atom of the substrate when it is bound 
to the cis-conformation. This negative charge would weaken the double bound character of the substrate 
pSer-Pro peptide bond allowing rotation from 0˚ (cis) to 180˚ (trans)304,305. 
The peptide bond linking two amino acids can either adopt cis or trans conformation but for all amino 
acids except proline trans conformation is thermodynamically more favoured than cis conformation; 
moreover, rotation around the peptide bond is energetically disfavoured due its partial double bond 
character. For proline the energy difference between the two conformations is far smaller and therefore 
the motifs Xxx-Pro could exist in both conformations. Both cis and trans conformation are substrates and 
product and, therefore, PIN1 acts catalysing the cis-trans and the trans-cis conversion306. 
The WW domain only recognizes phosphorylated Ser/Thr motifs followed by a Proline; PIN1 is the 
only PPIase having the WW domain and therefore it exclusively bind Ser/Thr-Pro motifs. Due to its 
affinity to phosphorylated Ser/Thr-Pro motifs, PIN1 works in concert with kinase and phosphatases 
proteins; the phosphorylation is carried out by different proteins which play important roles in many 
important biological processes such as cell-cycle regulation and cellular stress response. Kinases involved 
in these phosphorylation processes are i.e. the mitogen-activated protein kinase (MAPK), cycline-
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dependent kinase (CDK), extracellular signal-regulated protein kinase (ERK) and glycogen synthase 
kinase 3β (GSK-3). 
 
Role of PIN1 in cellular biochemical pathways  
PIN1 is involved in several different biological events and it plays important roles in many 
pathological condition such as cancer, Alzheimer’s disease, microbial infection, asthma and so on (Figure 
82). The reversible phosphorylation of Ser/Thr-Pro motifs is a key regulatory mechanism for the control 
of cellular processes. 
 
 
Figure 82. PIN1 regulates a spectrum of target activities322. 
 
PIN1 has been first identified in yeast as protein able to interact with never in mitosis gene a (NIMA) 
an essential mitotic kinase found in Aspergillus nidulans. NIMA overexpression induces cell death and 
therefore it was suggested that PIN1 has an important role in mitosis regulation acting as negative 
modulator. Moreover, depletion of its homologue in Saccaromyces cerivisiae ESS1 induces mitotic 
arrest301. 
Several evidences show that PIN1 acts on various mitotic-specific phosphoproteins. Cell cycle is 
regulated by many protein kinases known as Cdks which drive cells through different phases of the cell 
cycle. These kinases alter the function of proteins triggering the mitotic process by phosphorylating 
hundreds of proteins such as cyclin B-cdc2. PIN1 binds Cdc25 in vitro and in vivo which is the activating 
phosphatases of cyclin B-cdc2 and inhibits its activity; the activation of cyclin B-cdc2 is important for the 
progression from G2 to mitosis and such interaction between Cdc25 and PIN1 partially explains the 
ability of PIN1 to inhibit the G2/M transition307.     
Moreover, PIN1 inhibits the function of mitosis-inhibitory kinase Wee1 that inactivates cyclin B/cdc2 
through phosphorylation by interacting with Wee box308. In addition, PIN1 interacts with the early-mitotic 
inhibitor Emi1; Emi1 inhibits the activity of anaphase-promoting complex APC that controls the cell 
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division acting on various regulatory proteins. Emi1, required to induce S-phase and M-phase entry by 
stimulating cyclin B accumulation, is synthesized at G1-S transition and is degraded by ubiquitin-ligase 
SCFβtrpc pathway at prometaphase; PIN1 stabilize Emi1 by preventing its association with SCFβtrpc.309 
PIN1 also plays an important role in mitotic chromosome condensation; it interacts with chromatin 
during G2/M phase and modulates the mitotic protein at phosphorylation level310. 
All these results suggest that PIN1 is deeply involved in cell cycle regulation and therefore it is not 
surprising that it could have an impact on diseases caused by uncontrolled cells proliferation such as 
cancer. Many oncogenes and suppressor are regulated by Proline-directed phosphorylation and several 
evidences show that PIN1 is overexpressed in many human cancers such as breast, prostate, cervical, 
brain, lung and colon cancer311. 
PIN1 overexpression is correlated with the overexpression of two of its substrates, cyclin D1 and β-
catenin. PIN1 plays a critical role in regulation of cyclin D1. Overexpression of cyclin D1 has been found 
in 50% of patients with breast cancer and it is involved in oncogenesis; furthermore, inhibition of cyclin 
D1 expression causes growth arrest of tumor cells while its overexpression induce cell transformations. 
PIN1 increases levels of cellular cyclin D1 mRNA and protein, and activates its promoter through the AP-
1 site. The AP-1 complex is formed by c-Jun and c-Fos protein and c-Jun activity is modulated by 
phosphorylation induced by growth-factors, oncogenic proteins or stress (for example, c-Jun could be 
phosphorylated by JNKs, c-Jun N-terminal kinases, which could be also activated by oncogenic Ras). 
PIN1 binds phosphorylated c-Jun and increases its ability to activate cyclin D1 promoter (Figure 83)312. 
 
 
Figure 83. Role of PIN1 in regulating cyclin D1312. 
 
Moreover, it has been demonstrated that cyclin D1 may be phosphorylated at Thr286 and PIN1 could 
bind this Thr286/Pro motif stabilizing it by preventing its nuclear export and following cytoplasmatic 
degradation313.  
PIN1 is also able to stabilize β-catenin; it is involved in cancer development thanks to its ability to 
induce several genes critical for the cancerogenetic process such as those for cyclin D1, c-Myc and 
peroxisome-proliferator-activated receptor-δ (PPAR-δ). β-catenin is regulated by different proteins such 
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as adenomatus polyposis coli protein (APC) which is a nuclear-cytoplasmatic shuttling protein that can 
export β-catenin to cytoplasm where it is degradated; β-catenin contains different Ser/Pro motifs and, 
therefore, after phosphorylation of such sites it could be bind by PIN1. Such interaction takes place both 
in vitro and in vivo. The phosphorylation of β-catenin occurs at Ser246/Pro which is next to the APC-
binding site and PIN1 isomerizes this peptide bond preventing the ability of β-catenin to bind APC, thus, 
increasing the nuclear fraction of β-catenin. In addition, PIN1 transactivates several β-catenin target 
genes314.   
Another example of how PIN1 is linked to cell growth pathways derives from its interaction with the 
transcription factor NF-κB. It is an ubiquitous transcription factor that controls the expression of genes 
involved in immune responses, apoptosis, and cell cycle. NF-κB is a dimer of proteins belonging to the 
Rel family, including p65 (RelA), p50, p52, c-Rel, and the most abundant activated form consists of a p65 
and p60. It is normally sequestered in the cytoplasm by interacting with protein known as IkBs and it 
could be activated by a variety of stimuli, as cytokines, viral proteins and stress inducers; degradation of 
IkBs activates NF-κB allowing its nuclear translocations. It has been observed that after cytokine 
treatment, PIN1 binds to pThr254/Pro motif in p65 inhibiting its bond with IkBα (a type of IkBs) 
increasing therefore NF-κB’s nuclear accumulation and activity315. 
 
 
Figure 84. PIN1 regulates multiple oncogenic signalling322. 
 
PIN1 plays a critical role in regulating centrosome duplication. Deregulation of centrosome 
duplications leadsto abnormal centrosome numbers and aberrant mitosis. This duplication is modulate by 
multiple proteins such as Cdk-2 which are Pro-directed kinases. Suizu et al. reported that PIN1 is 
involved in regulation of centrosome duplications and its deregulation lead to centrosome amplifications, 
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chromosome instability and oncogenesis. It is believed that PIN1 could modulate centrosome duplications 
thought cyclin D1316.    
PIN1 also modulates the function of different proteins involved in cellular response to stress injury; 
for example, PIN1 is able to stabilize p53 and p73 following genotoxic stress. Several stresses could 
activate kinases, such as members of MAP kinase and CDKs, able to phosphorylate p53. Such p53 
phosphorylation occurs at Ser33, Ser46, Thr81 and Ser315 generating sites for PIN1 recognition. The 
binding of PIN1 generates conformational changes in p53 “leading to activation of genes required to cell-
cycle checkpoint or promote apoptosis”317,318. Moreover, the activity of p53 is also controlled by the 
apoptosis inhibitor iASPP which blocks p53 binding to cell-death related promoter: in presence of 
cytotoxic stress PIN1 induces dissociation of iASPP from p53319. 
Furthermore, PIN1 is able to bind che-1, an RNA polymerase II-binding protein that plays an 
important role in transcriptional activity of p53, which is down-regulated during the apoptotic process. In 
response to various stimuli che-1 is phosphorylated and it could be negatively modulated by 
HDM2/MDM2 proteins. The interaction between HDM2/MDM2and che-1 is regulated by PIN1; che-1 
interacts with PIN1 following apoptotic DNA damage and it increases che-1 degradation320. 
PIN1 seems to be able also to regulate phospho-Ser77 Retinoic Acid Receptors α (RAR α). RARα 
activity is regulated by phosphorylation that can occur at different sites: 
1. Ser369: protein kinase A phosphorylates Ser369 promoting heterodimerization and DNA 
binding; 
2. Ser157: Ser157 is phosphorylated by protein kinase C leading to destabilization of 
heterodimer-DNA complex; 
3. Ser77: Ser 77 is phosphorylated by cdk7 leading to receptor stabilization in presence of the 
ligand. 
 
The latter AA is located in a region whit several Pro residues and represents a substrate of PIN1; 
phosphorylation of Ser77 is moreover important for RARα stability; indeed, RARα is able to activate the 
fibroblast growth factor promoter fgf8 which is a gene involved in cancerogenesis. Therefore, PIN1 is 
able to modulate RARα degradation and so it is able to down regulate RARα activity on fgf8321. 
In addition to all above presented connections with cell growth regulation and desregulation processes, 
PIN1 is deeply involved in neuronal function322. PIN1 is expressed in neurons and although its 
physiological functions are still not totally elucidated, it is clear that PIN1 interacts with several proteins 
involved in the neuronal homeostasis, such as τ protein and Amyloid Precursor Protein APP323,324; τ 
phosphorylation precedes the formation of neurofibrillary tangles while from the phosphorylation of APP 
derived the Aβ peptide which leads to the formation of senile plaques. Extracellular senile plaques and 
intracellular neurofibrillary tangles are the neuropathological hallmarks of Alzheimer’s Disease (AD) and 
therefore PIN1, targeting τ and APP, results to be involved in AD. PIN1 binding pThr231-τ restore the 
functions of phosphorylated τ to bind microtubules and to promote microtubule assembly. Moreover, 
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PIN1 binding to pThr231 induces τ dephosphorylation by promoting the action of PP2A which is the 
physiological τ phosphatase325. Furthermore, PIN1 is involved in the Aβ production acting on 
phosphorylated APP326. APP is a transmembrane protein that could be processed by two distinct 
pathways; the non-amyloidogenic pathway which involves a proteolytic cleavage by α-secretase and leads 
to non-toxic product and an amyloidogenic pathway which consists a sequential cleavage by β- and γ-
secretase which leads to production of peptides, mainly of 40 or 42 amino acids in length, called Aβ40 and 
Aβ42 respectively. Of the two released products, Aβ42 is the more toxic even if both have been found in 
senile plaques. APP could be phosphorylated at Thr668 by different kinases, such as stress-activated 
protein kinase 1b, cyclin-dependent kinase and Cdc2 kinase, and such phosphorylation increases Aβ 
secretion in vitro. The effect of PIN1 on APP cascade is more complicated. In 2005 Akiyama and 
coworkers demonstrated, by studying the production of Aβ in both wild-type and PIN1-null mice, that 
PIN1 promotes Aβ production in vivo. This is because the levels of Aβ40 and Aβ42 were reduced in PIN1-
null mice compared with wild-type327. Soon later, Pastorino and coworkers showed that PIN1 is able to 
bind pThr668 both in vitro and in vivo experiments. Moreover, it has been shown that Thr668-Pro APP is 
largely in trans-conformation with a small amount of cis-conformation that could increase after the 
phosphorylation of Thr668. The “trans-conformation is more susceptible to non-amyloidogenic process 
while the cis-conformation favours the amyloidogenic process. The presence of PIN1 keeps the fraction 
of cis-Thr668-Pro APP low whereas a loss of PIN1 function leads to an accumulation of cis-Thr668-Pro 
APP and promotes amyloidogenic production of Aβ” (Figure 85)328.  
 
     
                       
 
Figure 85. Effect of the presence and the absence of PIN1 in APP 
processing328. 
 
Moreover, oxidative stress may play an important role in the pathogenesis and in the progression of 
AD. Such oxidative stress is manifested by nucleic acids oxidation, proteins oxidation, lipids 
peroxidations and ROS formation329. Butterfield et al showed that protein oxidation was increased in the 
hippocampi of Mild Cognitive Impairment (MCI) subjects (MCI is a transition zone between normal 
cognitive aging and early dementia), suggesting that such protein oxidation is important in AD 
development. Specifically they found that α-enolase, glutamine-synthetase, pyruvate kinase M2 and PIN1 
were more oxidized in the hippocampi of MCI subject330 PIN1 activity was found to be reduced in AD 
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hippocampus due to its oxidative modification. PIN1 could be oxidazed both in vitro and in vivo and the 
resulting reduced activity seems to be responsible of the increased concentration of phospho-τ in AD331. 
 
PIN1 inhibitors 
An increasing number of evidences suggest that PIN1 could be an attractive new target for anticancer 
drug development332; as above discussed PIN1 is overexpressed in many human cancers, it acts as critical 
catalyst for multiple oncogenic pathways and in several cancer cell lines depletion of PIN1 determines 
arrest of mitosis followed by apoptosis-induction. Moreover, it has been shown that PIN1 knockout mice 
developed normally suggesting that an anti-PIN1 therapy could not generate toxic effecta333.  
Up to now the only successful strategy leading to PIN1 inhibition in vitro and in vivo derived from the 
use of antisense strategies, dominant negative strategies, RNA interference and gene knockout333,334,335,336. 
Not so many small-molecule PIN1 inhibitors have been identified, and unfortunately none of them is 
clinically useful. 
The most known PIN1 inhibitor is the natural product Juglone (5-hydroxy-1,4-Naphtoquinone) which 
specifically inactivates the activity of parvulin-like PPIase from E. coli, the homologous PPIase Ess1 in 
yeast and the human PIN1 while it does not affect the other families of PPIase, cyclophilins and 
FK506BPs. 
 
OH
O
O
Juglone
 
 
Juglone covalently bind to the side chain of Cys41 probably by a Michael addition which occurs 
between the sulfhydryl group of the Cys and the α,β-unsaturated carbonyl system of the juglone337. 
Juglone induces apoptosis in Hela cells in dose-dependent manner and prevents cells from entering in 
apoptosis (Figure 86)333, 338. 
 
 
 
 
 
 
 
Figure 86. Ability of Juglone to inhibit PIN1338. 
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Moreover, Juglone blocks transcription by interacting with RNA polymerase II but the results show 
that such effect is not mediated by the inhibition of PIN1339; furthermore, Juglone inhibits also other 
enzymes such as pyruvate carboxylase and glutathione S-transferase337. 
In 2003 Uchida et al. identified new PIN1 inhibitors by screening a chemical library of compounds 
with double ring structure and compounds previously developed as potential anticancer (Figure 87). 
Among the different compounds tested, three of them resulted potent PIN1 competitive inhibitors: PiA 
which inhibits PIN1 with an IC50 of 2.0 µM, PiB and PiJ with both an IC50 of 1.5 µM. These derivatives 
are more potent than Juglone which showed an IC50 of 5 µM and they did not bind DNA or other target 
protein such as Topoisomerase I. Moreover, the effects of PiB and PiJ on cancer cell proliferation were 
tested in many cancer cells, such as HSC2, HCT116, OVK2, SKOV3, and they were the most potent 
inhibitor of cell proliferation showing an IC50 in µM range. 
 
 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
         
 
Figure 87. PIN1 inhibitors developed by Uchida et al.; 
in brackets are reported their IC50 expressed in µM340. 
 
 
Most of the compounds tested have symmetrical structure and this might lead to an increase in 
potency; moreover, docking studies on PiB have been performed showing how PiB inhibits PIN1: the 
aromatic rings of PiB may establish π-π interaction with the protein’s amino acids while the hydrogen 
atom of Arg69 and His157 and the backbone amide hydrogen of Lys57 form an H-bond with the oxygen 
atoms of PIN1 suggesting that the aromatic rings and the oxygen atoms are crucial for the PIN1-PiB 
interaction (Figure 88)340. 
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Figure 88. Docking model of PiB in PIN1340. 
 
In 2005, Bayer et al. discovered new peptidomimetic PIN1 inhibitors derived from the natural product 
Pepticinnamin E, an inhibitor of farnesyltransferase. These new derivatives synthesized by combinatorial 
synthesis were able to induce apoptosis but in some cases the connection between apoptosis-induction and 
farnesyltransferase inhibition was not clear; however, many evidences suggested a possible involvement of 
PIN1. Among all the Pepticinnamin analogues synthesized, the most potent resulted compounds LXXXVIII-
XC which showed an IC50 values in micromolar range (Figure 89). These compounds seem to inhibit hPIN1 
by decreasing the thermodynamic stability of the protein and/or lowering its solubility in aqueous media and 
are able to induce apoptosis in mammalian transformed cell line341. 
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Figure 89. PIN1 inhibitors derived from Pepticinnamin E341. 
 
 
In 2006 Wildemann and coworkers reported the screening of a combinatorial peptide library leading to 
the discovery of very potent PIN1 inhibitors. Starting from the structure of PIN1 bound to Ala-Pro dipeptide, 
they generated fifteen compounds having the following general structure: Ac-Lys(Nε-biotinoyl)-Ala-Ala-
Xaa-Thr(PO3H2)-Yaa-Zaa-Glm-NH2 where Xaa, Yaa, Zaa could be either natural amino acids, non-natural 
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amino acids or N-alkyl amino acids. The most potent compound of the series was the peptide Ac-Lys(Nε-
biotinoyl)-Ala-Ala-Bht-Thr(PO3H2)-Pip-Nal-Glm-NH2 which showed an IC50 value of 0.21 µM (Bth, β-(3-
benzothienyl)alanine; Nal, β-(2-naphthyl)alanine; Pip, piperidine-2-carboxylic acid).  
Another group of peptidomimetics able to inhibit PIN1 has been developed by Wang et al. using alkenes 
as amide isosters (Figure 90). This approach has been previously used by the same research group in order to 
obtain hCyPA inhibitors: for example, they showed that the peptidomimetic Ala-cis-Pro (Z)-alkene inhibited 
hCyPA with an IC50 of 6.5 µM342; moreover, the dipeptide Leu-trans-Pro (E)-alkene was able to inhibit 
FKPB with an IC50 of 8.6 µM343. Therefore, Wang and coworkers developed three conformationally locked 
PIN1 substrate isosters: Ac-Phe-Phe-pSer-ψ[(Z and E)CH=C]-Pro-Arg-NH2, XCI and XCII, and N-
methylamide XCIII. 
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Figure 90. PIN1-mediated pSer-Pro amide isomerisation and inhibitors 
cis-isoster XCI, trans-isoster XCII and XCIII and endocyclic isomer of 
XCIV344. 
 
Both peptidomimetics XCI and XCII are competitive inhibitors of PIN1 and the cis-isostere XCI (IC50 
1.3 µM, competitive inhibitor constant Kis 1.74 µM) was more potent than trans-isostere XCII (IC50 28 µM, 
Kis 40 µM respectively). These results suggested that PIN1 catalytic domain binds the cis-isostere stronger 
than the trans-isostere and that PIN1 preferentially binds the cis-isostere in acqueous solution. Moreover, 
XCIII which is more hydrophobic derivative of XCII did not improve the biological activity as well as the 
endocyclic isomer XCIV is a very poor inhibitor showing that the location of the double bond is fundamental 
in the protein-substrate recognition. In addition, XCI and XCII has been tested again A2780 ovarian cancer 
cells displaying an IC50 of 8.3 and 140 µM, respectively344. 
In 2006 Daum and coworkers designed a series of Aryl Indanyl Ketones as transition-state analogues of 
PIN1: they assert that the aryl 1-indanyl ketones motif could mimicked the “twisted-amide” transition states 
and the change of hybridization about the ring nitrogen atom (Figure 91). 
All the aryl indanyl ketones synthesized XCV-C showed Ki values in the micromolar range. The methoxy 
group in a adjacent position to the carbonyl group, XCV, was better than the hydroxy group, XCVI, leading 
to the more potent derivative (Ki 8.7 µM for XCV and 15.0 µM for XCVI); moreover the introduction of a 
 113 
nitro group on the phenyl ring, XCIX, caused an improvement of PIN1 inhibition to sub-micromolar range 
while the reduction of the nitro group to amino group, C, did not influence the inhibition values (Ki 0.5 µM 
for XCIX and 0.4 µM for C). The two enantiomers of XCVIII showed different Ki values (Ki 5.6 µM for 
(R)-XCVIII and 51.0 µM for (S)-XCVIII). (R)-XCVIII, (S)-XCVIII and rac-XCVIII have been found able 
to reduce the activity of p53 reporter gene in etoposide treated MCF-7 cells (human breast adenocarcinome); 
moreover, these compounds were able to decrease the level of β-catenin (in tumor cells, PIN1 regulates the 
β-catenin turnover) in SH-SY5Y cell lines (human neuroblastoma)345. 
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Figure 91. Selected aryl 1-indanyl ketones designed by Daum et al345. 
 
Some of the PIN1 inhibitors showed above are phosphorylated compounds that penetrate with difficulty 
the cellular membrane due to the negative charge located on the phosphate group. In 2007, Zhao and Ezkorn 
presented PIN1 inhibitor CI and its prodrug form CII; the phosphate group was masked by bis (bis-
pivalyloxymethyl) (POM) group that is enzymatically removed after its entry in the cell to give its active 
form (Figure 92). 
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Figure 92. PIN1 inhibitor CI and its prodrug form CII346.  
 
CI inhibits PIN1 in µM range and both compounds have been tested in A2780 ovarian cells; CI shows an 
IC50 of 46.2 µM and CII shows an IC50 of 26.9 µM suggesting that the introduction of POM on phosphate 
group of CI may help the entry into the cells by improving the hydrophobicity of the inhibitor346. 
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2.1.3 DNA as Target for anticancer drugs 
DNA plays a fundamental role in cell proliferation and cancerogenetic processes and therefore a large 
percentage of anticancer agents are molecules that are able to interact with it. Based on their possible 
interaction with DNA, such molecules have been classified in four wide groups: 
 
• Alkylating agents, which are able to covalently bound DNA; 
• Agents able to truncate DNA double helix; 
• Agents that reversibly interact with double helix of DNA; 
• Agents that intercalate between the DNA bases. 
 
Among decades many efforts have been made in order to discover new molecules and new biochemical 
pathways which could be targeted by these molecules. One of the most important reported anticancer 
compounds is represented by the intercalator agents. Such kinds of molecules are typically characterized by a 
planar heterocycle of approximately the size and shape of DNA base pair. They insert perpendicularly into 
the DNA without forming any covalent bonds and the formed complex is stabilized by hydrophobic, Van der 
Walls , hydrogen bonding and charge transfer forces. It has been reported that these interactions may affect 
the cells replication processes leading to cellular death347. 
 
 
Figura 93. Deformation of DNA by an intercalating agent347. 
 
 
Although their ability to insert directly into the molecular structure of DNA, this is just the first 
mechanisms used by this molecule to induce cytotoxicity. Indeed, many DNA-intercalators are able to 
induce changes in DNA-associated proteins, such as DNA-polymerase, transcription factors and 
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Topoisomerase347. The latter interaction is probably the most important mechanism of cytotoxicity induces 
by such molecules. They are able to stabilize the ternary complex DNA-drug-Topoisomerase, therefore, 
blocking the action of this important enzyme; once the ternary complex is detected by the cell as damage it 
will triggers a series of events, such as p53 activation, leading to apoptosis348.  
 
 
Figure 94. Schematic representation of the mechanism of cytotoxicity of 
a DNA-Intercalator348. 
 
 
Intercalators represent a wide group of compounds that could be classified in two main groups: 
• Classical intercalators, which display their cyctoxicity by inhibiting Topoisomerase II; 
• Non-classical intercalators, developed more recently. 
 
The most important differences between these two classes of intercalator concern the chemical structures: 
classical-intercalators contains bi- or tri-cyclic rings fused while non-classical intercalators present non fused 
rings system349. 
 
Classical intercalators could further be classificated in subfamily, based on the nature of their 
chromophore unit, in: 
• Naphthalimide and related compounds, such as Mitonafide, Amonafide, Azonafide and Elinafide; 
• Intercalators based on the pyridocarbazole system, such as Ellipticine and 9-methoxyellipticine; 
• Anthracycline, such as Doxorubicine, Daunomicine and Mitoxantrone; 
• Antibiotics of the Echinomycin family, such as Echinominine and Triostina; 
• Acridine and related compounds, such ad Amsacrine; 
• Actinomycin; 
• Analogues of Benzimidazo-[1,2,c]quinazoline350. 
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Figure 95. Selected examples of classical intercalators. 
 
These compounds so different from the chemical point of view, exert their cytotoxic effect by 
intercalating into DNA and by inhibiting TopoII; moreover, some of them could have different mechanism 
of action: for example, Anthracyclin thanks to their oxidoreductive properties are able to induce DNA-
damage through ROS-formation or Acridine could inhibit either TOPOI and TOPOII.  
Non-classical intercalators are characterized by the presence of a huge aromatic planar system able to 
intercalate and to stabilize triple-helix DNA more than duplex-helix. Also non-classical intercalators are 
divided in different groups: 
 
 Threading intercalators; 
 Tris-interacalator, such as triacridines. 
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Figure 96. Chemical structure of non-classical intercalators. 
 
 
Among all the intercalators developed, Braña and coworkers in 1970s published a series of 
Naphthalimides as anticancer agents351. SAR studies carried out on these structures showed that the presence 
of a basic terminal group is essential for activity and that such activity is maximal when the nitrogen atom on 
the side chain is two methylene units far from the aromatic ring; furthermore, it has been discovered that the 
better substituent on the nitrogen atom is a dimethyl ones and substitution in position 5 on the naphthalic ring 
is resulted the best for the activity; the prototypes of this series are Amonafide and Mitonafide (Figure 
97)352,353. 
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Figure 97. Naphtalimides developed by Braña and coworkers. 
 
 
The chemical structure of such compounds derived from the combination of chemical motifs that 
characterized other anticancer compounds: β-nitronaphthalene from Aristocholic Acid, the ring of CG-630 
and the basic chain of Tilorone (Figure 98). 
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Figure 98. Chemical motifs included in the anticancer drug design. 
 
Both Amonafide and Mitonafide have been tested in clinical trials; Amonafide is active against murine 
lymphocytic leukemia (P338) cells and lymphocytic mouse leukemic L1210 cells while Mitonafide is active 
against human epidermoid carcinoma KB cells and cervical cancer HeLa cells354,355. Both compounds 
intercalated into DNA356  and are able to induce a TOPOII-mediated DNA cleavage at Nucleotide No 1830 
on pBR322 DNA357. In particular, it has been seen that such cleavage is not observed in compounds without 
the basic side chain.   
Amonafide is substrate of a specific metabolic enzyme, N-acetyltransferase 2 (NAT2) that catalyzed the 
acetylation of a wide range of amines, including arylamines and heteroaromatic amines. Substrates of NAT2 
are also isoniazide, procainamide, hydralazine and sulfonamides. Amonafide could be metabolized through 
two different pathways: the first one by cytochrome CYP1A2 leading to a formation of oxidized derivative 
and the second one by NAT2 leading to N-acetylamonafide which is still metabolically active. Recently, it 
has been demonstrated that the most important side effects of Amonafide are caused by its acetylated 
metabolites (Figure 99)358. 
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Figura 99. Metabolization of Amonafide. 
 
 
Amonafide and Mitonafide are the most active compounds in the series of Naphthalimides and the only 
difference between them is constituted by the substituent on the aromatic ring: Mitonafide presents an 
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electron-donating amino group while Amonafide presents an electron-withdrawing nitro group. It has been 
suggested that the nitro-group promotes the formation of a charge transfer complex with DNA-bases while 
the amino-group promotes the stabilization of DNA-drug complex through the formation of hydrogen bond 
with the phosphate group of the DNA-backbone. Therefore, a number of SAR studies carried outon the ring-
substituent have been carried out leading to the compounds having an amino-group in 8 and a nitro-group in 
5; such derivatives were more active than Mitonafide and Amonafide on Human colon carcinoma cell line 
CX-1 and human hepatic stellate cell line LX-1. Moreover, a series of dinitro- and diamino-derivatives of 
Amonafide and Mitonafide, CIII and CIV have been described and they showed both in vitro and in vivo 
antileukemia and antimelanoma activities359. 
 
N NO O O O
R1
R2
R3
NH3C CH3
O2N NH2 X Y
General formula
of 5-amino-8-naphthalimides
CIII: X = Y = NH2 5,8-diaminonaphthalimides
CIV: X = Y = NO2 5,8-dinitronaphthalimides
 
 
Another modification is represented by the replacement of the naphthalene moiety by an anthracene 
obtaining Azonafide, which result more active than Amonafide on the cell lines of human melanoma 
UACC375, human ovarian cancer OVCAR3 and L1210360. Analogues of Azonafide have been synthesized 
by replacing the anthracene moiety with phenanthrene (CV) and azaphenanthrene (CVI, CVII): 
unfortunately these compounds were less potent than Azonafide pointing out that linear anthracene 
chromophore is better than other rings system361. 
. 
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In order to improve the antiproliferative activity of these compounds, other analogues have been designed 
where the naphthalene rings were fused to other heteroaromatic systems. Despite the introduction of an 
imidazolic ring did not lead to any improvement, the introduction of a π-deficient pyrazine ring lead to a new 
series, Pyrazinonaphthalimmides CVIII and CIX, endowed with a more potent intercalating activity; such 
compounds have been screened against human colon adenocarcinome HT-29, HeLa and human prostate 
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cancer PC-3 cell lines showing an IC50 in micromolar range. Compound CIX having a -CF3 group is less 
active than CVIII: this result could be explained by the steric hindrance of the trifluoromethyl group362,352.  
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CVIII: R = H
CIX:  R = CF3
 
 
 
Based on these promising results given by the introduction of a pyrazine ring, other similar compounds 
have been synthesized in which the aromatic system of Amonafide has been conjugated with a π-deficient 
ring, such as furane and thiophene (CX-CXIII).  
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CXI: R = S
CXII:  R = O
CXIII: R = S
 
 
All these compounds have been screened against HT-29, HeLa and PC-3 cell lines resulting to be more 
potent than Amonafide; in particular CX is active in a submicromolar concentration. In order to explain the 
activity of CX, Braña and coworkers proposed a model to clarify the interaction between it and DNA (Figure 
100). This model calculates four different possible orientations of CX into DNA: 
 
a. orientation with the side chain in the major groove and the furan ring stacking between 
the bases T and G; 
b. orientation with the side chain in the major groove and the furan ring stacking between A 
and C; 
c. orientation with the side chain in the minor groove and the furan stacking between T and 
G; 
d. orientation with the side chain in the minor groove and the furan ring stacking between A 
and C. 
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Figure 100. Possible interaction model of CX with DNA; the 
black square represents the orientation of the furan ring, and the 
sphere represents the protonated dimethylamino group of the side 
chain363. 
 
 
The more stable orientation is the one where the side chain remains in the major groove of the DNA and 
the furan ring is stacked between the bases A and C363. 
Furthermore, a series of molecules derived from the fusion of the aromatic rings of Amonafide and 
thiazolidine rings, calledThioazonaphthalimides, showed a very potent activity as intercalator (CXI-CXIII). 
In this case, the better length of the side chain has been found to correspond to three methylenes groups 
which allowed the nitrogen atom to stay at the right distance from DNA in order to establish H-bond, 
outlining the importance of the basic side chain. 
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All these compounds result to be more active than Amonafide against different cancer cell lines, such as 
A-549 human lung adenocarcinome and P388 lymphoblastic cell lines. In particular, CXII is more active 
against P388 and CXIII is more active against A-549 cell lines364. 
In order to improve the binding activity toward DNA a new series of bisintercalating agents have been 
designed basing on the structure of Amonafide and Mitonafide. Such compounds, called bis-naphthalimides, 
are structurally characterized by the presence of two naphthalimide units bound together by a chain 
containing at least one nitrogen atom and with different substituent on the aromatic rings. 
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In HT-29 cell lines all the bis-naphthalimides resulted more potent than Amonafide and Mitonafide; the 
susbstituent on the aromatic rings sensibly influenced the antiproliferative activity: 3-NHCOCH3 < 3-NH2 < 
3-NO2. However, the more active compound was that without substituents on the aromatic rings; such 
compound called Elinafide showed an excellent antiproliferative activity against HT-29; moreover, in vivo 
Elinafide has shown to be able not only to inhibit the cellular growth but also to induce regression of the 
cancer cell mass; furthermore, the absence of the nitro group on the aromatic ring seemed to reduce the 
neurotoxicity associate with Mitonafide365.366. 
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Elinafide acts by forming a sequence-specific complex with an exanucleotide d(ATGCAT)2 portion where 
two naphtalimide units bisintercalate at TpG and CpA steps of the DNA, stacking with G and A. Moreover, 
the N,N-bis(ethylene)-1,3-propylenediamine linker lies in the major groove; furthermore, one of the 
protonated amino groups of Elinafide is hydrogen-bonded to O6 of guanine in the major groove while the 
other one could form an hydrogen-bond to guanine O6 of the opposite strand or establishes a weaker 
hydrogen-bond with N7 of the same base (Figure 101)367,368. 
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Figure 101. Stereoview of the complex elinafide-
d(ATGCAT)2; Elinafide is in blue, guanine in 
yellow and the oxygen atom is in red368. 
 
Moreover, a series of symmetrically and non-symmetrically Linefeed derivatives have been developed 
by replacing the naphthalene system with an acenaphthene one. However, the latter compounds were less 
active than the symmetric homologues369,370. 
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In order to find compounds more potent than Elinafide, compound DMP-840 has been developed and it 
displaied biological effects similar to those of Elinafide; it binds DNA forming a stable ternary complex with 
DNA and TOPOII but it did not poison TOPOII371. 
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A further development of this series of derivatives is represented by the replacement of the 
naphthalendiimide structure with the 1,4,5,8-tetracarboxylicnaphthalendiimide (NDI) moiety to obtain new 
and more active intercalator agents. Indeed, both these features posses a big aromatic system and two co-
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planar carbonyl groups. Therefore, new intercalator moiety has been esigned (N-BDMPrNDI, DMe-
NDI,Phen-NDI) and, in addition, such compounds with NDI structure, beside their ability to intercalate into 
DNA, stabilize the triple helix DNA. Instability of triple-helix DNA is due to the repulsion between the 
nucleotides of these triple helix and such structure are strictly implicated in the genes regulation. Several 
studies point out that an increase in the stability of these structure could be useful in anti-genes and antisense 
therapy372. 
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2.2 Drug Design 
 
Design and synthesis of new anticancer agents represents one of the most challenging field in medicinal 
chemistry. Cancer is one of the main causes of death worldwide and despite several efforts have been made 
by scientists, anticancer drugs currently in therapy present a wide range of side effects due to their lack of 
selectivity159.  
One of the most interesting group of antiproliferative compounds used in therapy is represented by 
molecules targeting DNA, such as intercalators. These compounds, thanks to their chemical structures, are 
able to intercalate into the double helix of DNA and trigger different biochemical cascades leading to cell 
death. 
Furthermore, it is known that natural polyamines are extremely important as regulator of cell growth 
because they control the progression of the cell cycle and regulate the cellular entry in apoptosis. In 
particular, their strictly relationship with apoptosis is emerging as an important target to focus on. Indeed, it 
has been demonstrated that natural polyamines, such as spermine and spermidine, are able to trigger 
apoptosis acting on caspases and mitochondrial-mediated apoptotic pathway. Moreover, given their 
importance in maintaining cellular homeostasis, polyamines are widely distributed in all kind of cells. 
Polyamines could be either synthesized by cells or could be provided from outside sources by using a 
specific transport system (PAT). This active transport system is more expressed in cancer cells, because, 
thanks to their fast reproduction, they need high levels of polyamines. Therefore, PAT represents an ideal 
target to hit selectively cancer cells and to deliver specific anticancer drugs. As reported before several 
polyamines-intercalators conjugate have been developed and are actually under clinical investigation. 
Another recent and important cancer cell target is constituted by the enzyme called prolyl-peptidyl cis-
trans isomerase (PIN1). Current experimental evidences show that PIN1 is deeply involved in the 
development of carcinogenesis process. In particular, PIN1 is able to recognize specific phosphorylated 
Thr/Ser-Pro motifs of several proteins and to induce isomerisation of the peptide bound leading to change in 
protein structure and function. It has been shown that PIN1 inhibition prevents entry into mitosis and cell 
division and it is overexpressed in numerous human cancers. Therefore, PIN1 is proposed as a therapeutic 
target for cancer treatment and PIN1-inhibitors may represent promising anticancer agents332. The aim of 
this work is to design and synthesize new molecular entities acting as Multi-Target-Directed Ligands 
(MTDLs)7,156 able to hit different biochemical targets involved in cancerogenesis. Cancer can be considered 
a multifactorial disease and a single drug hitting a single target (one molecule-one target approach) may be 
inadequate for the treatment of such disease. Otherwise, compounds able to hit more than one therapeutic 
targets could be effective in treating of this complex disease (one molecule-multiple targets approach). The 
rational design of new MTDLs, that is compounds that simultaneously modulate different protein targets, 
either positively or negatively, at a comparable concentration for each target, remains a challenging task. 
Normally, the starting point to design new MTDLs is represented by a scaffold endowed with a particular 
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biological profile which can be widened by inserting new pharmacophoric units responsible of additive 
pharmacological properties. 
In literature there are several examples of synthetic polyamines characterized by antiproliferative activity, 
one of them is represented by MDL 27695295. This compound showed a good antiproliferative activity 
against HeLa and MCF-7 cell lines, probably due to its ability to interfere with intracellular polyamines 
pathways. Although its basic functions, protonated at physiological pH, it is capable to entry into cells by 
using PAT or other alternative transport systems. This compound, although investigated some years ago, 
called our attention for its particular chemical features very similar to many other polyamines synthesized by 
Melchiorre and coworkers. It is structurally characterized by a polyamine backbone endowed with two 
benzylic groups inserted on the outer nitrogen atoms. We thought to design new anticancer MTDLs by 
applying the “universal template approach”244 on the MDL 27695 structure with the aim to enlarge its 
biological profile. This approach has been successfully applied in the past and it asserts that the insertion of 
different pharmacophores onto the polymethylene tetraamine backbone can tune both affinity and selectivity 
for any given receptor and/or enzyme systems244. With this in mind, we searched some pharmacophores to 
introduce on the template, represented by the polyamine backbone, of MDL 27695. Two structures called 
our attention: N-BDMPrNDI and PiB. The first one is known as DNA intercalator, the second one represents 
a PIN1 inhibitor discovered by random screening by Uchida and coworkers. Both structures seem very 
similar, and in particular are characterized by a 1,4,5,8-naphthalenetetracarboxylic diimide (NTD) moiety. 
With the aim to widen the biological properties of MDL 27695, in order to obtain new MTDLs endowed 
with antiproliferative activity together with the ability to intercalate in DNA structure and to inhibit Pin1, we 
inserted the NTD moiety, peculiar chemical feature of N-BDMPrNDI and PiB, on the template structure of 
MDL 27695, obtaining 16-24, which differ by side chains length (Figure 102). The presence of the methoxy 
groups in orto positions on the two aromatic rings is justified by electronic effects exerted by these two 
substituents which contribute to increase the basicity of the two basic nitrogen atoms and the relative 
protonation at physiological pH, facilitating their binding with the phosphate groups of DNA167.  
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Figure 102. Drug design of compounds 16-24. 
 
Finally, the molecular simplification approach has been applied to 16-24 structures, obtaining 25-33, in 
order to verify the importance of the two basic side chains. To note that these derivatives resemble the 
structure of mitonafide, a well known anticancer drug in phase II of clinical trials (Figure 103). 
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Figura 103. Drug design for compounds 25-33. 
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2.3 Methods 
 
2.3.1 Synthesis 
Compounds 16 and 17 have been synthesized following the procedure showed in scheme 4. The 
appropriate diamine, 55 and 56, have been monoprotected at the nitrogen atom with tert-Buthoxycarbonyl 
group obtain amines 57 and 58 as reported in literature373. 61 and 62 have been synthesized following the 
procedure reported in literature374: 57 and 58 were directly condensated with naphthalenetetracarboxylic 
dianhydride to give conjugate 59 and 60; removal of the protecting group by acidic hydrolisys led to 
diamines 61 and 62. These diamines were treated with 2-methoxybenzaldehyde followed by reduction with 
sodium borohydride of the formed Schiff base to the corresponding dibenzyl derivatives 16 and 17. 
Compounds 18-24 have been synthesized following the procedure showed in scheme 5. 
Naphthalenetetracarbocylic dianhydride was condensed with the corresponding diamines 63-69 to obtain the 
derivatives 70-76; such compounds were treated with 2-methoxybenzaldehyde to form the Schiff base that is 
then reduced by sodium borohydride to give the corresponding diamine diimides 18-24.   
Finally, 25-33 were obtained by reacting 1,8-Naphthalic anhydride with the corresponding diamines 63-
69 leading to 77-85 following the procedure reported in literature375; then, 77-85 were condensate with 2-
methoxybenzaldehyde and then reduced by sodium borohydride giving the products 25-33. 
Salt ptoluenesulfonates of all compounds were prepared to obtain derivatives easier to handle. 
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                                 Scheme 4 
 
 
 
 
 
 
 
 
 
 
 
                    
Condition: (i) Boc2O, CHCl3, room temperature; (ii) Naphtaletetracarboxylic dianhydride Et3N, i-PrOH, 
reflux; (iii) CF3COOH, CH2Cl2 ; iv) (a) Et3N, 2-MeOC6H4CHO, MeOH, reflux, (b) NaBH4, MeOH, room 
temperature
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                                        Scheme 5 
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                                   Scheme 6 
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2.3.2 Biology 
Derivatives were tested for in vitro antiproliferative activity in human breast cancer (SKBR-3) and 
leukemia (CEM) cell lines. Growth inhibition induced by tested compounds was evaluated by the MTT [3-
(4,5-dimethylthiazolyil-2)-2,5-diphenyltetrazolium bromide] assay. 
The DNA-binding activity of the strongly cytotoxic compounds 16, 17 and mitonafide was determined 
using a fluorometric intercalator  displacement method376 and it s expressed as the drug concentration 
reducing by 50% the fluorescence of DNA-bound Ethidium bromide. From these data, an apparent binding 
constant (Kapp) can be calculated, that roughly estimate the affinity of the drug for calf thymus DNA376.377. 
All the experimental part of the biology assays has been reported in other PhD thesis. However, it will be 
described in a paper which will be published as soon as possible. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 134 
2.4 Results and Discussion 
 
Derivatives 16-33 were firstly evaluated by in vitro assays for their antiproliferative activity in human 
breast cancer (SKBR-3) cell and leukemia cell (CEM) lines to identify the lead compound of the series. 
Growth inhibition induced by tested compounds was assessed by the 3-(4,5-dimethylthiazolyil-2)-2,5-
diphenyltetrazolium bromide (MTT) assay, based on the assessment of mitochondrial dehydrogenase 
activities. In particular, the cells were treated with the test compounds at concentration ranging from 0.1 to 
10 µM for 24 h, 48 h and 72 h. Each quoted value is the mean of sextuple experiments. To compare the 
antiproliferative potencies in terms of concentrations required for 50% of the effect, all analogues were 
tested in dose-dependent manner, and the observed IC50 values are listed in Table 6. 
From an analysis of the results 17 (n=3) emerged as the most potent compound of the entire series on the 
two cells lines (IC50 values of 0.2 and 0.4 µM, respectively). From the general point of view, the bis 
substituted derivatives are generally more potent than the related mono substituted derivatives, with the 
exception of 22 and 23 which showed comparable activity values with that of corresponding 31 and 32. It 
can be observed that in the first series of the bis substituted derivatives, the growing homologation of the side 
chains influenced the cytotoxic activity. Indeed, the cytotoxic activity on the two cells lines, starting from 17, 
which was the most potent, showed a minimum level for 21 (n = 7), raising again with the increase of the 
chain length from 8 (22) to 10 (23) methylene units. To note that 24 showed a comparable biological profile 
with the most potent 17 on SKBR-3 cell line, but not on CEM one, where it displayed however a notable 
value of 0.7 µM. The same pattern was not observed in the mono substituted series, in which the only notable 
derivative was 32 endowed with an IC50 value on SKBR-3 of 0.5 µM. 
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Table 6. Cytotoxyc activity of 16-33 on SKBR-3 breast cancer and 
leukemia cells (CEM) after 72 hours compounds exposure. 
 
 
Compounda 
 
IC50 SKBR-3 (µM)b 
 
IC50 CEM (µM)b 
16 0.7 1.3 
17 0.2 0.4 
18 0.7 0.8 
19 1.1 1.1 
20 1.2 2.2 
21 1.7 2.5 
22 1.0 1.6 
23 0.4 1.4 
24 0.2 0.7 
25 2 N.A. 
26 N.A. N.A. 
27 1.7 3.2 
28 N.A. N.A. 
29 N.A. N.A. 
30 N.A. N.A. 
31 1.4 1.2 
32 0.5 1.3 
33 2 8 
 
a
 16-33 para-toluensulfonateb IC50 values represent the 
concentration causing 50% growth inhibition. They were 
determined by linear regression method. 
 
 
After this first screening investigation, 16 and 17 were selected for further investigation about their 
cytotoxic molecular mechanisms. Derivative 17 because was the most potent of the series, and 16 because 
characterized by similar chemical features, in particular for the same chain length, of mitonafide. To confirm 
the cytotoxic action of 16 and 17, their effects against HL60 leukemia cells were assessed. In particular, 16 
and 17 confirmed their antiproliferative activity (16, IC50 = 0.93 µM; 17, IC50 = 1.21 µM) toward this cell 
line with a comparable pattern with that of mitonafide (IC50 = 1.60 µM). (Figure 104). 
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Figure 104. Toxicity of 16 and 17 against HL60 
leukemia cells. The cells were incubated 24 h in the 
presence of the indicated concentration of compound, 
afterward cell death was determined by dye exclusion. 
 
 
As reported in the introduction part, mitonafide and diimides derivatives, are well known intercalators. To 
verified if 16 and 17 are able to interact with DNA, DNA-binding studies were carried out using mitonafide 
as reference compound. For this purpose the DNA-binding activities of 16 and 17 were determined by 
applying a fluorometric intercalator displacement method and it is expressed as the drug concentration 
reducing by 50% the fluorescence of DNA-bound Ethidium bromide. From these data, an apparent binding 
constant (Kapp) can be calculated, that roughly estimate the affinity of the drug for calf thymus DNA. Table 
7shows the ability of 16, 17 and mitonafide to bind DNA by Ethidium displacement assays. Both synthesized 
derivatives showed a more potent activity in comparison with the reference compound mitonafide. In 
particular 16 (EC50 about 90 nM) resulted 100 times more potent than mitonafide.  
 
 
Table 7. Determination of binding to DNA by 
Ethidium displacement assay. 
 
Compounda EC50 (nM)b Kapp (M-1)c 
Mitonafide 11500 ± 320 2.20 x 106 
16 93 ± 4 2.07 x 108 
17 122 ± 6 2.72 x 108 
 
a 16, 17, para-toluensulfonate.b EC50 values are defined as the drug 
concentrations which reduce the fluorescence of the DNA-bound 
ethidium by 50%, and are reported as the mean of three 
determinations ± sem. C Apparent binding constant (Kapp) values have 
been calculated taking as 107 M−1 the ethidium binding constant. 
 
 
To verify if the cytotoxic effects of 16 and 17 were caused by apoptosis induction caspase activation 
experiments were carried out. To this aim the cells were treated with a 5 µM concentration of the compounds 
and after 4 and 24 h the activity of caspase proteases acting on the substrate sequence Asp-Glu-Val-Asp 
(DEVD), i.e. mainly effector caspases, were measured. Caspases activation represents a marker of apoptotic 
16 
17 
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cell death. Figure 105A shows that 16 and 17, as well as mitonafide, triggered caspase activation. The 
analysis by Western blotting of protein extracted from cells treated 4 h with the aforementioned compounds, 
confirmed the activation of caspase-3, the main caspase effector (Figure 105B). Actually, in treated cells, it 
can be observed a reduction of the inactive precursor procaspase 3 (32 kDa), associated with the appearance 
of the proteolytic fragments, costitutive of the active enzyme (Figure 105B). It is noteworthy that the novel 
compounds trigger caspase activation rapidly, and after a few hours of treatment a large part of the 
procaspase 3 is processed into the active form, leading to apoptosis. The caspases activation carried out by 
16 was confirmed by further assays on different cell lines. These results reported in Figure 105C, show that 
16 caused caspase activation in different cell lines, such as SH-SY5Y neuroblastoma cells, H9c2 heart cells, 
and Jurkat T-cells. To note the behaviour of mitonafide which caused, quite surprisingly, caspases activation.  
 
 
 
 
 
 
Figure 105. 16, 17 and mitonafide trigger caspase-
dependent cell death. 
 
 
The involvement of some putative signal transduction pathways involved in apoptosis induction by the 
strongly cytotoxic compounds 16 and 17 and by reference compound mitonafide, was examined in SH-
SY5Y neuroblastoma cells (Figure 106). The treatment of the cells with 16 or 17 (5 µM) for 20 hours caused 
a large accumulation of p53 protein, that was observed also in mitonafide-treated cells. At the same time, 16, 
17 and mitonafide caused a profound down regulation of the survival kinase Akt and also abolished its 
phosphorylation. In the case of the ERK1/2 mitogen-activated protein kinases, the effects of 16 and 17 were 
completely different with respect to mitonafide. Indeed, mitonafide caused a decrease of the p42 and p44 
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ERK proteins, but did not block their phosphorylation. On the other hand, 16 and 17 caused a decrease of the 
p42 ERK2 protein, and completely inhibited the phosphorylation of both p42 and p44 ERKs.  
 
 
 
 
Figure 106. Effect of 16 and 17 on signal transduction 
pathway correlated to cell survival. 
 
 
 
Furthermore, compounds 16, 17 and juglone, a well known PIN1-inhibitor, have been tested on HCT116 
(colon carcinoma cell line) and MDA-MB-231 (human breast adenocarcinome) (Table 8). 
 
Table 8. IC50 values of compound 1, 2 and 4 and juglone on HCT116 and  
MDA-MB-231 cell lines. 
 
Compound IC50 HCT116 (µM) IC50 MDA-MB-231(µM) 
Juglone n.d 5.48 
16 1.11 1.27 
17 1.01 0.84 
 
 
Both compounds confirmed antiproliferative activity in these cell lines in micromolar range; in 
particular, 16 and 17 were more active than Juglone on MDA-MB-231 cell lines. 
 
In order to determine a possible interaction with Pin1, 16 and 17 have been tested in murine embrional 
fibroblasts PIN1+/+ and PIN1-/-. Figure 107 shows that PiB, 16 and 17 determine an effect on cell growth 
stronger in cells PIN+/+, in comparison with PIN1 -/- cell line, suggesting that their effects on cell growth 
could be dependent by PIN1 inhibition.  
 
 
 
 ctrl        16       17       mito 
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DMSO          16             17          PiB 
         2µM        2µM        2µM      2µM  
 
Figure 107. 
 
This last experiment experiment points out, in very preliminary fashion, that 16 and 17 could interact 
with PIN1. However, to confirm the direct activity on PIN1 by 16 and 17, further additional experiments 
are necessary. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cells % 
 140 
2.5 Conclusion 
 
This study allowed us to discover of new MTDLs endowed with different biological activities as 
anticancer agents. All the compounds designed displayed a citotoxic activity against SKBr-3 and CEM cell 
lines in micromolar range. In particular, compounds 16 and 17 emerged as the most potent of the series 
showing a profile of activity similar to that of Mitonafide, choose as reference compound. They showed an 
affinity toward DNA (16, EC50 = 93 nM; 17, EC50 = 122 nM) nearly 100 times higher than that of 
Mitonafide. Furthermore, 16 and 17 were able to rapidly trigger caspases activation in different cell lines 
(SH-SY5Y, H9c2, and Jurkat T-cells). During this study was discovered that Mitonafide is also able to 
trigger caspase activation: such biological property of Mitonafide was not reported in literature until now. 
Moreover, 16 and 17 caused a large accumulation of p53 protein in SH-SY5Y cells. In addition, they seemed 
able to interact with the protein PIN1 as suggested by preliminary assays performed in murine embrional 
fibroblasts PIN1+/+ and PIN1-/-. However, further tests should be performed in order to elucidate a possible 
interaction between 16 and 17 compounds and PIN1. 
All together these data point out that 16 and 17 interact/activate several targets involved in vcancer 
development, therefore this study may represent a promising starting point for the development of new 
MTDLs hopefully useful for the cancer treatment. 
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2.6 Experimental Section 
 
2.6.1 Chemistry  
Melting point were taken in glass capillary tubes on a Buchi SMP-20 apparatus and are uncorrected. ESI-
MS spectra were recorded on Perkin-Elmer 297 and WatersZQ 4000. 1H NMR and 13C NMR were recorded 
on Varian VRX 200 and 300 instruments. Chemical shift are reported in parts per millions (ppm) relative to 
peak of tetrmethylsilane (TMS) and spin multiplicities are given as s (singlet), br s (broad singlet), d 
(doublet), t (triplet), q (quartet) or m (multiplet) Although IR spectral data are not included (because of the 
lack of unusual features), they were obtained for all compounds reported, and they were consistent with the 
assigned structures. The elemental compositions of the compounds agreed to within ±0.4% of the calculated 
value. Where the elemental analysis is not included, crude compounds were used in the next step without 
further purification. Chromatographic separations were performed on silica gel columns by flash (Kieselgel 
40, 0.040-0.063 mm, Merck) or gravity (Kieselgel 60, 0.063-0.200 mm, Merck) column chromatography. 
Reactions were followed by thin layer chromatography (TLC) on Merck (0.25 mm) glass-packed precoated 
silica gel plates (60 F254) and then visualized in an iodine chamber or with a UV lamp.The term “dried” 
refers to the use of anhydrous sodium sulfate. 
 
General procedure for the synthesis of derivatives 16, 17: the appropriate diamine 61, 62(1.15mmol) 
was dissolved in MeOH at 0˚ C and the solution was made basic adding Et3N; the 2-methoxybenzaldehyde 
(2.3 mmol) was added and resulting mixture was refluxed for 4h and the formation of a yellow solid was 
observed. After cooling down, NaBH4 (23 mmol) was added at 0˚ C and stirred overnight. The mixture was 
then made acidic with 3 N HCl and the solvent was removed under vacuum. The residue was dissolved in 
water, and the resulting solution made basic with K2CO3, and extracted with CH2Cl2 (3 x 30 mL); the organic 
phase was dried and the solvent was evaporated. The crude product was purified by flash chromatography to 
afford the desired compound 16 and 17. The two purified compounds were converted in di-p-toluen-
sulfonate (foam solids). 
2,7-bis(2-(2-methoxybenzylamino)ethyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(16): yellow oil, 26% yield from 61 as starting diamine, purified by flash chromatography eluting with 
toluene/EtOAc/CH3OH/aqueous 28% ammonia (5:4.5:0.5:0.01); 1H NMR (free base, 300MHz CDCl3) δ 1.83 
(br s, 2H exchangeable with D2O), 3.02 (t, J = 6.3, 4H), 3.85 (s, 4H), 3.88(s, 6H), 4.40 (t, J = 6.6, 4H), 6.84-
6.92 (m, 4H), 7.19-7.25(m, 4H), 8.78 (s, 4H); MS (ESI+) m/z = 593 (M+H)+. Anal. (C34H32N4O6), C, H, N. 
2,7-bis(3-(2-methoxybenzylamino)propyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(17): yellow oil, 27% yield from 62 as starting diamine, purified by flash chromatography eluting with 
toluene/EtOAc/CH2Cl2/CH3OH/aqueous 28% ammonia (4:4:1:1:0.03); 1H NMR (free base, 300MHz CDCl3) 
δ 1.99-2.07 (m, 4H + 2H exchangeable with D2O), 2.77 (t, J = 6.9, 4H), 3.83 (s, 4H), 3.87 (s, 6H), 4.33 (t, J 
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= 7.2, 4H), 6.86-6.91 (m, 4H), 7.20-7.25 (m, 4H), 8.76 (s, 4H); MS (ESI+) m/z = 621 (M+H)+. Anal. 
(C36H36N4O6), C, H, N. 
General procedure for the synthesis of derivatives 70-76: the appropriate diamine 63-69 (25 mmol) 
was dissolved in a mixture of toluene/ethanol 1:1 under a stream of dry nitrogen and a solution of 
isochromeno[6,5,4-def]isochromene-1,3,6,8-tetraone (5 mmol) dissolved in toluene/ethanol 1:1 was added; 
the mixture was refluxed for 24h. Then, the solvent was evaporated, affording a residue that was suspended 
in water. The solid residue was filtered off and washed several times with water to afforded the desired crude 
product70-76. 
2,7-bis(4-aminobutyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (70): was synthesized 
from 63; brown solid; quantitative yield; m.p 213-215°C; 
2,7-bis(5-aminopentyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (71): was synthesized 
from 64; red solid; quantitative yield; m.p 213-215°C; 
2,7-bis(6-aminohexyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (72): was synthesized 
from 65; red solid; quantitative yield; m.p 216-219°C; 
2,7-bis(7-aminoheptyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (73): was synthesized 
from 66; red solid; quantitative yield; m.p 203-206°C; 
2,7-bis(8-aminooctyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (74): was synthesized 
from 67; red solid; quantitative yield; m.p 144-147°C; 
2,7-bis(9-aminononyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (75): was synthesized 
from 68; red solid; quantitative yield; m.p 115-118°C; 
2,7-bis(10-aminodecyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone (76): was synthesized 
from 69; red solid; quantitative yield; m.p 110:112°C. 
 
General procedure for the synthesis of 18-24: a mixture of the appropriate diamine 70-76 and 2-
methoxybenzaldehyde (in a ratio 1:2.4) in toluene was refluxed in a Dean-Stark apparatus for 3 h. Following 
solvent removal, the residue was taked up in EtOH, NaBH4 (in a 1:5 molar ratio) was added, and the stirring 
was continued at room temperature for 4 h. The mixture was then made acidic with 6N HCl and the solvent 
removed. Then, the residue was dissolved in water and the resulting solution was washed with ether, made 
basic with KOH and extracted with CH2Cl2 (3 x 30 mL). Removal of the dried solvent gave the desired 
products 18-24 which were finally converted in the para-toluenesulfonate salts (foam solid). 
2,7-bis(4-(2-methoxybenzylamino)butyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(18): it was synthesized from 70; brown solid; 25% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.46-1.77 
(m, 8H+ 2H exchangeable with D2O), 2.62 (t, J = 6.7, 4H), 3.82 (s, 4H), 3.86(s, 6H), 4.21(t, J = 7.2, 4H), 
6.86-6.96(m, 4H), 7.27-7.31(m,4H), 8.77(s, 4H); MS (ESI+) m/z = 649 (M)+ 
2,7-bis(5-(2-methoxybenzylamino)pentyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(19): it was synthesized from 71; brown solid; 37% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.41-1.82 
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(m, 12H+ 2H exchangeable with D2O), 2.57 (t, J = 6.9, 4H), 3.87 (s, 4H), 3.92(s, 6H), 4.27(t, J = 7.2, 4H), 
6.73-6.91(m, 4H), 7.29-7.33(m,4H), 8.74(s, 4H); MS (ESI+) m/z = 677 (M)+ 
2,7-bis(6-(2-methoxybenzylamino)hexyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(20): it was synthesized from 72; brown solid; 23% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.35-1.87 
(m, 16H+ 2H exchangeable with D2O), 2.85 (t, J = 6.7, 4H), 3.79 (s, 4H), 3.88(s, 6H), 4.30(t, J =7.1, 4H), 
6.84-6.99(m, 4H), 7.30-7.37(m,4H), 8.78(s, 4H); MS (ESI+) m/z = 705 (M)+ 
2,7-Bis-[7-(2-methoxy-benzylamino)-heptyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone (21): it 
was synthesized from 73; brown solid; 27% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.29-1.72 (m, 
20H+ 2H exchangeable with D2O), 2.93 (t, J = 6.6, 4H), 3.83 (s, 4H), 3.90(s, 6H), 4.26(t,  J = 7.2, 4H), 6.80-
6.99(m, 4H), 7.28-7.42(m,4H), 8.75(s, 4H); MS (ESI+) m/z = 733 (M)+ 
2,7-Bis-[8-(2-methoxy-benzylamino)-octyl]-benzo[lmn][3,8]phenanthroline-1,3,6,8-tetraone (22): it 
was synthesized from 74; brown solid; 21% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.37-1.73 (m, 
24H+ 2H exchangeable with D2O), 2.79 (t, J = 6.8, 4H), 3.87 (s, 4H), 3.94 (s, 6H), 4.31(t, J = 7.3, 4H), 6.75-
6.97(m, 4H), 7.29-7.41(m,4H), 8.71(s, 4H); MS (ESI+) m/z = 761 (M)+ 
2,7-bis(9-(2-methoxybenzylamino)nonyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(23): It was synthesized from 75; brown solid; 30% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.25-1.63 
(m, 28H+ 2H exchangeable with D2O), 2.69 (t, J = 6.9, 4H), 3.85 (s, 4H), 3.96 (s, 6H), 4.27(t, J = 7.3, 4H), 
6.75-7.01(m, 4H), 7.28-7.47(m,4H), 8.78(s, 4H); MS (ESI+) m/z = 790 (M)+ 
2,7-bis(10-(2-methoxybenzylamino)decyl)benzo[lmn][3,8]phenanthroline-1,3,6,8(2H,7H)-tetraone 
(24): It was synthesized from 76; yellow solid; 70% yield; 1H NMR (free base, 300 MHz, CDCl3) δ 1.19-
1.75 (m, 32H+ 2H exchangeable with D2O), 2.76 (t, J = 6.7, 4H), 3.93 (s, 4H), 4.01 (s, 6H), 4.29(t, J = 7.2, 
4H), 6.83-6.97(m, 4H), 7.29-7.45(m,4H), 8.74(s, 4H); MS (ESI+) m/z = 818 (M)+ 
 
General procedure for the synthesis of 77-85: compounds 77-85 have been synthesized following the 
procedure reported in literature375. 
2-(6-aminohexyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (81): it was synthesized from 65; yellow 
oil; 77% yield; 1H NMR ( 200 MHz, CDCl3) δ 1.45-1.77 (m, 8H), 2.71 (t, J = 7.0, 2H), 4.21 (t, J = 7.6, 2H), 
7.78 (t, J = 7.9, 2H), 8.22-8.26 (d, J = 8.0, 2H) 8.61-8.65 (d, J = 7.4, 2H). 
2-(7-aminoheptyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (82): It was synthesized from 66; yellow 
oil; 85% yield; 1H NMR ( 200 MHz, CDCl3) δ 1.42-1.77 (m, 10H), 2.71 (t, J = 7.1, 2H), 4.21 (t, J = 7.2, 2H), 
7.79 (t, J = 7.6, 2H), 8.23-8.27 (d, J = 8.0, 2H) 8.62-8.66 (d, J = 7.4, 2H). 
2-(8-aminooctyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (83): It was synthesized from 67; yellow 
oil; 20% yield; 1H NMR ( 200 MHz, CDCl3) δ 1.35-1.65 (m, 12H), 2.69 (t, J = 6.6, 2H), 4.20 (t, J = 6.6, 2H), 
7.78 (t, J = 7.2, 2H), 8.22-8.26 (d, J = 8.0, 2H) 8.61-8.65 (d, J = 7.4, 2H). 
2-(9-aminononyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (84): It was synthesized from 68; yellow 
oil; 55% yield; 1H NMR ( 200 MHz, CDCl3) δ 1.32-1.64 (m, 14H), 2.69 (t, J = 7.0, 2H), 4.20 (t, J = 7.8, 2H), 
7.78 (t, J = 7.6, 2H), 8.22-8.26 (d, J = 8.0, 2H) 8.61-8.65 (d, J = 7.4, 2H). 
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2-(10-aminodecyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (85): It was synthesized from 69; yellow 
oil; 82% yield; 1H NMR ( 200 MHz, CDCl3) δ 1.30-1.64 (m, 16H), 2.69 (t, J = 7.0, 2H), 4.19 (t, J = 7.8, 2H), 
7.77 (t, J = 7.8, 2H), 8.21-8.25 (d, J = 8.0, 2H) 8.61-8.64 (d, J = 7.4, 2H). 
General procedure for the synthesis of derivatives 25-33: a mixture of  77-85 and  2-
methoxybenzaldehyde (in a ratio 1:1.2) in toluene was refluxed in a Dean-Stark apparatus for 3 h. Following 
solvent removal, the residue was taked up in EtOH, NaBH4 (in a 1:2.5 molar ratio) was added, and the 
stirring was continued at room temperature for 12 h. The mixture was then made acidic with 6N HCl and the 
solvent removed. Then, the residue was dissolved in water and the resulting solution was washed with ether, 
made basic with K2CO3 and extracted with CHCl3 (3 x 30 mL). Removal of the dried solvent gave the 
desired products 25-33 which were purified by flash chromatography. 25-33 were finally converted into the 
para-toluensulfonate salt (foam solid). 
2-(2-(2-methoxybenzylamino)ethyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (25): was synthesized 
from 77; yellow oil; 24% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 200 MHz, CDCl3) δ 1.92 (br s, 1H exchangeable with D2O), 2.97 (t, J = 
6.6,2H), 3.77 (s, 3H), 3.84 (s, 2H), 4.32 (t, J = 8.0, 2H), 6.76-6.88 (m, 2H), 7.12-7.24 (m, 2H), 7.62-7.70 (m, 
2H), 8.08-8.13 (m, 2H), 4.48-8.52 (m,2H); MS (ESI+) m/z = 361 (M+H)+. 
2-(3-(2-methoxybenzylamino)propyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (26): was synthesized 
from 78; yellow oil; 24% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 200 MHz, CDCl3) δ  1.91-2.05 (m, 2H), 2.36 (br s, 1H exchangeable 
with D2O), 2.73 (t, J = 7.0, 2H), 3.81 (s, 3H), 3.84 (s, 2H), 4.25 (t, J = 7.0, 2H), 6.82-6.90 (m, 2H), 7.15-7.25 
(m, 2H), 7.65-7.74 (m, 2H), 8.13-8.17 (m, 2H), 8.52-8.55 (m, 2H); MS (ESI+) m/z = 375 (M+H)+. 
2-(4-(2-methoxybenzylamino)butyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (27): was synthesized 
from 79 yellow oil; 29% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 200 MHz, CDCl3) δ  1.60-1.82 (m, 4H), 2.45 (br s, 1H exchangeable 
with D2O), 2.67 (t, J = 7.0, 2H), 3.79 (s, 3H), 3.83 (s, 2H), 4.17 (t, J = 7.4, 2H), 6.81-6.92 (m, 2H), 7.16-7.25 
(m, 2H), 7.69 (t, J = 8.0,  2H), 8.12-8.17 (m, 2H), 8.51-8.55 (m, 2H); MS (ESI+) m/z = 389 (M+H)+. 
2-(5-(2-methoxybenzylamino)pentyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (28): was synthesized 
from 80; yellow oil; 34% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 200 MHz, CDCl3) δ  1.27-1.80 (m, 6H+1H exchangeable with D2O ), 
2.65 (t, J = 7.4, 2H), 3.81 (s, 2H), 3.84 (s, 3H), 4.17 (t, J = 7.8, 2H), 6.84-6.94 (m, 2H), 7.19-7.30 (m, 2H), 
7.72 (t, J= 8.2,  2H), 8.15-8.19 (m, 2H), 8.53-8.57 (m, 2H); 13C NMR (free base, CDCl3) δ 24.76, 27.91, 
29.18, 40.19, 48.57, 48.76, 55.15, 110.11, 120.32, 122.57, 126.58, 127.18, 127.98, 128.35, 130.02, 131.02, 
131.45, 133.72, 157.55, 164.02;MS (ESI+) m/z = 403 (M+H)+. 
2-(6-(2-methoxybenzylamino)hexyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (29): was synthesized 
from 81; yellow oil; 25% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 200 MHz, CDCl3) δ  1.22-1.74 (m, 8H+1H exchangeable with D2O ), 
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2.68 (t, J = 7.3, 2H), 3.85 (s, 2H), 3.89 (s, 3H), 4.18 (t, J = 7.9, 2H), 6.89-6.99 (m, 2H), 7.15-7.26 (m, 2H), 
7.73 (t, J = 8.0, 2H), 8.13-8.19 (m, 2H), 8.50-8.55 (m, 2H); MS (ESI+) m/z = 417 (M+H)+. 
2-(7-(2-methoxybenzylamino)heptyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (30): was synthesized 
from 82 yellow oil; 27% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 300 MHz, CDCl3) δ  1.22-1.74 (m, 10+1H exchangeable with D2O ), 
2.68 (t, J = 7.3, 2H), 3.85 (s, 2H), 3.89 (s, 3H), 4.18 (t, J = 7.9, 2H), 6.89-6.99 (m, 2H), 7.15-7.26 (m, 2H), 
7.73 (t, J = 8.0,  2H), 8.13-8.19 (m, 2H), 8.50-8.55 (m, 2H); MS (ESI+) m/z = 431 (M+H)+. 
2-(8-(2-methoxybenzylamino)octyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (31): was synthesized 
from 83; yellow oil; 36% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 200 MHz, CDCl3) δ  1.27-1.73 (m, 12H+1H exchangeable with D2O ), 
2.63 (t,  J= 7.7, 2H), 3.86 (s, 2H), 3.88 (s, 3H), 4.18 (t, J = 7.8, 2H), 6.85-6.96 (m, 2H), 7.22-7.29 (m, 2H), 
7.76 (t, J = 8.0, 2H), 8.19-8.23 (m, 2H), 8.58-8.62 (m, 2H); MS (ESI+) m/z = 445 (M+H)+. 
2-(9-(2-methoxybenzylamino)nonyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (32): was synthesized 
from 84; yellow oil; 25% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 300 MHz, CDCl3) δ  1.32-1.81 (m, 14H+1H exchangeable with D2O ), 
2.62 (t, J = 7.5, 2H), 3.83 (s, 2H), 3.87 (s, 3H), 4.20 (t, J=7.8, 2H), 6.88-6.97 (m, 2H), 7.24-7.30 (m, 2H), 
7.78 (t, J = 8.1,  2H), 8.21-8.25 (m, 2H), 8.61-8.64 (m, 2H); MS (ESI+) m/z = 459 (M+H)+. 
2-(10-(2-methoxybenzylamino)decyl)-1H-benzo[de]isoquinoline-1,3(2H)-dione (33): was synthesized 
from 85; yellow oil; 32% yield; eluting solvent petroleum ether/CHCl3/MeOH/ aqueous 33% ammonia 
(6:3.5:0.5/0.1); 1H-NMR (free base, 300 MHz, CDCl3) δ  1.28-1.77 (m, 16H+1H exchangeable with D2O ), 
2.59 (t, J = 6.6, 2H), 3.80 (s, 2H), 3.84 (s, 3H), 4.18 (t, J =7.8, 2H), 6.85-6.95 (m, 2H), 7.20-7.28 (m, 2H), 
7.75 (t, J = 7.8, 2H), 8.18-8.22 (m, 2H), 8.58-8.61 (m, 2H); MS (ESI+) m/z = 473 (M+H)+. 
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